Document:

EX-4.4

 Exhibit 4.4 

SYMMETRICOM, INC. 
 2006
INCENTIVE AWARD PLAN 
 STOCK OPTION GRANT NOTICE AND 

STOCK OPTION AGREEMENT 

Symmetricom, Inc., a Delaware corporation (the “Company”), pursuant to its 2006 Incentive Award Plan (the
“Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s common stock, par value $0.0001 (“Stock”),
set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein and in the Stock Option Agreement attached hereto as Exhibit A (the “Stock Option
Agreement”) and the Plan, which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Stock Option Agreement.

  

			
	Participant:	  	
		
	Grant Date:	  	
		
	Exercise Price per Share:	  	
		
	Total Exercise Price:	  	$
		
	Total Number of Shares Subject to the Option:	  	                shares
		
	Expiration Date:	  	
		
	Type of Option:	  	Non-Qualified Stock Option
		
	Vesting Schedule:	  	 Twenty-five percent (25%) of the total number of shares subject to the Option shall become vested and exercisable on the on each of
the first and second anniversaries of the Grant Date; and the remaining fifty percent (50%) of the total number of shares subject to the Option shall become vested and exercisable on the third anniversary of the Grant Date, so that the Option
is 100% vested and exercisable on the third anniversary of the Grant Date, subject to Participant not experiencing a Termination of Services through such dates.
  

The shares subject to this Option shall vest on an accelerated basis in the event of the occurrence of a Change of Control as described in Section 3.1(c)
of the Stock Option Agreement.
  

 By his or her signature, the Participant agrees to be bound by the terms and conditions of the Plan, the Stock
Option Agreement and this Grant Notice. The Participant has reviewed the Stock Option Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully
understands all provisions of this Grant Notice, the Stock Option Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the
Plan or relating to the Option. 
  

							
	SYMMETRICOM, INC.	  	PARTICIPANT
				
	By:	 	 	  	By:	 	 
				
	Print Name:    	 	 	  	Print Name:    	 	
				
	Title:	 	CFO	  		 	
				
	Address:	 	2300 Orchard Parkway	  	Address:	 	 
		 	 San Jose, CA 95131-1017
  
	  		 	
		 		  		 	 

 EXHIBIT A 

TO STOCK OPTION GRANT NOTICE 

STOCK OPTION AGREEMENT 

Pursuant to the Stock Option Grant Notice (the “Grant Notice”) to which this Stock Option Agreement
(this “Agreement”) is attached, Symmetricom, Inc., a Delaware corporation (the “Company”), has granted to the Participant an option under the Company’s 2006 Incentive Award Plan (the
“Plan”) to purchase the number of shares of Stock indicated in the Grant Notice. 
 ARTICLE I. 

 GENERAL 
 1.1
Defined Terms. Wherever the following terms are used in this Agreement they shall have the meanings specified below, unless the context clearly indicates otherwise. Capitalized terms not specifically defined herein shall have the meanings
specified in the Plan and the Grant Notice. 
 (a) “Administrator” shall mean the Board or the Committee responsible
for conducting the general administration of the Plan in accordance with Article 12 of the Plan; provided that if the Participant is an Independent Director, “Administrator” shall mean the Board. 

(b) “Termination of Consultancy” shall mean the time when the engagement of the Participant as a Consultant to the
Company or a Subsidiary is terminated for any reason, with or without cause, including, but not by way of limitation, by resignation, discharge, death or retirement, but excluding: (a) terminations where there is a simultaneous employment or
continuing employment of the Participant by the Company or any Subsidiary, and (b) terminations where there is a simultaneous re-establishment of a consulting relationship or continuing consulting relationship between the Participant and the
Company or any Subsidiary. The Administrator, in its absolute discretion, shall determine the effect of all matters and questions relating to Termination of Consultancy, including, but not by way of limitation, the question of whether a particular
leave of absence constitutes a Termination of Consultancy. Notwithstanding any other provision of the Plan, the Company or any Subsidiary has an absolute and unrestricted right to terminate a Consultant’s service at any time for any reason
whatsoever, with or without cause, except to the extent expressly provided otherwise in writing. 
 (c) “Termination of
Directorship” shall mean the time when the Participant, if he or she is or becomes an Independent Director, ceases to be a Director for any reason, including, but not by way of limitation, a termination by resignation, failure to be
elected, death or retirement. The Board, in its sole and absolute discretion, shall determine the effect of all matters and questions relating to Termination of Directorship with respect to Independent Directors. 

(d) “Termination of Employment” shall mean the time when the employee-employer relationship between the Participant
and the Company or any Subsidiary is terminated for any reason, with or without cause, including, but not by way of limitation, a termination by resignation, discharge, death, disability or retirement; but excluding: (a) terminations where
there is a simultaneous reemployment or continuing employment of the Participant by the Company or any Subsidiary, and (b) terminations where there is a simultaneous establishment of a consulting relationship or continuing consulting
relationship between the Participant and the Company or any Subsidiary. The Administrator, in its absolute discretion, shall determine the effect of all matters and questions relating to Termination of Employment, including, but not by way of
limitation, the question of whether a particular leave of absence constitutes a Termination of Employment. 

  
 A-1 

 (e) “Termination of Services” shall mean the Participant’s
Termination of Consultancy, Termination of Directorship or Termination of Employment, as applicable. 
 1.2 Incorporation of Terms of
Plan. The Option is subject to the terms and conditions of the Plan which are incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control. 

ARTICLE II.  
 GRANT OF
OPTION 
 2.1 Grant of Option. In consideration of the Participant’s past and/or continued employment with or service to the
Company or a Subsidiary and for other good and valuable consideration, effective as of the Grant Date set forth in the Grant Notice (the “Grant Date”), the Company irrevocably grants to the Participant the Option to purchase
any part or all of an aggregate of the number of shares of Stock set forth in the Grant Notice, upon the terms and conditions set forth in the Plan and this Agreement. As designated in the Grant Notice, the Option shall be treated as a Non-Qualified
Stock Option. 
 2.2 Exercise Price. The exercise price of the shares of Stock subject to the Option shall be as set forth in the
Grant Notice, without commission or other charge; provided, however, that the price per share of the shares of Stock subject to the Option shall not be less than 100% of the Fair Market Value of a share of Stock on the Grant Date. 

2.3 Consideration to the Company. In consideration of the grant of the Option by the Company, the Participant agrees to render faithful
and efficient services to the Company or any Subsidiary. Nothing in the Plan or this Agreement shall confer upon the Participant any right to continue in the employ or service of the Company or any Subsidiary or shall interfere with or restrict in
any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of the Participant at any time for any reason whatsoever, with or without cause, except to the extent
expressly provided otherwise in a written agreement between the Company or a Subsidiary and the Participant. 
 ARTICLE III.  

PERIOD OF EXERCISABILITY 

3.1 Commencement of Exercisability. 

(a) Subject to Sections 3.2, 3.3, 5.8 and 5.10, the Option shall become vested and exercisable in such amounts and at such times as are set
forth in the Grant Notice. 
 (b) No portion of the Option which has not become vested and exercisable at the date of the Participant’s
Termination of Employment, Termination of Directorship or Termination of Consultancy shall thereafter become vested and exercisable, except as may be otherwise provided by the Administrator or as set forth in a written agreement between the Company
and the Participant. 

  
 A-2 

 (c) Notwithstanding Sections 3.1(a) and 3.1(b), in the event of the occurrence of a Change of
Control, the Option shall become fully vested and exercisable. 
 3.2 Duration of Exercisability. The installments provided for in
the vesting schedule set forth in the Grant Notice are cumulative. Each such installment which becomes vested and exercisable pursuant to the vesting schedule set forth in the Grant Notice shall remain vested and exercisable until it becomes
unexercisable under Section 3.3. 
 3.3 Expiration of Option. The Option may not be exercised to any extent by anyone after the
first to occur of the following events: 
 (a) The expiration of seven years from the Grant Date; or 

(b) The expiration of one year from the date of the Participant’s Termination of Services for any reason. 

ARTICLE IV.  
 EXERCISE
OF OPTION 
 4.1 Person Eligible to Exercise. Except as provided in Sections 5.2(b) and 5.2(c), during the lifetime of the
Participant, only the Participant may exercise the Option or any portion thereof. After the death of the Participant, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section 3.3, be
exercised by the Participant’s personal representative or by any person empowered to do so under the deceased the Participant’s will or under the then applicable laws of descent and distribution. 

4.2 Partial Exercise. Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised in whole
or in part at any time prior to the time when the Option or portion thereof becomes unexercisable under Section 3.3. 
 4.3 Manner
of Exercise. The Option, or any exercisable portion thereof, may be exercised solely by delivery to the Secretary of the Company (or any third party administrator or other person or entity designated by the Company) of all of the following prior
to the time when the Option or such portion thereof becomes unexercisable under Section 3.3: 
 (a) An Exercise Notice in a form
specified by the Administrator, stating that the Option or portion thereof is thereby exercised, such notice complying with all applicable rules established by the Administrator; 

(b) The receipt by the Company of full payment for the shares of Stock with respect to which the Option or portion thereof is exercised,
including payment of any applicable withholding tax, which may be in one or more of the forms of consideration permitted under Section 4.4; 

(c) Any other written representations as may be required in the Administrator’s reasonable discretion to evidence compliance with the
Securities Act or any other applicable law rule, or regulation; and 
 (d) In the event the Option or portion thereof shall be exercised
pursuant to Section 4.1 by any person or persons other than the Participant, appropriate proof of the right of such person or persons to exercise the Option. 

  
 A-3 

 Notwithstanding any of the foregoing, the Company shall have the right to specify all conditions of the manner of
exercise, which conditions may vary by country and which may be subject to change from time to time. 
 4.4 Method of Payment.
Payment of the exercise price shall be by any of the following, or a combination thereof, at the election of the Participant: 
 (a) Cash;

 (b) Check; 
 (c) With the
consent of the Administrator, delivery of a notice that the Participant has placed a market sell order with a broker with respect to shares of Stock then issuable upon exercise of the Option, and that the broker has been directed to pay a sufficient
portion of the net proceeds of the sale to the Company in satisfaction of the aggregate exercise price; provided, that payment of such proceeds is then made to the Company upon settlement of such sale; 

(d) With the consent of the Administrator, surrender of other shares of Stock which (A) have been held for such period of time as the
Administrator may require in order to avoid adverse accounting consequences, and (B) have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the shares of Stock with respect to which the Option or portion
thereof is being exercised; 
 (e) With the consent of the Administrator, surrendered shares of Stock issuable upon the exercise of the
Option having a Fair Market Value on the date of exercise equal to the aggregate exercise price of the shares of Stock with respect to which the Option or portion thereof is being exercised; or 

(f) With the consent of the Administrator, property of any kind which constitutes good and valuable consideration. 

4.5 Conditions to Issuance of Stock Certificates. The shares of Stock deliverable upon the exercise of the Option, or any portion
thereof, may be either previously authorized but unissued shares of Stock or issued shares of Stock which have then been reacquired by the Company. Such shares of Stock shall be fully paid and nonassessable. The Company shall not be required to
issue or deliver any shares of Stock purchased upon the exercise of the Option or portion thereof prior to fulfillment of all of the following conditions: 

(a) The admission of such shares of Stock to listing on all stock exchanges on which such Stock is then listed; 

(b) The completion of any registration or other qualification of such shares of Stock under any state or federal law or under rulings or
regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable; 

(c) The obtaining of any approval or other clearance from any state or federal governmental agency which the Administrator shall, in its
absolute discretion, determine to be necessary or advisable; 

  
 A-4 

 (d) The receipt by the Company of full payment for such shares of Stock, including payment of any
applicable withholding tax, which may be in one or more of the forms of consideration permitted under Section 4.4; and 
 (e) The lapse
of such reasonable period of time following the exercise of the Option as the Administrator may from time to time establish for reasons of administrative convenience. 

4.6 Rights as Stockholder. The holder of the Option shall not be, nor have any of the rights or privileges of, a stockholder of the
Company in respect of any shares of Stock purchasable upon the exercise of any part of the Option unless and until such shares of Stock shall have been issued by the Company to such holder (as evidenced by the appropriate entry on the books of the
Company or of a duly authorized transfer agent of the Company). No adjustment will be made for a dividend or other right for which the record date is prior to the date the shares of Stock are issued, except as provided in Section 11.2 of the
Plan. 
 ARTICLE V.  

OTHER PROVISIONS 
 5.1
Administration. The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or
revoke any such rules. All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon Participant, the Company and all other interested persons. No member of the Committee or the
Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the Option. 

5.2 Option Not Transferable. 

(a) Subject to Section 5.2(b), the Option may not be sold, pledged, assigned or transferred in any manner other than by will or the laws
of descent and distribution, unless and until the shares of Stock underlying the Option have been issued, and all restrictions applicable to such shares of Stock have lapsed. Neither the Option nor any interest or right therein shall be liable for
the debts, contracts or engagements of Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be
voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to
the extent that such disposition is permitted by the preceding sentence. 
 (b) Notwithstanding any other provision in this Agreement, with
the consent of the Administrator, the Participant may transfer the Option (or any portion thereof) to any one or more Permitted Transferees (as defined below), subject to the following terms and conditions: (i) any portion of the Option
transferred to a Permitted Transferee shall not be assignable or transferable by the Permitted Transferee other than by will or the laws of descent and distribution; (ii) any portion of the Option which is transferred to a Permitted Transferee
shall continue to be subject to all the terms and conditions of the Option as applicable to the Participant (other than the ability to further transfer the Option); and (iii) the Participant and the Permitted Transferee shall execute any and
all documents requested by the Administrator, including, without limitation documents to (A) confirm the status of the transferee as a Permitted Transferee, (B) satisfy any requirements for an exemption for the transfer under applicable
federal and state securities laws and (C) evidence the transfer. For purposes of this Section 5.2(b), “Permitted Transferee” shall mean, with 

  
 A-5 

 
respect to a Participant, any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the Participant’s household (other than a tenant or employee), a trust in which these persons (or the Participant) control the management of
assets, and any other entity in which these persons (or the Participant) own more than fifty percent of the voting interests, or any other transferee specifically approved by the Administrator after taking into account any state or federal tax or
securities laws applicable to transferable Options. 
 (c) Unless transferred to a Permitted Transferee in accordance with
Section 5.2(b), during the lifetime of Participant, only Participant may exercise the Option or any portion thereof. Subject to such conditions and procedures as the Administrator may require, a Permitted Transferee may exercise the Option or
any portion thereof during Participant’s lifetime. After the death of Participant, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section 3.3, be exercised by Participant’s
personal representative or by any person empowered to do so under the deceased Participant’s will or under the then applicable laws of descent and distribution. 

5.3 Adjustments. The Participant acknowledges that the Option is subject to modification and termination in certain events as provided
in this Agreement and Article 11 of the Plan. 
 5.4 Notices. Any notice to be given under the terms of this Agreement to the Company
shall be addressed to the Company in care of the Secretary of the Company at the address given beneath the signature of the Company’s authorized officer on the Grant Notice, and any notice to be given to Participant shall be addressed to
Participant at the address given beneath Participant’s signature on the Grant Notice. By a notice given pursuant to this Section 5.4, either party may hereafter designate a different address for notices to be given to that party. Any
notice which is required to be given to Participant shall, if Participant is then deceased, be given to the person entitled to exercise his or her Option pursuant to Section 4.1 by written notice under this Section 5.4. Any notice shall be
deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service. 

5.5 Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this
Agreement. 
 5.6 Governing Law; Severability. The laws of the State of Delaware shall govern the interpretation, validity,
administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws. 

5.7 Conformity to Securities Laws. The Participant acknowledges that the Plan and this Agreement are intended to conform to the extent
necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, and state securities laws and regulations. Notwithstanding anything
herein to the contrary, the Plan shall be administered, and the Option is granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by applicable law, the Plan and this Agreement
shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. 
 5.8 Amendments, Suspension and
Termination. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board, provided, that, except as
may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the Option in any material way without the prior written consent of the Participant. 

  
 A-6 

 5.9 Successors and Assigns. The Company may assign any of its rights under this Agreement
to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in Section 5.2, this Agreement shall be binding upon
Participant and his or her heirs, executors, administrators, successors and assigns. 
 5.10 Limitations Applicable to Section 16
Persons. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Option and this Agreement shall be subject to any additional limitations set forth in any
applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, this
Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule. 
 5.11 Not a Contract of
Employment. Nothing in this Agreement or in the Plan shall confer upon the Participant any right to continue to serve as an employee or other service provider of the Company or any of its Subsidiaries. 

5.12 Entire Agreement. The Plan, the Grant Notice and this Agreement (including all Exhibits thereto) constitute the entire agreement
of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. 

5.13 Section 409A. Notwithstanding any other provision of the Plan, this Agreement or the Grant Notice, the Plan, this Agreement
and the Grant Notice shall be interpreted in accordance with, and incorporate the terms and conditions required by, Section 409A of the U.S. Internal Revenue Code of 1986, as amended (together with any Department of Treasury regulations and
other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, “Section 409A”). The Committee may, in its discretion, adopt such
amendments to the Plan, this Agreement or the Grant Notice or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Committee determines are necessary or
appropriate to comply with the requirements of Section 409A. 

  
 A-7 

 SYMMETRICOM, INC. 

2006 INCENTIVE AWARD PLAN 

STOCK OPTION GRANT NOTICE AND 

STOCK OPTION AGREEMENT 

Symmetricom, Inc., a Delaware corporation (the “Company”), pursuant to its 2006 Incentive Award Plan
(the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s common stock, par value $0.0001
(“Stock”), set forth below (the “Option”). This Option is subject to all of the terms and conditions set forth herein and in the Stock Option Agreement attached hereto as Exhibit A (the
“Stock Option Agreement”) and the Plan, which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Stock Option
Agreement. 
  

			
	Participant:	  	
		
	Grant Date:	  	
		
	Exercise Price per Share:	  	
		
	Total Exercise Price:	  	$
		
	Total Number of Shares Subject to the Option:	  	                shares
		
	Expiration Date:	  	
		
	Type of Option:	  	Non-Qualified Stock Option
		
	Vesting Schedule:	  	 This Option shall become vested and exercisable with respect to all of the shares subject to the Option on the earlier to occur of
(a) first anniversary of the Grant Date or (b) the dater of the Company’s first annual stockholders meeting following the Grant Date, subject to Participant not experiencing a Termination of Services through such dates.

 
 The shares subject to this Option shall vest on an accelerated basis in the event of the
occurrence of a Change of Control as described in Section 3.1(c) of the Stock Option Agreement.
  

 By his or her signature, the Participant agrees to be bound by the terms and conditions of the Plan, the Stock
Option Agreement and this Grant Notice. The Participant has reviewed the Stock Option Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully
understands all provisions of this Grant Notice, the Stock Option Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the
Plan or relating to the Option. 
  

							
	SYMMETRICOM, INC.	  	PARTICIPANT
				
	By:	  	 	  	By:	 	 
				
	Print Name:    	  	 	  	Print Name:    	 	 
				
	Title:	  	CFO	  		 	
				
	Address:	  	2300 Orchard Parkway	  	Address:	 	 
		  	 San Jose, CA 95131-1017
  
	  		 	
		  		  		 	 

 EXHIBIT A 

TO STOCK OPTION GRANT NOTICE 

STOCK OPTION AGREEMENT 

Pursuant to the Stock Option Grant Notice (the “Grant Notice”) to which this Stock Option Agreement
(this “Agreement”) is attached, Symmetricom, Inc., a Delaware corporation (the “Company”), has granted to the Participant an option under the Company’s 2006 Incentive Award Plan (the
“Plan”) to purchase the number of shares of Stock indicated in the Grant Notice. 
 ARTICLE I. 

 GENERAL 
 1.1
Defined Terms. Wherever the following terms are used in this Agreement they shall have the meanings specified below, unless the context clearly indicates otherwise. Capitalized terms not specifically defined herein shall have the meanings
specified in the Plan and the Grant Notice. 
 (a) “Administrator” shall mean the Board or the
Committee responsible for conducting the general administration of the Plan in accordance with Article 12 of the Plan; provided that if the Participant is an Independent Director, “Administrator” shall mean the Board. 

(b) “Termination of Consultancy” shall mean the time when the engagement of the Participant as a
Consultant to the Company or a Subsidiary is terminated for any reason, with or without cause, including, but not by way of limitation, by resignation, discharge, death or retirement, but excluding: (a) terminations where there is a
simultaneous employment or continuing employment of the Participant by the Company or any Subsidiary, and (b) terminations where there is a simultaneous re-establishment of a consulting relationship or continuing consulting relationship between
the Participant and the Company or any Subsidiary. The Administrator, in its absolute discretion, shall determine the effect of all matters and questions relating to Termination of Consultancy, including, but not by way of limitation, the question
of whether a particular leave of absence constitutes a Termination of Consultancy. Notwithstanding any other provision of the Plan, the Company or any Subsidiary has an absolute and unrestricted right to terminate a Consultant’s service at any
time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in writing. 
 (c)
“Termination of Directorship” shall mean the time when the Participant, if he or she is or becomes an Independent Director, ceases to be a Director for any reason, including, but not by way of limitation, a
termination by resignation, failure to be elected, death or retirement. The Board, in its sole and absolute discretion, shall determine the effect of all matters and questions relating to Termination of Directorship with respect to Independent
Directors. 
 (d) “Termination of Employment” shall mean the time when the employee-employer relationship between the
Participant and the Company or any Subsidiary is terminated for any reason, with or without cause, including, but not by way of limitation, a termination by resignation, discharge, death, disability or retirement; but excluding:
(a) terminations where there is a simultaneous reemployment or continuing employment of the Participant by the Company or any Subsidiary, and (b) terminations where there is a simultaneous establishment of a consulting relationship or
continuing consulting relationship between the Participant and the Company or any Subsidiary. The Administrator, in its absolute discretion, shall determine the effect of all matters and questions relating to Termination of Employment, including,
but not by way of limitation, the question of whether a particular leave of absence constitutes a Termination of Employment. 

  
 A-1 

 (e) “Termination of Services” shall mean the Participant’s
Termination of Consultancy, Termination of Directorship or Termination of Employment, as applicable. 
 1.2 Incorporation of Terms of
Plan. The Option is subject to the terms and conditions of the Plan which are incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control. 

ARTICLE II.  
 GRANT OF
OPTION 
 2.1 Grant of Option. In consideration of the Participant’s past and/or continued employment with or service to the
Company or a Subsidiary and for other good and valuable consideration, effective as of the Grant Date set forth in the Grant Notice (the “Grant Date”), the Company irrevocably grants to the Participant the Option to purchase
any part or all of an aggregate of the number of shares of Stock set forth in the Grant Notice, upon the terms and conditions set forth in the Plan and this Agreement. As designated in the Grant Notice, the Option shall be treated as a Non-Qualified
Stock Option. 
 2.2 Exercise Price. The exercise price of the shares of Stock subject to the Option shall be as set forth in the
Grant Notice, without commission or other charge; provided, however, that the price per share of the shares of Stock subject to the Option shall not be less than 100% of the Fair Market Value of a share of Stock on the Grant Date. 

2.3 Consideration to the Company. In consideration of the grant of the Option by the Company, the Participant agrees to render faithful
and efficient services to the Company or any Subsidiary. Nothing in the Plan or this Agreement shall confer upon the Participant any right to continue in the employ or service of the Company or any Subsidiary or shall interfere with or restrict in
any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of the Participant at any time for any reason whatsoever, with or without Cause, except to the extent
expressly provided otherwise in a written agreement between the Company or a Subsidiary and the Participant. 
 ARTICLE III. 

PERIOD OF EXERCISABILITY 

3.1 Commencement of Exercisability. 
  

(a) Subject to Sections 3.2, 3.3, 5.8 and 5.10, the Option shall become vested and exercisable in such amounts and at such times as are set
forth in the Grant Notice. 
 (b) No portion of the Option which has not become vested and exercisable at the date of the Participant’s
Termination of Employment, Termination of Directorship or Termination of Consultancy shall thereafter become vested and exercisable, except as may be otherwise provided by the Administrator or as set forth in a written agreement between the Company
and the Participant. 

  
 A-2 

 (c) Notwithstanding Sections 3.1(a) and 3.1(b), in the event of the occurrence of a Change of
Control, the Option shall become fully vested and exercisable. 
 3.2 Duration of Exercisability. The installments provided for in
the vesting schedule set forth in the Grant Notice are cumulative. Each such installment which becomes vested and exercisable pursuant to the vesting schedule set forth in the Grant Notice shall remain vested and exercisable until it becomes
unexercisable under Section 3.3. 
 3.3 Expiration of Option. The Option may not be exercised to any extent by anyone after the
first to occur of the following events: 
 (a) The expiration of seven years from the Grant Date; or 

(b) The expiration of one year from the date of the Participant’s Termination of Services for any reason. 

ARTICLE IV. 
 EXERCISE
OF OPTION 
 4.1 Person Eligible to Exercise. Except as provided in Sections 5.2(b) and 5.2(c), during the lifetime of the
Participant, only the Participant may exercise the Option or any portion thereof. After the death of the Participant, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section 3.3, be
exercised by the Participant’s personal representative or by any person empowered to do so under the deceased the Participant’s will or under the then applicable laws of descent and distribution. 

4.2 Partial Exercise. Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised in whole
or in part at any time prior to the time when the Option or portion thereof becomes unexercisable under Section 3.3. 
 4.3 Manner
of Exercise. The Option, or any exercisable portion thereof, may be exercised solely by delivery to the Secretary of the Company (or any third party administrator or other person or entity designated by the Company) of all of the following prior
to the time when the Option or such portion thereof becomes unexercisable under Section 3.3: 
 (a) An Exercise Notice in a form
specified by the Administrator, stating that the Option or portion thereof is thereby exercised, such notice complying with all applicable rules established by the Administrator; 

(b) The receipt by the Company of full payment for the shares of Stock with respect to which the Option or portion thereof is exercised,
including payment of any applicable withholding tax, which may be in one or more of the forms of consideration permitted under Section 4.4; 

(c) Any other written representations as may be required in the Administrator’s reasonable discretion to evidence compliance with the
Securities Act or any other applicable law rule, or regulation; and 
 (d) In the event the Option or portion thereof shall be exercised
pursuant to Section 4.1 by any person or persons other than the Participant, appropriate proof of the right of such person or persons to exercise the Option. 

  
 A-3 

 Notwithstanding any of the foregoing, the Company shall have the right to specify all conditions of the manner of
exercise, which conditions may vary by country and which may be subject to change from time to time. 
 4.4 Method of Payment.
Payment of the exercise price shall be by any of the following, or a combination thereof, at the election of the Participant: 
 (a) Cash;

 (b) Check; 
 (c) With the
consent of the Administrator, delivery of a notice that the Participant has placed a market sell order with a broker with respect to shares of Stock then issuable upon exercise of the Option, and that the broker has been directed to pay a sufficient
portion of the net proceeds of the sale to the Company in satisfaction of the aggregate exercise price; provided, that payment of such proceeds is then made to the Company upon settlement of such sale; 

(d) With the consent of the Administrator, surrender of other shares of Stock which (A) have been held for such period of time as the
Administrator may require in order to avoid adverse accounting consequences, and (B) have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the shares of Stock with respect to which the Option or portion
thereof is being exercised; 
 (e) With the consent of the Administrator, surrendered shares of Stock issuable upon the exercise of the
Option having a Fair Market Value on the date of exercise equal to the aggregate exercise price of the shares of Stock with respect to which the Option or portion thereof is being exercised; or 

(f) With the consent of the Administrator, property of any kind which constitutes good and valuable consideration. 

4.5 Conditions to Issuance of Stock Certificates. The shares of Stock deliverable upon the exercise of the Option, or any portion
thereof, may be either previously authorized but unissued shares of Stock or issued shares of Stock which have then been reacquired by the Company. Such shares of Stock shall be fully paid and nonassessable. The Company shall not be required to
issue or deliver any shares of Stock purchased upon the exercise of the Option or portion thereof prior to fulfillment of all of the following conditions: 

(a) The admission of such shares of Stock to listing on all stock exchanges on which such Stock is then listed; 

(b) The completion of any registration or other qualification of such shares of Stock under any state or federal law or under rulings or
regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable; 

(c) The obtaining of any approval or other clearance from any state or federal governmental agency which the Administrator shall, in its
absolute discretion, determine to be necessary or advisable; 

  
 A-4 

 (d) The receipt by the Company of full payment for such shares of Stock, including payment of any
applicable withholding tax, which may be in one or more of the forms of consideration permitted under Section 4.4; and 
 (e) The lapse
of such reasonable period of time following the exercise of the Option as the Administrator may from time to time establish for reasons of administrative convenience. 

4.6 Rights as Stockholder. The holder of the Option shall not be, nor have any of the rights or privileges of, a stockholder of the
Company in respect of any shares of Stock purchasable upon the exercise of any part of the Option unless and until such shares of Stock shall have been issued by the Company to such holder (as evidenced by the appropriate entry on the books of the
Company or of a duly authorized transfer agent of the Company). No adjustment will be made for a dividend or other right for which the record date is prior to the date the shares of Stock are issued, except as provided in Section 11.2 of the
Plan. 
 ARTICLE V. 

OTHER PROVISIONS 
 5.1
Administration. The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or
revoke any such rules. All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon Participant, the Company and all other interested persons. No member of the Committee or the
Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the Option. 

5.2 Option Not Transferable. 

(a) Subject to Section 5.2(b), the Option may not be sold, pledged, assigned or transferred in any manner other than by will or the laws
of descent and distribution, unless and until the shares of Stock underlying the Option have been issued, and all restrictions applicable to such shares of Stock have lapsed. Neither the Option nor any interest or right therein shall be liable for
the debts, contracts or engagements of Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be
voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to
the extent that such disposition is permitted by the preceding sentence. 
 (b) Notwithstanding any other provision in this Agreement, with
the consent of the Administrator, the Participant may transfer the Option (or any portion thereof) to any one or more Permitted Transferees (as defined below), subject to the following terms and conditions: (i) any portion of the Option
transferred to a Permitted Transferee shall not be assignable or transferable by the Permitted Transferee other than by will or the laws of descent and distribution; (ii) any portion of the Option which is transferred to a Permitted Transferee
shall continue to be subject to all the terms and conditions of the Option as applicable to the Participant (other than the ability to further transfer the Option); and (iii) the Participant and the Permitted Transferee shall execute any and
all documents requested by the Administrator, including, without limitation documents to (A) confirm the status of the transferee as a Permitted Transferee, (B) satisfy any requirements for an exemption for the transfer under applicable
federal and state securities laws and (C) evidence the transfer. For purposes of this Section 5.2(b), “Permitted Transferee” shall mean, with 

  
 A-5 

 
respect to a Participant, any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the Participant’s household (other than a tenant or employee), a trust in which these persons (or the Participant) control the management of
assets, and any other entity in which these persons (or the Participant) own more than fifty percent of the voting interests, or any other transferee specifically approved by the Administrator after taking into account any state or federal tax or
securities laws applicable to transferable Options. 
 (c) Unless transferred to a Permitted Transferee in accordance with
Section 5.2(b), during the lifetime of Participant, only Participant may exercise the Option or any portion thereof. Subject to such conditions and procedures as the Administrator may require, a Permitted Transferee may exercise the Option or
any portion thereof during Participant’s lifetime. After the death of Participant, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section 3.3, be exercised by Participant’s
personal representative or by any person empowered to do so under the deceased Participant’s will or under the then applicable laws of descent and distribution. 

5.3 Adjustments. The Participant acknowledges that the Option is subject to modification and termination in certain events as provided
in this Agreement and Article 11 of the Plan. 
 5.4 Notices. Any notice to be given under the terms of this Agreement to the Company
shall be addressed to the Company in care of the Secretary of the Company at the address given beneath the signature of the Company’s authorized officer on the Grant Notice, and any notice to be given to Participant shall be addressed to
Participant at the address given beneath Participant’s signature on the Grant Notice. By a notice given pursuant to this Section 5.4, either party may hereafter designate a different address for notices to be given to that party. Any
notice which is required to be given to Participant shall, if Participant is then deceased, be given to the person entitled to exercise his or her Option pursuant to Section 4.1 by written notice under this Section 5.4. Any notice shall be
deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service. 

5.5 Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this
Agreement. 
 5.6 Governing Law; Severability. The laws of the State of Delaware shall govern the interpretation, validity,
administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws. 

5.7 Conformity to Securities Laws. The Participant acknowledges that the Plan and this Agreement are intended to conform to the extent
necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, and state securities laws and regulations. Notwithstanding anything
herein to the contrary, the Plan shall be administered, and the Option is granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by applicable law, the Plan and this Agreement
shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. 
 5.8 Amendments, Suspension and
Termination. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board, provided, that, except as
may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the Option in any material way without the prior written consent of the Participant. 

  
 A-6 

 5.9 Successors and Assigns. The Company may assign any of its rights under this Agreement
to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in Section 5.2, this Agreement shall be binding upon
Participant and his or her heirs, executors, administrators, successors and assigns. 
 5.10 Limitations Applicable to Section 16
Persons. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Option and this Agreement shall be subject to any additional limitations set forth in any
applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, this
Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule. 
 5.11 Not a Contract of
Employment. Nothing in this Agreement or in the Plan shall confer upon the Participant any right to continue to serve as an employee or other service provider of the Company or any of its Subsidiaries. 

5.12 Entire Agreement. The Plan, the Grant Notice and this Agreement (including all Exhibits thereto) constitute the entire agreement
of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. 

5.13 Section 409A. Notwithstanding any other provision of the Plan, this Agreement or the Grant Notice, the Plan, this Agreement
and the Grant Notice shall be interpreted in accordance with, and incorporate the terms and conditions required by, Section 409A of the U.S. Internal Revenue Code of 1986, as amended (together with any Department of Treasury regulations and
other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, “Section 409A”). The Committee may, in its discretion, adopt such
amendments to the Plan, this Agreement or the Grant Notice or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Committee determines are necessary or
appropriate to comply with the requirements of Section 409A. 

  
 A-7EX-10.1

 EXHIBIT 10.1 

Portions Subject to Confidential Treatment Request Under Rule 24b-2 

Collaboration, Option and 

License Agreement 
 This Agreement is
entered into with effect as of the Effective Date (as defined below) 
 by and between 

F. Hoffmann-La Roche Ltd 
 with an office and place of
business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) 
 and 

Hoffmann-La Roche Inc. 
 with an office and place of
business at 340 Kingsland Street, Nutley, New Jersey 07110, U.S.A. (“Roche Nutley”; Roche Basel and Roche Nutley together referred to as “Roche”) 

on the one hand 
 and 

Inovio Pharmaceuticals, Inc. 
 with an office and place of
business at 1787 Sentry Parkway West, Building 18, Suite 400, Blue Bell, Pennsylvania 19422 U.S.A. (“Inovio”), 
 on the other hand. 

 Table of Contents 

 

									
	1.	 	Definitions	  	 	6	  
		 	1.1	 	 5150 Product
	  	 	6	  
		 	1.2	 	 Adjuvant
	  	 	6	  
		 	1.3	 	 Affiliate
	  	 	7	  
		 	1.4	 	 Agreement
	  	 	7	  
		 	1.5	 	 Agreement Term
	  	 	7	  
		 	1.6	 	 Antigen
	  	 	7	  
		 	1.7	 	 Bioequivalent Product
	  	 	7	  
		 	1.8	 	 BLA
	  	 	7	  
		 	1.9	 	 Calendar Quarter
	  	 	7	  
		 	1.10	 	 Calendar Year
	  	 	7	  
		 	1.11	 	 Change of Control
	  	 	7	  
		 	1.12	 	 Change of Control Group
	  	 	8	  
		 	1.13	 	 Clinical Study
	  	 	8	  
		 	1.14	 	 Collaboration IP
	  	 	8	  
		 	1.15	 	 Combination Product
	  	 	8	  
		 	1.16	 	 Commercially Reasonable Efforts
	  	 	8	  
		 	1.17	 	 Companion Diagnostic
	  	 	9	  
		 	1.18	 	 Compulsory Sublicense
	  	 	9	  
		 	1.19	 	 Compulsory Sublicensee
	  	 	9	  
		 	1.20	 	 Confidential Information
	  	 	9	  
		 	1.21	 	 Continuation Election Notice
	  	 	9	  
		 	1.22	 	 Control
	  	 	10	  
		 	1.23	 	 Cover
	  	 	10	  
		 	1.24	 	 Data Package
	  	 	10	  
		 	1.25	 	 Delivery Device
	  	 	10	  
		 	1.26	 	 Delivery Device Patents
	  	 	10	  
		 	1.27	 	 Development Plan
	  	 	10	  
		 	1.28	 	 DNA Plasmid
	  	 	10	  
		 	1.29	 	 Effective Date
	  	 	10	  
		 	1.30	 	 EMA
	  	 	11	  
		 	1.31	 	 Enabling Technologies
	  	 	11	  
		 	1.32	 	 Enabling Technology Patents
	  	 	11	  
		 	1.33	 	 EU
	  	 	11	  
		 	1.34	 	 Existing Agreements
	  	 	11	  
		 	1.35	 	 Expert
	  	 	11	  
		 	1.36	 	 FBMC
	  	 	11	  
		 	1.37	 	 FDA
	  	 	11	  
		 	1.38	 	 FDCA
	  	 	11	  
		 	1.39	 	 Field
	  	 	11	  
		 	1.40	 	 First Commercial Sale
	  	 	11	  
		 	1.41	 	 FTE
	  	 	11	  
		 	1.42	 	 FTE Rate
	  	 	12	  
		 	1.43	 	 GLP Tox
	  	 	12	  
		 	1.44	 	 GMP
	  	 	12	  
		 	1.45	 	 Group Sublicensee
	  	 	12	  
		 	1.46	 	 Handle
	  	 	12	  
		 	1.47	 	 HBV
	  	 	12	  
		 	1.48	 	 HBV Product
	  	 	12	  
		 	1.49	 	 IFRS
	  	 	12	  
		 	1.50	 	 IND
	  	 	12	  

  
 - 2 - 

									
		 	1.51	 	 Initiation
	  	 	13	  
		 	1.52	 	 Inovio 5150 Trial
	  	 	13	  
		 	1.53	 	 Inovio 5150 Trial Plan
	  	 	13	  
		 	1.54	 	 Inovio Background Patent Rights
	  	 	13	  
		 	1.55	 	 Inovio IP Rights
	  	 	13	  
		 	1.56	 	 Inovio Know-How
	  	 	13	  
		 	1.57	 	 Inovio Patent Rights
	  	 	13	  
		 	1.58	 	 Insolvency Event
	  	 	13	  
		 	1.59	 	 Invention
	  	 	13	  
		 	1.60	 	 Joint IP
	  	 	13	  
		 	1.61	 	 Joint Know-How
	  	 	14	  
		 	1.62	 	 Joint Patent Rights
	  	 	14	  
		 	1.63	 	 JSC
	  	 	14	  
		 	1.64	 	 Know-How
	  	 	14	  
		 	1.65	 	 Net Sales
	  	 	14	  
		 	1.66	 	 Oncology Product
	  	 	14	  
		 	1.67	 	 Option Period
	  	 	14	  
		 	1.68	 	 Option Right
	  	 	14	  
		 	1.69	 	 Orphan Drug Product
	  	 	15	  
		 	1.70	 	 Party
	  	 	15	  
		 	1.71	 	 Patent Rights
	  	 	15	  
		 	1.72	 	 Phase I Study
	  	 	15	  
		 	1.73	 	 Phase II Study
	  	 	15	  
		 	1.74	 	 Phase III Study
	  	 	15	  
		 	1.75	 	 Product
	  	 	15	  
		 	1.76	 	 RC Product
	  	 	15	  
		 	1.77	 	 Regulatory Approval
	  	 	15	  
		 	1.78	 	 Regulatory Authority
	  	 	16	  
		 	1.79	 	 Research Plan
	  	 	16	  
		 	1.80	 	 Research Program
	  	 	16	  
		 	1.81	 	 Roche Group
	  	 	16	  
		 	1.82	 	 Roche IP Rights
	  	 	16	  
		 	1.83	 	 Roche Know-How
	  	 	16	  
		 	1.84	 	 Roche Patent Rights
	  	 	16	  
		 	1.85	 	 Royalty Term
	  	 	16	  
		 	1.86	 	 Sales
	  	 	17	  
		 	1.87	 	 Sphergen Cross-License
	  	 	17	  
		 	1.88	 	 Sublicensee
	  	 	17	  
		 	1.89	 	 Territory
	  	 	17	  
		 	1.90	 	 Third Party
	  	 	18	  
		 	1.91	 	 Third Party Product
	  	 	18	  
		 	1.92	 	 UPenn Agreement
	  	 	18	  
		 	1.93	 	 UPenn Patent Rights
	  	 	18	  
		 	1.94	 	 US
	  	 	18	  
		 	1.95	 	 US$
	  	 	18	  
		 	1.96	 	 Valid Claim
	  	 	18	  
		 	1.97	 	 VGXI Supply Agreement
	  	 	18	  
		 	1.98	 	 Additional Definitions
	  	 	18	  
	2.	 	Research Collaboration	  	 	19	  
		 	2.1	 	 Conduct of the Research Programs
	  	 	19	  
		 	2.2	 	 Records; Reports
	  	 	21	  

  
 - 3 - 

									
	3.	 	Licenses and Exclusive Option Right	  	 	22	  
		 	3.1	 	 Research Cross License
	  	 	22	  
		 	3.2	 	 5150 Product Development and Commercialization License
	  	 	22	  
		 	3.3	 	 License to Inovio for Improvements to Inovio Background Technology
	  	 	22	  
		 	3.4	 	 Option Right
	  	 	23	  
		 	3.5	 	 Retained Rights
	  	 	24	  
	4.	 	Governance	  	 	24	  
		 	4.1	 	 Joint Steering Committee
	  	 	24	  
		 	4.2	 	 Members
	  	 	25	  
		 	4.3	 	 Responsibilities of the JSC
	  	 	25	  
		 	4.4	 	 Meetings
	  	 	25	  
		 	4.5	 	 Minutes
	  	 	26	  
		 	4.6	 	 Decisions
	  	 	26	  
		 	4.7	 	 Alliance Director
	  	 	26	  
		 	4.8	 	 Limitations of Authority
	  	 	26	  
		 	4.9	 	 Expenses
	  	 	27	  
		 	4.10	 	 Lifetime
	  	 	27	  
	5.	 	Clinical Development and Commercialization	  	 	27	  
		 	5.1	 	 Development
	  	 	27	  
		 	5.2	 	 Regulatory Responsibility
	  	 	28	  
		 	5.3	 	 Supply in General
	  	 	28	  
		 	5.4	 	 Development and Supply of Delivery Devices
	  	 	30	  
		 	5.5	 	 GMP
	  	 	32	  
		 	5.6	 	 Commercialization
	  	 	32	  
		 	5.7	 	 Diligence
	  	 	32	  
		 	5.8	 	 Updates to Inovio
	  	 	32	  
	6.	 	Payment	  	 	32	  
		 	6.1	 	 Option Signing and Exclusivity Fee
	  	 	32	  
		 	6.2	 	 Research and Development Support Payments
	  	 	33	  
		 	6.3	 	 Development Event Payments
	  	 	33	  
		 	6.4	 	 First Commercial Sale Event Payments
	  	 	35	  
		 	6.5	 	 Sales Based Payments
	  	 	35	  
		 	6.6	 	 Roche Royalty Payments
	  	 	36	  
		 	6.7	 	 Disclosure of Payments
	  	 	39	  
	7.	 	Accounting and reporting	  	 	39	  
		 	7.1	 	 Invoices
	  	 	39	  
		 	7.2	 	 DSRP Reports for Development Support Payments
	  	 	39	  
		 	7.3	 	 Timing of Payments
	  	 	39	  
		 	7.4	 	 Late Payment
	  	 	39	  
		 	7.5	 	 Method of Payment
	  	 	40	  
		 	7.6	 	 Currency Conversion
	  	 	40	  
		 	7.7	 	 Royalty Reports
	  	 	40	  
	8.	 	Taxes	  	 	40	  
	9.	 	Auditing	  	 	40	  
		 	9.1	 	 Right to Audit
	  	 	40	  
		 	9.2	 	 Audit reports
	  	 	41	  
		 	9.3	 	 Over-or Underpayment
	  	 	41	  
		 	9.4	 	 Duration of Audit Rights
	  	 	41	  
	10.	 	Intellectual Property	  	 	42	  
		 	10.1	 	 Disclosure of Inventions
	  	 	42	  
		 	10.2	 	 Ownership of Inventions
	  	 	42	  
		 	10.3	 	 German Statute on Employee’s Inventions
	  	 	42	  
		 	10.4	 	 Prosecution of Patent Rights Covering Inventions
	  	 	42	  

  
 - 4 - 

									
		 	10.5	 	 CREATE Act
	  	 	43	  
		 	10.6	 	 Infringement
	  	 	43	  
		 	10.7	 	 Defense
	  	 	44	  
		 	10.8	 	 Common Interest Disclosures
	  	 	44	  
		 	10.9	 	 Hatch-Waxman
	  	 	45	  
		 	10.10	 	 Biosimilar or interchangeable biological products
	  	 	45	  
		 	10.11	 	 Patent Term Extensions
	  	 	45	  
	11.	 	Representations, Warranties and Covenants	  	 	46	  
		 	11.1	 	 Inovio Representations, Warranties and Covenants
	  	 	46	  
		 	11.2	 	 Roche Representations, Warranties and Covenants
	  	 	47	  
	12.	 	Indemnification	  	 	48	  
	13.	 	Liability	  	 	49	  
	14.	 	Obligation Not to Disclose Confidential Information	  	 	49	  
		 	14.1	 	 Non-Use and Non-Disclosure
	  	 	49	  
		 	14.2	 	 Permitted Disclosure
	  	 	49	  
		 	14.3	 	 Press Releases
	  	 	49	  
		 	14.4	 	 Publications
	  	 	50	  
		 	14.5	 	 Commercial Considerations
	  	 	50	  
	15.	 	Term and Termination	  	 	51	  
		 	15.1	 	 Commencement and Term
	  	 	51	  
		 	15.2	 	 Termination
	  	 	51	  
		 	15.3	 	 Consequences of Termination
	  	 	52	  
		 	15.4	 	 Survival
	  	 	56	  
	16.	 	Miscellaneous	  	 	56	  
		 	16.1	 	 Bankruptcy
	  	 	56	  
		 	16.2	 	 Change of Control
	  	 	56	  
		 	16.3	 	 Governing Law
	  	 	57	  
		 	16.4	 	 Disputes
	  	 	57	  
		 	16.5	 	 Arbitration
	  	 	57	  
		 	16.6	 	 Assignment
	  	 	57	  
		 	16.7	 	 Debarment
	  	 	57	  
		 	16.8	 	 Independent Contractor
	  	 	57	  
		 	16.9	 	 Unenforceable Provisions and Severability
	  	 	58	  
		 	16.10	 	 Waiver
	  	 	58	  
		 	16.11	 	 Appendices
	  	 	58	  
		 	16.12	 	 Entire Understanding
	  	 	58	  
		 	16.13	 	 Amendments
	  	 	58	  
		 	16.14	 	 Invoices
	  	 	58	  
		 	16.15	 	 Notice
	  	 	59	  

  
 - 5 - 

 Collaboration, Option and License Agreement 

WHEREAS, Inovio has developed novel SynCon® DNA vaccine construct technology that may enable
development of synthetic DNA vaccines targeted against, among other things, cancers (including the DNA vaccine known as INO-5150) and hepatitis B virus (including the DNA vaccine known as INO-1800); and 

WHEREAS, Inovio has expertise in the research, development, and manufacture of electroporation-based DNA delivery technology; and 

WHEREAS, Roche has expertise in the research, development, manufacture and commercialization of pharmaceutical and diagnostic products; and 

WHEREAS, Roche and Inovio are willing to conduct a research program in the field of oncology, with a focus on prostate cancer, for the development of a DNA
vaccine for potential development and commercialization by Roche; and 
 WHEREAS, Inovio is willing to grant to Roche an exclusive option for an exclusive
license for Roche to make, use, offer for sale, sell and import and export certain DNA vaccines, including the use of Inovio’s electroporation-based DNA delivery technology; and 

WHEREAS, Inovio is willing to grant to Roche an exclusive license for Roche to make, use, offer for sale, sell and import and export DNA vaccines based on
INO-1800 that are directed to hepatitis B viral infections and INO-5150 that are directed to prostate cancer, including the use of Inovio’s electroporation-based DNA delivery technology, as contemplated herein. 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: 
  

	1.	Definitions 

 As used in this Agreement, the following terms, whether used in the singular or plural,
shall have the following meanings: 
  

	1.1	5150 Product 

 The term “5150 Product” shall mean a product that contains as an active
ingredient at least one (1) DNA Plasmid that encodes for an engineered PSA and/or PSMA found in the Inovio DNA vaccine known as INO-5150. 
  

	1.2	Adjuvant 

 The term “Adjuvant” shall mean a substance contained in a vaccine or delivered
separately to increase a patient’s immune response to the antigen(s) found in or encoded by such vaccine. Adjuvants include, but are not limited to, DNA plasmids encoding an immunomodulatory molecule, such as IL-12. 

  
 - 6 - 

	1.3	Affiliate 

 The term “Affiliate” shall mean any individual, corporation, association or other
business entity that directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of Affiliate, the term “control” shall mean the direct or indirect ownership of more
than fifty percent (>50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting securities, by contract,
resolution, regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, Chugai Pharmaceutical Co., Ltd, a Japanese corporation (“Chugai”), shall not be deemed an Affiliate of Roche unless Roche provides
written notice to Inovio of its desire to include Chugai as an Affiliate of Roche. 
  

	1.4	Agreement 

 The term “Agreement” shall mean this document including any and all appendices and
amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement. 
  

	1.5	Agreement Term 

 The term “Agreement Term” shall mean the period of time commencing on the
Effective Date and, unless this Agreement is terminated sooner as provided in Article 15, expiring on the date when no royalty or other payment obligations to Inovio under this Agreement are or will become due. 

 

	1.6	Antigen 

 The term “Antigen” shall mean a distinct and uniquely identifiable macromolecule that
is capable, under appropriate conditions, of inducing a specific immune response, and shall include peptides, proteins, protein-constructs, and post-translational modifications or variants of such macromolecules, as well as other immunogens derived
therefrom. 
  

	1.7	Bioequivalent Product 

 The term “Bioequivalent Product” shall mean, with respect to a given
Product sold in a given country of the Territory by Roche, its Affiliate or Sublicensee, a product sold by a Third Party in such country that is approved as a biosimilar or interchangeable biological product under 42 U.S.C. 262(k) or equivalent
Regulatory Approval outside the US. 
  

	1.8	BLA 

 The term “BLA” shall mean a Biologics License Application, or similar application for
marketing approval of the Products for use in the Field submitted to the FDA, or a foreign equivalent of the FDA. 
  

	1.9	Calendar Quarter 

 The term “Calendar Quarter” shall mean each period of three
(3) consecutive calendar months, ending March 31, June 30, September 30, and December 31. 
  

	1.10	Calendar Year 

 The term “Calendar Year” shall mean the period of time beginning on
January 1 and ending December 31, except for the first year which shall begin on the Effective Date and end on December 31. 
  

	1.11	Change of Control 

 The term “Change of Control” shall mean, with respect to a Party:
(a) the acquisition by any Third Party of beneficial ownership of fifty percent (50%) or more of the then outstanding common shares or voting power of such Party, other than acquisitions by employee benefit

  
 - 7 - 

 
plans sponsored or maintained by such Party; (b) the consummation of a business combination involving such Party, unless, following such business combination, the stockholders of such Party
immediately prior to such business combination beneficially own directly or indirectly more than fifty percent (50%) of the then outstanding common shares or voting power of the entity resulting from such business combination; or (c) the
sale of all or substantially all of such Party’s assets or business relating to the subject matter of the Agreement. 
  

	1.12	Change of Control Group 

 The term “Change of Control Group” shall mean with respect to a
Party, the person or entity, or group of persons or entities, that is the acquirer of, or a successor to, a Party in connection with a Change of Control, together with affiliates of such persons or entities that are not Affiliates of such Party
immediately prior to the completion of such Change of Control of such Party. 
  

	1.13	Clinical Study 

 The term “Clinical Study” shall mean a Phase I Study, a Phase II Study or a
Phase III Study, as applicable. 
  

	1.14	Collaboration IP 

 The term “Collaboration IP” shall mean all information, Inventions, Know-How
(whether or not patentable), including but not limited to, data and results and deliverables, which are first conceived, reduced to practice, or otherwise first made, discovered, or created pursuant to the activities conducted under a Research
Program or pursuant to a Development Plan either by (i) Inovio or its Affiliates, and/or their employees, contractors or agents (including Inovio Inventions), or (ii) jointly by the Parties, and/or their Affiliates, and/or their employees,
contractors or agents (including Joint Inventions). 
  

	1.15	Combination Product 

 The term “Combination Product” shall mean 

 

	a)	a single pharmaceutical formulation containing as its active ingredients both (i) the DNA Plasmid(s) found in a Product and (ii) one or more other therapeutically or prophylactically active ingredients,

  

	b)	a combination therapy comprised of (i) the DNA Plasmid(s) found in a Product and (ii) one or more other therapeutically or prophylactically active products, priced and sold in a single package containing such
multiple products, or 

  

	c)	a combination therapy comprised of (i) the DNA Plasmid(s) found in a Product and (ii) one or more other therapeutically or prophylactically active products, packaged separately but sold together for a single
price, 

 in each case, including all dosage forms, formulations, presentations, line extensions, and package configurations. All references
to Product in this Agreement shall be deemed to include Combination Product. 
  

	1.16	Commercially Reasonable Efforts 

 The term “Commercially Reasonable Efforts” shall mean such
level of efforts required to carry out such obligation in sustained manner consistent with the efforts Roche or Inovio, as applicable, devotes at the same stage of research, development or commercialization, as applicable, for its own internally
developed pharmaceutical products in a similar area with similar market potential, at a similar stage of their product life taking into account the existence of other competitive products in the market place or under development, the proprietary
position of the product, the regulatory structure involved, the anticipated profitability of the product and other relevant factors. It is understood that such product potentially may change from time to time based upon changing scientific, business
and marketing and return on investment considerations, and that Roche and its Affiliates do not always seek to market its own products 

  
 - 8 - 

 
in every country or seek to obtain regulatory approval in every country or for every potential indication. As a result, the exercise of diligence by Roche is to be determined by judging
Roche’s commercially reasonable efforts, taken as a whole. 
  

	1.17	Companion Diagnostic 

 The term “Companion Diagnostic” shall mean any product that is used for
predicting and/or monitoring the response of a human being to treatment with a Product (e.g. device, compound, kit, biomarker or service that contains a component that is used to detect or quantify the presence or amount of an analyte in body or
tissue that affects the pathogens of the disease, etc.). 
  

	1.18	Compulsory Sublicense 

 The term “Compulsory Sublicense” shall mean a sublicense granted to a
Third Party, through an order, decree or grant of a governmental authority having competent jurisdiction, authorizing such Third Party to manufacture, use, sell, offer for sale, import or export a Product in a country or countries in the Territory.

  

	1.19	Compulsory Sublicensee 

 The term “Compulsory Sublicensee” shall mean the sublicensee of a
Compulsory Sublicense. 
  

	1.20	Confidential Information 

 The term “Confidential Information” shall mean any and all
information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates (“Disclosing Party”) to the other Party or its Affiliates (“Receiving
Party”). Confidential Information shall not include any information, data or know-how that: 
  

	 	(i)	was generally available to the public at the time of disclosure, or information that becomes available to the public after disclosure by the Disclosing Party other than through fault (whether by action or inaction) of
the Receiving Party or its Affiliates, 

  

	 	(ii)	can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior to its receipt from the Disclosing Party, 

 

	 	(iii)	is obtained at any time lawfully from a Third Party under circumstances permitting its use or disclosure, 

  

	 	(iv)	is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than through knowledge of Confidential Information, 

 

	 	(v)	is required to be disclosed by the Receiving Party of its Affiliates to comply with a court or administrative order providing the Receiving Party or its Affiliates furnishes prompt notice (in no event less than three
(3) days) to the Disclosing Party to enable it to resist such disclosure, or 

  

	 	(vi)	is approved in writing by the Disclosing Party for release by the Receiving Party. 

 Subject to
(i)-(vi) above, the terms of this Agreement and Collaboration IP shall be considered Confidential Information of all Parties. 
  

	1.21	Continuation Election Notice 

 The term “Continuation Election Notice” shall mean the notice
Inovio provides to Roche under to Section 15.3.1 or 15.3.3 describing (i) Inovio’s bona fide intention to continue ongoing development and commercialization of Termination Product(s) and (ii) Inovio’s request for
Roche’s continuation of activities during the termination period and/or transfer of the data, material and information relating to the Termination Product(s) in accordance with Section 15.3.1 or 15.3.3. 

  
 - 9 - 

	1.22	Control 

 The term “Control” shall mean (as an adjective or as a verb including conjugations
and variations such as “Controls” “Controlled” or “Controlling”) (a) with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights
and/or Know-How without violating the terms of any agreement or arrangement between such Party and any other party and (b) with respect to proprietary materials, the possession by a Party of the ability to supply such proprietary materials to
the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. 
  

	1.23	Cover 

 The term “Cover” shall mean (as an adjective or as a verb including conjugations and
variations such as “Covered,” “Coverage” or “Covering”) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given compound, formulation or product would infringe a
Valid Claim in the absence of a license under the Patent Rights to which such Valid Claim pertains. The determination of whether a compound, formulation, process or product is Covered by a particular Valid Claim shall be made on a country-by-country
basis. 
  

	1.24	Data Package 

 The term “Data Package” shall mean, with respect to a Termination Product, all
material information in Roche’s Control that relates to the safety, efficacy, toxicity and potential adverse effects related to the Termination Product, and all Regulatory Approvals and filings therefor for the Termination Product. 

 

	1.25	Delivery Device 

 The term “Delivery Device” shall mean an electroporation-based DNA delivery
device developed using Inovio’s proprietary DNA delivery technology necessary or useful for the delivery of a Product. Delivery Device shall include all future versions and delivery devices developed by Inovio, jointly by the Parties, or by
Roche in connection with the exercise of Roche’s option to optimize the Delivery Device in accordance with Section 5.4.3. 
  

	1.26	Delivery Device Patents 

 The term “Delivery Device Patents” shall mean all patent rights owned
or Controlled by Inovio which Cover the Delivery Device. 
  

	1.27	Development Plan 

 The term “Development Plan” shall mean any plan for collaborative clinical
development of a Product outlining the work expected to be performed by Inovio and Roche, as such plan may be updated from time to time as provided in this Agreement. There may be more than one (1) Development Plan, including, for example:
(i) a 5150 Product Development Plan, (ii) RC Product Development Plan(s), and (iii) an HBV Product Development Plan. 
  

	1.28	DNA Plasmid 

 The term “DNA Plasmid” shall mean a plasmid that encodes for at least one
(1) Antigen and was either (i) selected by Inovio and provided to Roche under this Agreement, or (ii) was synthesized by or on behalf of a Party in the course of a Research Program hereunder. For example, the DNA Plasmids in the 5150
Product encode engineered PSA and PSMA, and the DNA Plasmids in the HBV Product encode HBV consensus core protein, HBV clade A consensus large surface antigen, and HBV clade C surface consensus large surface antigen. 

 

	1.29	Effective Date 

 The term “Effective Date” shall mean September 9, 2013. 

  
 - 10 - 

	1.30	EMA 

 The term “EMA” shall mean the European Medicines Agency or any successor agency with
responsibilities comparable to those of the European Medicines Agency. 
  

	1.31	Enabling Technologies 

 The term “Enabling Technologies” shall mean (a) DNA leader
sequences, (b) DNA Adjuvants, and/or (c) DNA vectors. 
  

	1.32	Enabling Technology Patents 

 The term “Enabling Technology Patents” shall mean all Patent
Rights owned or Controlled by Inovio which Cover the Enabling Technologies, a complete list of Enabling Technology Patents as of the Effective Date is set forth in Appendix 1.54. 

 

	1.33	EU 

 The term “EU” shall mean the European Community and all its then current member countries.

  

	1.34	Existing Agreements 

 The term “Existing Agreements” shall mean the UPenn Agreement, Sphergen
Cross-License, and VGXI Supply Agreement. 
  

	1.35	Expert 

 The term “Expert” shall mean a person with no less than ten (10) years of
pharmaceutical industry experience and expertise having occupied at least one senior position within a large pharmaceutical company relating to product development and/or licensing but excluding any current or former employee or consultant of either
Party. Such person shall be fluent in the English language. 
  

	1.36	FBMC 

 The term “FBMC” shall mean Inovio’s fully burdened manufacturing cost as such
calculated on a consistent basis by Inovio in accordance with generally accepted accounting practices. 
  

	1.37	FDA 

 The term “FDA” shall mean the US Food and Drug Administration. 

 

	1.38	FDCA 

 The term “FDCA” shall mean the US Food, Drug and Cosmetics Act. 

 

	1.39	Field 

 The term “Field” shall mean all uses. 

 

	1.40	First Commercial Sale 

 The term “First Commercial Sale” shall mean, on a country-by-country
basis, the first invoiced sale of a Product to a Third Party by the Roche Group following the receipt of any Regulatory Approval required for the sale of such Product, or if no such Regulatory Approval is required, the date of the first invoiced
sale of a Product to a Third Party by the Roche Group in such country. 
  

	1.41	FTE 

 The term “FTE” shall mean a full-time equivalent person-year, based upon a total of no
less than one thousand eight hundred (1,800) working hours per year, undertaken in connection with the conduct of research in the Research Program. In no circumstance can the work of any given person exceed one (1) FTE. 

  
 - 11 - 

	1.42	FTE Rate 

 The term “FTE Rate” shall mean a fully burdened rate ‘’’’ ‘’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’
‘’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’ ‘’’’’’’’’’’ ‘’’’’’’’’
‘’’’’’’’’’’’, and incorporates all of Inovio’s internal costs for performing its obligations under the Research Plan. The FTE Rate
includes the costs of infrastructure and supplies used in the ordinary course of providing such services (including consumables). 
  

	1.43	GLP Tox 

 The term “GLP Tox” shall mean a toxicology study that is conducted in compliance with
Good Laboratory Practice and is intended to be used or is actually used to meet the requirements for filing an IND. 
  

	1.44	GMP 

 The term “GMP” shall mean Good Manufacturing Practice according to the then current
guidelines of the ICH (International Conference on Harmonization of Technical Requirement for Registration of Pharmaceuticals for Human Use). 
  

	1.45	Group Sublicensee 

 The term “ Group Sublicensee” shall mean any Sublicensee that is
(i) not an Affiliate of Roche; (ii) directly or indirectly controlled by Roche; and (iii) consolidated within Roche’s externally published audited financial statements. The term “control” in the previous sentence means
the direct or indirect ownership of more than fifty percent (>50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the
ownership of voting securities, by contract, resolution, regulation or otherwise. 
  

	1.46	Handle 

 The term “Handle” shall mean preparing, filing, prosecuting (including interference
and opposition proceedings) and maintaining (including interferences, reissue, re-examination, post grant reviews, inter partes reviews, and opposition proceedings), whether in-house or through an external law firm. 

 

	1.47	HBV 

 The term “HBV” shall mean hepatitis B virus. 

 

	1.48	HBV Product 

 The term “HBV Product” shall mean a product that contains as an active ingredient
at least one (1) DNA Plasmid that encodes for HBV consensus core protein and/or HBV clade A consensus large surface antigen and/or HBV clade C consensus large surface antigen found in the Inovio DNA vaccine known as INO-1800. 

 

	1.49	IFRS 

 The term “IFRS” shall mean International Financial Reporting Standards. 

 

	1.50	IND 

 The term “IND” shall mean an application as defined in the FDCA and applicable
regulations promulgated by the FDA, or the equivalent application to the equivalent agency in any other country or group of countries, the filing of which is necessary to commence clinical testing of the Products in humans. 

  
 - 12 - 

	1.51	Initiation 

 The term “Initiation” shall mean with respect to a Clinical Study, the date that a
human is first dosed with the Product in a Clinical Study approved by the respective Regulatory Authority. 
  

	1.52	Inovio 5150 Trial 

 The term “Inovio 5150 Trial” shall mean that Phase I Study conducted in
accordance with the Inovio 5150 Trial Plan and consistent with Section 5.1.1. 
  

	1.53	Inovio 5150 Trial Plan 

 The term “Inovio 5150 Trial Plan” shall mean the plan for the conduct
of the Inovio 5150 Trial, including the budget, which is current and agreed as of the Effective Date . 
  

	1.54	Inovio Background Patent Rights 

 The term “Inovio Background Patent Rights” shall mean all
Patent Rights owned or Controlled by Inovio as of the Effective Date and during the Agreement Term which are useful or necessary to research, develop, manufacture or commercialize Products and Delivery Devices, including the Delivery Device Patents
and Enabling Technology Patents, associated therewith, a complete listing of these patent rights as of the Effective Date are set forth in Appendix 1.54 in which such Patent Rights are categorized as Product Patents, Device Patents, and Enabling
Technology Patents. 
  

	1.55	Inovio IP Rights 

 The term “Inovio IP Rights” shall mean the Inovio Patent Rights and Inovio
Know-How. 
  

	1.56	Inovio Know-How 

 The term “Inovio Know-How” shall mean the Know-How that Inovio Controls at
the Effective Date and during the Agreement Term. 
  

	1.57	Inovio Patent Rights 

 The term “Inovio Patent Rights” shall mean the Inovio Background Patent
Rights and any Patent Rights claiming an Inovio Invention. 
  

	1.58	Insolvency Event 

 The term “Insolvency Event” shall mean circumstances under which a Party
(i) has a receiver or similar officer appointed over all or a material part of its assets or undertaking; (ii) passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation
or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction); (iii) enters into any composition or arrangement with its creditors (other than relating to
a solvent restructuring); (iv) ceases to carry on business; (v) is unable to pay its debts as they become due in the ordinary course of business. 
  

	1.59	Invention 

 The term “Invention” shall mean an invention that is conceived or reduced to
practice in connection with any activity carried out pursuant to this Agreement. Under this definition, an Invention may be made by employees or consultants of Inovio solely or jointly with a Third Party (an “Inovio Invention”), by
employees or consultants of the Roche Group solely or jointly with a Third Party (a “Roche Invention”), or jointly by employees or consultants of Inovio and a member of the Roche Group with or without a Third Party (a “Joint
Invention”). 
  

	1.60	Joint IP 

 The term “Joint IP” shall mean the Joint Patent Rights and Joint Know-How. 

  
 - 13 - 

	1.61	Joint Know-How 

 The term “Joint Know-How” shall mean Know-How that is made jointly by the
Parties or their Affiliates or their Sublicensees in connection with any activity carried out pursuant to this Agreement. 
  

	1.62	Joint Patent Rights 

 The term “Joint Patent Rights” shall mean all Patent Rights Covering a
Joint Invention or an Inovio Invention jointly owned by Inovio and Roche. 
  

	1.63	JSC 

 The term “JSC” shall mean, as applicable, one or both of the joint steering committees
described in Article 4. 
  

	1.64	Know-How 

 The term “Know-How” shall mean data, knowledge and information, including materials,
samples, chemical manufacturing data, toxicological data, pharmacological data, preclinical data, assays, platforms, formulations, specifications, quality control testing data, that are necessary or useful for the discovery, manufacture, development
or commercialization of Products. 
  

	1.65	Net Sales 

 The term “Net Sales” shall mean, for a Product in a particular period, the amount
calculated by subtracting from the Sales of such Product for such period: (i) a lump sum deduction of four percent (4%) of Sales in lieu of those deductions that are not accounted for on a Product-by-Product basis (e.g., freight,
postage charges, transportation insurance, packing materials for dispatch of goods, custom duties); (ii) uncollectible amounts accrued during such period based on a proportional allocation of the total bad debts accrued during such period and
not already taken as a gross-to-net deduction in accordance with the then currently used IFRS in the calculation of Sales of such Product for such period; (iii) credit card charges (including processing fees) accrued during such period on such
Sales and not already taken as a gross-to-net deduction in accordance with the then currently used IFRS in the calculation of Sales of such Product for such period; and (iv) government mandated fees and taxes and other government charges
accrued during such period not already taken as a gross-to-net deduction in accordance with the then currently used IFRS in the calculation of Sales of such Product for such period, including, for example, any fees, taxes or other charges that
become due in connection with any healthcare reform, change in government pricing or discounting schemes, or other action of a government or regulatory body. 
  

	1.66	Oncology Product 

 The term “Oncology Product” shall mean a 5150 Product or an RC Product. 

 

	1.67	Option Period 

 The term “Option Period” shall mean the period of time beginning on the
Effective Date and continuing until six (6) months after Roche receives a final report following expiration or termination of the Oncology Research Program. 
  

	1.68	Option Right 

 The term “Option Right” shall mean the option right granted to Roche in
Section 3.4.1 of this Agreement. 

  
 - 14 - 

	1.69	Orphan Drug Product 

 The term “Orphan Drug Product” shall mean, with respect to a given
Product sold in a given country of the Territory by Roche, its Affiliate or Sublicensee, a product sold by a Third Party in such country that is approved as an orphan drug under the Orphan Drug Action of 1983, as amended (or successor law or
regulation), or equivalent regulatory approval granted by another Regulatory Authority. 
  

	1.70	Party 

 The term “Party” shall mean Inovio or Roche, as the case may be, and
“Parties” shall mean Inovio and Roche collectively. 
  

	1.71	Patent Rights 

 The term “Patent Rights” shall mean all rights under any patent or patent
application, in any country of the Territory, including any patents issuing on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division,
continuation or continuation-in-part of any of the foregoing. 
  

	1.72	Phase I Study 

 The term “Phase I Study” shall mean a human clinical trial in any country that
would satisfy the requirements of 21 C.F.R. § 312.21(a) (FDCA), as amended from time to time, and the foreign equivalent thereof. 
  

	1.73	Phase II Study 

 The term “Phase II Study” shall mean a human clinical trial, for which the
primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  

	1.74	Phase III Study 

 The term “Phase III Study” shall mean a human clinical trial that is
prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as
described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof. 
  

	1.75	Product 

 The term “Product” shall mean any product that is a 5150 Product, RC Product, and/or
HBV Product, regardless of its finished form or formulation or dosage. A Product may optionally include one or more Adjuvants. Product does not include the Delivery Device. 
  

	1.76	RC Product 

 The term “RC Product” means a product containing or comprising a vaccine first
reduced to practice under the Oncology Research Collaboration, which is directed to an RC Target for which Roche has exercised its Option Right and does not contain a DNA Plasmid that encodes for the engineered PSA and/or PSMA encoded by the Inovio
DNA vaccine known as INO-5150. 
  

	1.77	Regulatory Approval 

 The term “Regulatory Approval” shall mean any approvals (including
pricing and reimbursement approvals), licenses, registrations or authorizations by Regulatory Authority, necessary for the manufacture and sale of a Product in the Field in a regulatory jurisdiction in the Territory. 

  
 - 15 - 

	1.78	Regulatory Authority 

 The term “Regulatory Authority” shall mean any national, supranational
(e.g., the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country
involved in the granting of Regulatory Approval for the Product. 
  

	1.79	Research Plan 

 The term “Research Plan” shall mean the plans of research and preclinical
development that is current and agreed as of the Effective Date, outlining the work expected to be performed by Inovio and Roche, as such plan may be updated from time to time as provided in this Agreement. There shall be two (2) Research
Plans: (i) Oncology Research Plan, and (ii) HBV Research Plan. 
  

	1.80	Research Program 

 The term “Research Program” shall mean the activities undertaken by the
Parties pursuant to a Research Plan to identify and preclinically develop DNA vaccines, and such other activities as the Parties may agree in writing. There are envisaged two (2) Research Programs: (i) an Oncology Research Program, and
(ii) an HBV Research Program. As used herein, the term “Research Program” shall be deemed to mean either or both the Oncology Research Program and the HBV Research Program, as applicable. 

 

	1.81	Roche Group 

 The term “Roche Group” shall mean collectively Roche, its Affiliates and its
Sublicensees. 
  

	1.82	Roche IP Rights 

 The term “Roche IP Rights” shall mean the Roche Know-How and Roche Patent
Rights. 
  

	1.83	Roche Know-How 

 The term “Roche Know-How” shall mean all Know-How that Roche Controls during
the Agreement Term and which is necessary for the development or commercialization of Products. 
  

	1.84	Roche Patent Rights 

 The term “Roche Patent Rights” shall mean all Patent Rights Covering a
Product or Improvements to Inovio Background Technology that Roche Controls (excluding via licenses granted to Roche from Inovio under this Agreement) during the Agreement Term. For purposes of clarity, the Patent Rights identified in Appendix 1.84
are specifically excluded from the Roche Patent Rights. 
  

	1.85	Royalty Term 

 The term “Royalty Term” shall mean, with respect to a Product and for a given
country, the period of time commencing on the date of First Commercial Sale of the Product in such country and ending on the later of the date that is (a) ten (10) years after the date of the First Commercial Sale of the Product in such
country, or (b) the expiration of the last to expire Inovio Patent Right or Joint Patent Right in such country Covering the use, import, offering for sale, or sale of the Product in such country. With regard to the calculation of the ten
(10) year period, the EU shall be considered as one country, provided there is a centralized EMA regulatory filing. 

  
 - 16 - 

	1.86	Sales 

 The term “Sales” shall mean, for a Product in a particular period, the sum of
(i) and (ii): 
 i) the amount stated in Roche “Sales” line of its externally published audited financial statements with
respect to such Product for such period (excluding sales to any Sublicensees that are not Affiliates of Roche). This amount reflects the gross invoice price at which such Product was sold or otherwise disposed of (other than for use as clinical
supplies or free samples) by Roche, its Affiliates and Group Sublicensees to such Third Parties (excluding sales to any Sublicensees that are not Affiliates of Roche) in such period reduced by gross-to-net deductions, if not previously deducted from
such invoiced amount, taken in accordance with the then currently used IFRS. 
 By way of example, the gross-to-net deductions taken in
accordance with IFRS as of the Effective Date include the following: 
  

	 	a)	credits, reserves or allowances granted for (i) damaged, outdated, returned, rejected, withdrawn or recalled Product, (ii) wastage replacement and short-shipments; (iii) billing errors and
(iv) indigent patient and similar programs (e.g., price capitation); 

  

	 	b)	governmental price reductions and government mandated rebates; 

  

	 	c)	chargebacks, including those granted to wholesalers, buying groups and retailers; 

  

	 	d)	customer rebates, including cash sales incentives for prompt payment, cash and volume discounts; and 

  

	 	e)	taxes, duties and any other governmental charges or levies imposed upon or measured by the import, export, use, manufacture or sale of a Product (excluding income or franchise taxes). 

For the purpose of clarity, sales by Roche and its Affiliates to any Third Party Sublicensee and Group Sublicensee shall be excluded from “Sales”.

 ii) for Sublicensees, excluding Compulsory Sublicensees, that are not Roche Affiliates, the sales amounts reported to Roche and its
Affiliates in accordance with the Sublicensee’s contractual terms and their then-currently used accounting standards. Sales under a Compulsory Sublicense shall be excluded from Sales, and instead shall be addressed in accordance with
Section 6.6.2.7. 
  

	1.87	Sphergen Cross-License 

 The term “Sphergen Cross-License” shall mean the agreement between
Sphergen, having its registered office at Genopole Enterprise 4 rue Pierre Fontaine 91058 Evry cedex, and Genetronics, Inc., a wholly owned subsidiary of Inovio, dated May 3, 2006, as amended. 

 

	1.88	Sublicensee 

 The term “Sublicensee” shall mean an entity to which Roche or its Affiliates have
licensed rights pursuant to this Agreement. 
  

	1.89	Territory 

 The term “Territory” shall mean all countries of the world. 

  
 - 17 - 

	1.90	Third Party 

 The term “Third Party” shall mean a person or entity other than (i) Inovio
or any of its Affiliates or (ii) a member of the Roche Group. 
  

	1.91	Third Party Product 

 The term “Third Party Product” shall mean a Bioequivalent Product or
Orphan Drug Product. 
  

	1.92	UPenn Agreement 

 The term “UPenn Agreement” shall mean the agreement between VGX
Pharmaceuticals, Inc. (a fully owned subsidiary of Inovio) and the Trustees of the University of Pennsylvania dated April 16, 2007, as amended. 
  

	1.93	UPenn Patent Rights 

 The term “UPenn Patent Rights” shall mean all Patent Rights Controlled by
Inovio by virtue of the UPenn Agreement. 
  

	1.94	US 

 The term “US” shall mean the United States of America and its territories and possessions.

  

	1.95	US$ 

 The term “US$” shall mean US dollars. 

 

	1.96	Valid Claim 

 The term “Valid Claim” shall mean, as applicable, a claim in any
(i) unexpired and issued patent encompassed by the Inovio Patent Rights that has not been disclaimed, revoked or held invalid by a final nonappealable decision of a court of competent jurisdiction or government agency or (ii) pending
patent application in any country of the Territory that (a) is on file with the applicable patent office and has shown evidence of reasonably consistent activity to advance to issuance of a patent and (b) which application is on file with
the applicable patent office for no more than seven (7) years from the earliest date to which the patent application claims its earliest priority. 
  

	1.97	VGXI Supply Agreement 

 The term “VGXI Supply Agreement” shall mean the agreement among VGXI,
Inc., VGX International, Inc., and VGX Pharmaceuticals, Inc. dated June 28, 2008, as amended. 
  

	1.98	Additional Definitions 

 Each of the following definitions is set forth in the Section of this Agreement
indicated below: 
  

			
	 Definition
	  	 Section

	5150 Development Support Payments	  	5.1.2.1
	Accounting Period	  	7.1
	Alliance Director	  	4.7
	Bankruptcy Code	  	16.1
	Breaching Party	  	15.2.1
	CAPA Plan	  	5.4.1
	Chairperson	  	4.2
	Decision Period	  	10.5
	Development and Commercialization License	  	3.2
	Device Supply Agreements	  	5.4.2
	Disclosing Party	  	1.18
	DSRP Report	  	7.2

  
 - 18 - 

			
	 Definition
	  	 Section

	EEC	  	1.52
	EH&S	  	5.5
	Enabling Technologies	  	1.31
	HBV Development and Commercialization License	  	3.4.4
	H-W Suit Notice	  	10.9
	Improvements to Inovio Background Patent Rights	  	3.3
	Indemnified Party	  	12.3
	Indemnifying Party	  	12.3
	Initiating Party	  	10.5
	Joint Invention	  	1.59
	Members	  	4.2
	Inovio Invention	  	1.59
	Non-Breaching Party	  	15.2.1
	Option Period	  	1.66
	Patent Term Extensions	  	10.11
	Payment Currency	  	7.5
	Peremptory Notice Period	  	15.2.1
	Product Supply Agreements	  	5.3.1
	Publishing Notice	  	14.4
	Publishing Party	  	14.4
	RC Adjuvant	  	2.1.3.1
	RC Development and Commercialization License	  	3.4.3
	RC Targets	  	2.1.3.1
	Receiving Party	  	1.18
	Reference Product Sponsor	  	10.10
	Research Term	  	2.1.6
	Roche Invention	  	1.59
	Samples	  	15.3.1(a)
	Sensitive Information	  	16.2
	Settlement	  	10.5
	SPCs	  	10.11
	Suit Notice	  	10.5
	Termination Product	  	15.3.1
	Third Party Offset	  	6.6.2.6

  

	2.	Research Collaboration 

  

	2.1	Conduct of the Research Programs 

  

	2.1.1	Scope 

 Roche and Inovio shall conduct mutually agreed Research Programs pursuant to the Research Plans. There
shall be an Oncology Research Program and an HBV Research Program. The activities conducted in connection with the Research Program will be overseen by the applicable JSC. 

  
 - 19 - 

	2.1.2	Diligent Efforts 

 Roche and Inovio shall each use Commercially Reasonable Efforts to perform their respective
tasks and obligations in conducting all activities ascribed to it in the then-current Research Plan, in accordance with the time parameters set forth therein. 
  

	2.1.3	Research Plans 

 The appropriate JSC will agree upon any updates or changes to the relevant Research Plan,
including required deliverables from Inovio. Each Research Plan will set forth (i) the scope of the relevant Research Program and the resources that will be dedicated to the activities contemplated within the scope of the relevant Research
Program, including the responsibilities of each Party, (ii) specific objectives for each year, which objectives will be updated or amended, as appropriate, by the appropriate JSC as research progresses, (iii) detailed budgets for such
activities, (iv) Inovio personnel assigned to the core team and the assignment of other Inovio personnel from specified functional areas, and (v) any activities to be performed by Third Party contractors. The appropriate JSC shall review
the relevant Research Plan on an ongoing basis and may amend the Research Plan. Any such changes shall be reflected in written amendments to the relevant Research Plan 
  

	 	2.1.3.1	Oncology Research Plan 

 The objective of the Oncology Research Plan is to establish a research collaboration on
up to five (5) Antigen targets (“RC Targets”) with primary activity in oncology indications and up to two (2) Adjuvants (“RC Adjuvants”) to be nominated by Roche and mutually agreed by the Parties. If,
during the Research Term, the Parties discontinue work on one or more RC Targets or RC Adjuvants, then Roche may nominate an Antigen target or Adjuvant to replace each discontinued RC Target or Adjuvant, as applicable. Roche and Inovio shall
collaborate to develop DNA vaccines directed to the RC Targets in accordance with the mutually agreed Oncology Research Plan. 
  

	 	2.1.3.2	HBV Research Plan 

 The objective of the HBV Research Plan is to further research and develop the INO-1800 DNA
vaccine and potentially backup DNA vaccines based thereon. 
  

	 	2.1.3.3	Funded Inovio FTEs. 

‘’’’’’’’’’’’’’
‘’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’ ‘’’’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’’’’’’’ ‘’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’ of the research and other
activities for which Inovio is responsible under the Oncology Research Plan. Each individual included in the funded FTEs shall possess a bachelor’s degree or higher in a relevant scientific discipline and shall be experienced in the type
of research or other activities to be performed by such individual under the Research Plan. At Roche’s request, Inovio shall provide resumes or curricula vitae for funded FTEs in order for Roche to ensure such individuals have the
appropriate qualifications. 
  

	 	2.1.3.4	Third Party Contractors. 

 If specified in the Research Plan, or agreed to in writing by the JSC, Inovio may use
Third Party contractors to perform Inovio’s activities under the Research Plan, provided Inovio shall ensure such activities are subject to a written agreement under which such third party contractor assigns and/or exclusively licenses all
right, title and interest in the results of such activities to Inovio. 
  

	2.1.4	Personnel 

 The Inovio personnel assigned to work on the Research Plan shall comprise a core team which will be
dedicated to such plan. Inovio shall use the collaboration funding it receives from Roche 

  
 - 20 - 

 
solely to carry out its activities under a Research Program in accordance with this Agreement. Roche, upon request of Inovio and at Roche’s discretion, may provide in-kind contributions to
Inovio. 
  

	2.1.5	Exclusivity 

 Inovio shall work exclusively with Roche on the RC Targets and Products during the Research Term
and, if applicable, the Option Period. For clarity, RC Target exclusivity extends beyond the uniquely identifiable gene product encoded by a DNA Plasmid to post-translational modifications or variants of such product, as well as proteins,
protein-constructs, peptides and other immunogens derived therefrom. This Section 2.1.5 shall not limit Inovio’s right to use the Delivery Device or Enabling Technologies in connection with other products that are not Products. 

 

	2.1.6	Research Term 

 Each Research Program shall commence on the Effective Date and shall continue until (i) for
the Oncology Research Program, three (3) years unless terminated earlier in accordance with the other provisions of this Agreement, or (ii) for the HBV Research Program, until the completion or cessation of the activities under the HBV
Research Plan. The duration of each Research Program is its research term (“Research Term”). 
  

	2.2	Records; Reports 

  

	2.2.1	Progress Reports 

 At least quarterly during the Research Term for each Research Program, Inovio shall prepare
and provide to the JSC a detailed written report summarizing the progress of the work performed by Inovio in the course of the Research Program during the preceding Calendar Quarter. Within sixty (60) days after completion or cessation of the
HBV Research Program, Inovio shall provide to Roche a final written report summarizing its activities under the HBV Research Program, including any material data and information generated in the course of the HBV Research Program not previously
provided to Roche. With regard to the Oncology Research Program, with respect to each RC Target, within sixty (60) days after completion or cessation of the Oncology Research Plan activities related to such RC Target, Inovio will provide to
Roche a written final report summarizing its activities under the Oncology Research Program related to such RC Target, including any material data and information generated in the course of the Oncology Research Program not previously provided to
Roche. 
  

	2.2.2	Materials 

 During the Research Term and, if applicable, the Option Period, at Roche’s request, Inovio will
provide Roche with reasonable quantities of those vaccines or other materials generated during the Oncology Research Program to allow Roche to conduct activities related to the Research Program and as necessary or useful for determining whether to
exercise its option for a RC Target. 
  

	2.2.3	Research Records 

 Each Party shall maintain records of the Research Programs (or cause such records to be
maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of the Research Programs. All laboratory notebooks shall be maintained for no
less than the term of any Patent Rights issuing therefrom. 

  
 - 21 - 

	3.	Licenses and Exclusive Option Right 

  

	3.1	Research Cross License 

 Each Party grants to the other Party, on a Research Program-by-Research Program
basis, a non-exclusive right and license under Know-How and Patent Rights Controlled by such Party and that are necessary or useful for performing the activities assigned under the applicable Research Plan. 

 

	3.2	5150 Product Development and Commercialization License 

 Inovio hereby grants to Roche: 

a) a sole and exclusive (even as to Inovio), worldwide, irrevocable, royalty-bearing right and license (with the right to sublicense through
multiple tiers) under the Inovio IP Rights and Inovio’s interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made import, have
imported, export, have exported, market, have marketed, distribute, have distribute, offer to sell, sell and have sold 5150 Products in the Field in the Territory; and 

b) an exclusive, worldwide, irrevocable, royalty-free right and license (with the right to sublicense through multiple tiers) under the Inovio IP Rights and Inovio’s interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop,
have developed, register, have registered, use, have used, make, have made import, have imported, export, have exported, market, have marketed, distribute, have distribute, offer to sell, sell and have sold Delivery Devices and Enabling Technologies
for the sole purpose of use in connection with 5150 Product(s) in the Field in the Territory; and 
 c) a sole and exclusive (even as
to Inovio), worldwide, irrevocable, royalty-free right and license (with the right to sublicense through multiple tiers) under the
Inovio Patent Rights and Inovio Know-How and Inovio’s interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made import, have
imported, export, have exported, market, have marketed, distribute, have distribute, offer to sell, sell and have sold Companion Diagnostics for 5150 Products in the Field in the Territory. 

d) Roche hereby grants to the Inovio a non-exclusive right and license under Know-How and Patent Rights Controlled by Roche and that are
necessary or useful for performing the activities assigned to Inovio under the 5150 Product Development Plan. 
  

	3.3	License to Inovio for Improvements to Inovio Background Technology 

 Roche hereby grants to Inovio a
non-exclusive, worldwide, irrevocable, sub licensable license under those patent rights Controlled by Roche that claim a Roche Invention, to make, use, sell, offer for sale and import inventions that are both (i) improvements to inventions
Covered by Device Patents and Enabling Technology Patents within the Inovio Background Patent Rights and (ii) conceived, reduced to practice, or otherwise first made, discovered, or created pursuant to the activities conducted under a Research
Program or pursuant to a Development Plan by Roche or its Affiliates, and/or their employees, contractors or agents (“Improvements to Inovio Background Patent Rights”). This license shall be royalty-free unless Roche has expended
more than ‘’’’’’’’’’’ ‘’’’’’’’’’’’’’
‘’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ in the development of the Delivery Device, in which case the license shall be on commercially reasonable terms to be negotiated in good faith by the Parties. Inovio shall have the right to use Improvements to
Inovio Background 

  
 - 22 - 

 
Patent Rights in Third Party collaborations provided that ‘’’’’
‘’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’
‘’’’’’’’’’’ ‘’’’’ ‘’’’’’’’’’’’’’ ‘’’
‘’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’ ‘’’’’’’’’’ ‘’’’’ ‘’’’’’’’’’’’ ‘’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’
‘’’’’’’’’’’’’’’’’’’ ‘’’’’ ‘’’’’’’’’
‘’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’ ‘’’’’’ ‘’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’ ‘’’’ ‘’’’’’’’’’
‘’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’
‘’’’’’’’’’ ‘’’’’’ ‘’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’ ‘’’’’’’
‘’’’’’’’’’’’’ ‘’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’ ‘’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’
‘’’’’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’
‘’’’’’’’’ ‘’’’’’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’’’’ ‘’’’’’’’’’’ ‘’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’ ‘’’’’’’
‘’’’’’’’’’’’’’’ ‘’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’ ‘’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’ Notwithstanding anything to the contrary,
Improvements to Inovio Background Patent Rights exclude the right to research, have researched, develop, have developed, register, have registered, use, have used, make, have made import, have imported, export, have exported, market,
have marketed, distribute, have distribute, offer to sell, sell and have sold Products and Companion Diagnostics. 
  

	3.4	Option Right 

  

	3.4.1	Grant of Option Right 

 For each RC Target included under the Oncology Research Program, Inovio hereby grants to
Roche during the Option Period an exclusive right to obtain the RC Development and Commercialization License set forth in Section 3.4.3 (the “Option Right”). 

 

	3.4.2	Exercise of Option Right 

 On a RC Target-by-RC Target basis, Roche shall have the right to exercise the Option
Right at any time during the Option Period by giving a written notice to Inovio indicating the RC Target(s) (including any associated Product(s)) selected by Roche to be included in the RC Development and Commercialization License. At the end of the
exclusive Option Period (including any extensions thereof), Roche’s Option Right shall expire. 
  

	3.4.3	RC Development and Commercialization License 

 For any RC Target(s) that Roche selects to exercise its Option
Right in accordance with Section 3.4.2, which upon exercise, Products directed to each such RC Target then shall be referred to as an RC Product; Inovio hereby grants to Roche: 

a) a sole and exclusive (even as to Inovio), worldwide, irrevocable, royalty-bearing right and license (with the right to sublicense through
multiple tiers) under the Inovio IP Rights and Inovio’s interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made import, have
imported, export, have exported, market, have marketed, distribute, have distribute, offer to sell, sell and have sold (i) such RC Products and/or (ii) Products directed to such RC Target, in each case (i) and (ii) in the Field
in the Territory; and 
 b) an exclusive, worldwide, irrevocable,
royalty-free right and license (with the right to sublicense through multiple tiers) under the Inovio Patent Rights and Inovio
Know-How and Inovio’s interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made import, have imported, export, have exported, market,
have marketed, distribute, have distribute, offer to sell, sell and have sold Delivery Devices and Enabling Technologies for the sole purpose of use in connection with (i) such RC Product(s) and/or (ii) Products directed to such RC Target
in each case (i) and (ii) in the Field in the Territory; and 

  
 - 23 - 

 c) a sole and exclusive (even as to Inovio), worldwide, irrevocable, royalty-free right and license (with the right to sublicense through multiple tiers) under the Inovio IP Rights and Inovio’s interest
in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made import, have imported, export, have exported, market, have marketed, distribute, have
distribute, offer to sell, sell and have sold Companion Diagnostics for (i) such RC Products and/or (ii) Products directed to such RC Target, in each case (i) and (ii) in the Field in the Territory (a, b, and c, collectively, the
“RC Development and Commercialization License”). 
  

	3.4.4	HBV Development and Commercialization License 

 Inovio hereby grants to Roche: 

a) a sole and exclusive (even as to Inovio), worldwide, irrevocable, royalty-bearing right and license (with the right to sublicense through
multiple tiers) under the Inovio IP Rights and Inovio’s interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have
imported, export, have exported, market, have marketed, distribute, have distribute, offer to sell, sell and have sold HBV Products in the Field in the Territory; and 

b) an exclusive, worldwide, irrevocable, royalty-free right and license (with the right to sublicense through multiple tiers) under the Inovio IP Rights and Inovio’s interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop,
have developed, register, have registered, use, have used, make, have made import, have imported, export, have exported, market, have marketed, distribute, have distribute, offer to sell, sell and have sold Delivery Devices and Enabling Technologies
for the sole purpose of use in connection with HBV Product(s) in the Field in the Territory; and 
 c) a sole and exclusive (even as
to Inovio), worldwide, irrevocable, royalty-free right and license (with the right to sublicense through multiple tiers) under the
Inovio IP Rights and Inovio’s interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made import, have imported, export, have exported,
market, have marketed, distribute, have distribute, offer to sell, sell and have sold Companion Diagnostics for HBV Products in the Field in the Territory (a, b, and c, collectively, the “HBV Development and Commercialization
License”). 
  

	3.5	Retained Rights 

 At the end of the Option Period, Inovio shall retain all rights under Inovio’s
interest in the Inovio IP Rights; and Inovio’s interest in the Joint Patent Rights and Joint Know-How to any RC Targets generated by Inovio under the Oncology Research Program and not selected by Roche in exercising its Option Right. 

 

	4.	Governance 

  

	4.1	Joint Steering Committee 

 Within thirty (30) days after the Effective Date of this Agreement, the
Parties shall establish a JSC for each of the Oncology Research Program and the HBV Research Program to oversee the research activities under this Agreement. If a Research Program moves to development, and the Parties agree to conduct joint
development activities, then the JSC for such Research Program shall continue for the duration of any joint development activities related to such development activities. For clarity, the JSC shall oversee the presently planned Phase I Study and the
timing of the transition of clinical activities to Roche. 

  
 - 24 - 

	4.2	Members 

 Each JSC shall be composed of an equal number of persons (“Members”) from each
Party. Roche and Inovio each shall appoint Members with appropriate seniority and functional expertise. The number of Members on the JSC shall be decided by the mutual agreement of the Parties based on the needs of the JSC. Each Party may replace
any of its Members and appoint a person to fill the vacancy arising from each such replacement. A Party that replaces a Member shall notify the other Party at least ten (10) days prior to the next scheduled meeting of the JSC. Both Parties
shall use Commercially Reasonable Efforts to keep an appropriate level of continuity in representation. Both Parties may invite a reasonable number of additional experts and/or advisors to attend part or the whole JSC meeting with prior notification
to the JSC. Members may be represented at any meeting by another person designated by the absent Member. The JSC shall be chaired by a Roche Member (“Chairperson”). 

 

	4.3	Responsibilities of the JSC 

 Each JSC shall have the responsibility and authority to: 

 

	a)	approve the Research Plan and Development Plan, if applicable, and associated budgets; 

  

	b)	revise and approve any revisions to the Research Plan and Development Plan, if applicable, and associated budgets; 

  

	c)	review and oversee the Research Program and execution of the Research Plan, and the development activities under any agreed upon Development Plan, if applicable; 

 

	d)	revise and approve any revisions to the CAPA Plan; 

  

	e)	review and oversee the execution of the CAPA Plan, and the implementation of any activities under the CAPA Plan and subsequent auditing and rectifying activities, if applicable; 

 

	f)	discuss in-kind contributions from Roche; 

  

	g)	review all data arising out of the Research Program or joint development activities; 

  

	h)	review manufacturing activities and plans directed to developing manufacturing capability and capacity; 

  

	i)	monitor and advise on activities related to the development, manufacture and supply of the Delivery Device; 

  

	j)	make decisions on the Research Plan and Development Plan, if applicable, and associated budgets; 

  

	k)	monitor and implement the transfer of Inovio Know-How to Roche; 

  

	l)	create subcommittees to the extent necessary for the governance and operation of the activities under this Agreement; and 

  

	m)	attempt to resolve any disputes on an informal basis. 

 The JSC shall have no responsibility and authority
other than that expressly set forth in this section. 
  

	4.4	Meetings 

 The Chairperson or his/her delegate shall be responsible for sending invitations and agendas
for all JSC meetings to all Members at least ten (10) days before the next scheduled meeting of 

  
 - 25 - 

 
the JSC. The venue for the meetings shall be agreed by the JSC. The JSC shall hold meetings at least four (4) times per Calendar Year, either in person or by tele-/video-conference, and in
any case as frequently as the Members of the JSC may agree shall be necessary. 
  

	4.5	Minutes 

 The Chairperson shall be responsible for designating a Member to record in reasonable detail
and circulate draft minutes of JSC meetings to all members of the JSC for comment and review within twenty (20) days after the relevant meeting. The Members of the JSC shall have ten (10) days to provide comments. The Party preparing the
minutes shall incorporate timely received comments and distribute finalized minutes to all Members of the JSC within thirty-five (35) days of the relevant meeting. The Chairperson shall approve the final version of the minutes before its
distribution. 
  

	4.6	Decisions 

  

	4.6.1	Decision Making Authority 

 The JSC shall decide matters within its responsibilities set forth in
Section 4.3. 
  

	4.6.2	Consensus; Good Faith 

 The Members of the JSC shall act in good faith to cooperate with one another and seek
agreement with respect to issues to be decided by the JSC. The Parties shall endeavor to make decisions by consensus. 
  

	4.6.3	Failure to Reach Consensus 

 If the JSC is unable to decide a matter by consensus, then 

a) Roche shall have the final decision authority on any matter with respect to Products that are subject to a Development and Commercialization
License; and 
 b) Roche shall have the final decision authority on any matter under a Research Plan or Development Plan that Roche is
funding; and 
 c) all other matters shall be referred to the Chief Executive Officer of Inovio or equivalent position or his/her nominee and
the Head of Roche Partnering or equivalent position or his/her nominee for resolution, who together shall use reasonable and good faith efforts to reach a decision by consensus within thirty (30) days after the date such matter is referred to
them. If the Parties still fail to reach a decision within such thirty (30) days, then the final decision shall be Roche’s, which shall be exercised in good faith. Any such decision shall constitute a decision of the JSC. 

 

	4.7	Alliance Director 

 Each Party shall appoint one person to be the point of contact within each Party with
responsibility for facilitating communication and collaboration between the Parties (each, an “Alliance Director”). The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable
the JSC to reach consensus and avert escalation of such issues or potential disputes. 
  

	4.8	Limitations of Authority 

 The JSC shall have no authority to amend or waive any terms of this Agreement.

  
 - 26 - 

	4.9	Expenses 

 Each Party shall be responsible for its own expenses including travel and accommodation costs
incurred in connection with the JSC. 
  

	4.10	Lifetime 

 The JSC shall exist during the Option Period and for so long as the Parties agree to conduct
joint development activities. 
  

	5.	Clinical Development and Commercialization 

  

	5.1	Development 

  

	5.1.1	Standards for Development 

 Inovio shall conduct all development activities assigned to it under this Agreement
using Commercially Reasonable Efforts in compliance with all applicable laws and regulations. If Inovio files an IND for any clinical study contemplated by this Agreement, then Inovio shall (i) provide Roche with an opportunity to review the
IND prior to Inovio’s initial submission and (ii) make any reasonable revision or amendment to the IND requested by Roche. At the conclusion of any such clinical study, Inovio shall prepare and deliver to Roche a clinical study report
detailing the data generated and summarizing the results of such clinical study. Inovio shall keep Roche informed of all communications with Regulatory Authorities and any data and results associated with all such clinical studies, whether generated
in such study or peripheral to such study. At Roche’s written request, Inovio shall transfer those INDs it has filed for the clinical studies contemplated by this Agreement to Roche and thereafter Roche shall be responsible for running the
study in cooperation with Inovio and the appropriate JSC. At Roche’s request and expense, Inovio shall cooperate and assist Roche as reasonably requested in providing feedback or performing agreed upon activities in accordance with the relevant
Development Plan. 
  

	5.1.2	Development of Oncology Products 

  

	 	5.1.2.1	Development of 5150 Product 

 Inovio shall be responsible for filing the mutually agreed IND for the Inovio 5150
Trial and for operational execution of the Inovio 5150 Trial in cooperation with Roche via the JSC. If, after filing the IND, additional toxicology studies are required for the 5150 Product, then Inovio shall conduct these studies, in cooperation
with Roche, at Inovio’s expense. Roche shall reimburse Inovio for (a) actual costs and expenses incurred for activities performed in the conduct of the Inovio 5150 Trial, provided that in no event shall the total amount reimbursed by Roche
exceed one hundred ten percent (110%) of the total budget amount that is current and agreed as of the Effective Date, or as otherwise approved by the JSC, for the conduct of the Inovio 5150 Trial; and (b) costs and expenses actually
incurred by Inovio in the conduct of any other development activities expressly authorized by the JSC under the 5150 Product Development Plan and set forth in the budget provided that in no event shall the total amount reimbursed by Roche exceed one
hundred ten percent (110%) of such budget (which costs will not include the aforementioned toxicology study) ((a) and (b) together, the “5150 Development Support Payments”). 

 

	 	5.1.2.2	Development of RC Products 

 Unless otherwise agreed by the Parties in writing, Roche shall be solely
responsible, at its own expense, for filing the IND and for all other development and commercialization activities concerning RC Products, including conducting clinical trials, regulatory submissions, sales and marketing. At Roche’s request and
expense, Inovio shall cooperate and assist Roche as reasonably requested in the clinical development of such Products in accordance with the relevant Development Plan. 

  
 - 27 - 

	5.1.3	Development of HBV Products 

 Unless otherwise agreed by the Parties in writing, Roche shall be solely
responsible, at its own expense, for all clinical and commercial development and commercialization activities concerning HBV Products, including conducting clinical trials, regulatory submissions, sales and marketing, except Inovio shall be
responsible for filing the mutually agreed IND for the first INO-1800 Phase I Study, and for operational execution of the first INO-1800 Phase I Study in cooperation with Roche via the JSC. Roche shall reimburse Inovio for (a) actual costs and
expenses incurred for activities performed in the conduct of the first INO-1800 Phase I Study and approved by the JSC together with a budget, provided that in no event shall the total amount reimbursed by Roche exceed one hundred ten percent
(110%) of such budget; and (b) costs and expenses actually incurred by Inovio in the conduct of any other development activities expressly authorized by the JSC under the HBV Development Plan and its associated budget, provided that in no
event shall the total amount reimbursed by Roche exceed one hundred ten percent (110%) of such budget. 
  

	5.2	Regulatory Responsibility 

 Except as set forth in Section 5.1.1, Roche, at its sole cost, shall
pursue all regulatory affairs related to Products in the Territory including the preparation and filing of applications for regulatory approval, as well as any or all governmental approvals required to develop, have developed, make, have made, use,
have used, manufacture, have manufactured, import, have imported, sell and have sold Products. Roche shall be responsible for pursuing, compiling and submitting all regulatory filing documentation, and for interacting with regulatory agencies, for
all Products in the Territory. Roche or its Affiliates shall own and file in their discretion all regulatory filings and regulatory approvals for all Products in the Territory. Roche, at its sole cost, shall report to appropriate authorities in
accordance with local requirements all adverse events related to use of Products in the Territory. 
  

	5.3	Supply in General 

  

	5.3.1	In General 

 Roche shall have the right to assume any and all manufacturing and supply responsibilities for
Products at its sole discretion. Manufacture by Inovio pursuant to this agreement may be conducted by Inovio or by Inovio’s Third Party manufacturer provided (i) such Third Party manufacturer is obligated to supply in a manner consistent
with the terms and conditions of this Agreement and (ii) Inovio shall be responsible for any breach of these obligations by such Third Party manufacturer. The Parties anticipate that they and/or the Third Party manufacturer and/or their
Affiliates will enter into additional agreements that are reasonable and customary in connection with supplying the Products (“Product Supply Agreements”), including manufacturing and quality agreements. The Product Supply
Agreements shall contain terms and conditions consistent with this Agreement, in addition to other terms that are reasonable and customary, including provisions to ensure quality and audit by or on behalf of Roche. 

 

	5.3.2	Oncology Product Supply 

  

	 	5.3.2.1	Preclinical Supply 

 Unless otherwise expressly stated in the applicable Research Plan and associated budget,
Inovio shall be responsible, at its own expense, for the preclinical manufacture (and, if requested or contemplated by the Research Plan, supply to Roche) of DNA Plasmid (i.e. the active pharmaceutical ingredient), Adjuvant, and the Delivery Device,
for use under the Oncology Research Plan. 

  
 - 28 - 

	 	5.3.2.2	Early Clinical Supply 

  

	 	5.3.2.2.1	5150 Product 

 Inovio shall be responsible for the manufacture and supply of the 5150 Product and the Delivery
Device for use in the clinical development of the 5150 Product, including the completion of the Inovio 5150 Trial. For 5150 Product and Delivery Device manufactured after the Effective Date, Roche shall reimburse Inovio for such manufacture and
supply at Inovio’s FBMC or the actual amount paid by Inovio to its current Inovio’s Third Party manufacturer. 
  

	 	5.3.2.2.2	RC Product 

 At Roche’s Request, Inovio shall be responsible for the manufacture and supply of DNA Plasmid
(i.e. the active pharmaceutical ingredient), Adjuvant, and/or the Delivery Device to Roche, an Affiliate, or to a Third Party identified by Roche for use in the clinical development of any RC Product. Such manufacture and supply shall be provided at
Inovio’s FBMC or the actual amount paid by Inovio to its current Inovio’s Third Party manufacturer. 
  

	 	5.3.2.3	Pivotal Trial and Commercial Supply 

 Roche shall consider Inovio as a supplier for the commercial manufacture
of DNA Plasmid and/or Adjuvant and/or the Delivery Device, provided that Inovio can demonstrate that it is able to supply Roche with its commercial requirements on commercially reasonable terms. If Inovio is not chosen as a supplier for Roche, and,
even if Inovio is chosen as a supplier in order to enable a manufacturing process for DNA Plasmid, Adjuvant and/or the Delivery Device to Roche, or to an Affiliate or Third Party identified by Roche, technology transfer activities will be governed
by a technology transfer agreement under commercially reasonable terms. 
  

	5.3.3	HBV Product Supply 

  

	 	5.3.3.1	Preclinical Supply 

 Unless otherwise expressly stated in the applicable Research Plan and associated budget
with regard to external costs, Inovio shall be responsible, at its own expense, for the preclinical manufacture (and, if requested or contemplated by the Oncology Research Plan, supply to Roche) of DNA Plasmid (i.e. the active pharmaceutical
ingredient), Adjuvant, and the Delivery Device. 
  

	 	5.3.3.2	Early Clinical Supply 

 Inovio shall manufacture and supply HBV Product and the Delivery Device for Roche for
use in the clinical development of the HBV Product. Roche shall reimburse Inovio for such manufacture and supply at Inovio’s FBMC and/or the actual amount paid by Inovio to its current Inovio’s Third Party manufacturer. 

 

	 	5.3.3.3	Pivotal Trial and Commercial Supply 

 Roche shall consider Inovio as a supplier for the commercial manufacture
of DNA Plasmid and/or Adjuvant and/or the Delivery Device, provided that Inovio can demonstrate that it is able to supply Roche with its commercial requirements on commercially reasonable terms. If Inovio is not chosen as a supplier for Roche, and,
even if Inovio is chosen as a supplier in order to enable a manufacturing process for DNA Plasmid and the Delivery Device to Roche, or to an Affiliate or Third Party identified by Roche, technology transfer activities will be governed by a
technology transfer agreement under commercially reasonable terms. 

  
 - 29 - 

	5.3.4	Transfer of Manufacturing Technology 

 At any time during the term, following notice from Roche, (i) Inovio
shall use diligent efforts to transfer to Roche and/or its Affiliates and/or a Third Party manufacturer designated by Roche, ‘’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’’’’’’’’’’’ ‘’’’’ ‘’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’ ‘’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’ ‘’’’’
‘’’’’’’ ‘’’’’’’’’’ ‘’’’’ ‘’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’ ‘’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’ ‘’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’
‘’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’ ‘’’’
‘’’’’’’’’’’’ ‘’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’ ‘’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’ and (ii) Inovio shall use diligent efforts to assign or license to Roche and/or its Affiliates and/or a Third Party manufacturer designated by Roche’’ ‘’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’ ‘’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’
‘’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’
‘’’’’ ‘’’’’’’’ ‘’’’’’’’’’’ ‘’’’’ ‘’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’
‘’’’’ ‘’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’ ‘’’’
‘’’’’’’’’’’’ ‘’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’’ ‘’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’ to manufacture Product and
Delivery Device. In addition, at Roche’s request Inovio shall use diligent efforts to assist Roche with obtaining additional manufacturing services from
‘’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’ ‘’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
for use in the conduct of clinical trials, ‘’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’ ‘’’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’
‘’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’ ‘’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’ ‘’’’’ ‘’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’
‘’’’’’ ‘’’’’’’’’’’ ‘’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’
‘’’’’’’’’’’’’’’’’’’’ ‘’’’’ ‘’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’
‘’’’’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’ ‘’’’
‘’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’
‘’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’
‘’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’
‘’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’’ ‘’’’
‘’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’ ‘’’’’’’’’
‘’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’
‘’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’. 

 

	5.4	Development and Supply of Delivery Devices 

  

	5.4.1	CAPA Plan. Inovio shall implement and maintain those response and action items identified in the corrective and preventative action plan that is current and agreed as of the Effective Date (the “CAPA
Plan”). Inovio shall provide Roche, through the JSC with regular updates on its ongoing compliance with the CAPA Plan. During any time period in which Inovio is supplying the Delivery Device to Roche or is optimizing the Delivery Device
that will be supplied to Roche, Roche shall have the right, on reasonable notice to Inovio, to audit Inovio and any Third Party contractors of Inovio to the extent Roche determines is necessary to confirm compliance with the CAPA plan.

  

	5.4.2	Delivery Device Optimization and Supply by Inovio. 

  

	 	5.4.2.1	Subject to Roche’s options set forth in Section 5.4.3 below, the Parties currently anticipate that Inovio will be responsible for the further development and supply to Roche of Delivery Devices that are useful
or necessary to deliver any Product and/or conduct activities under this Agreement. The Parties or their Affiliates will enter into a separate Delivery Device supply agreement (“Device Supply Agreements”), including manufacturing
and quality agreements, within six (6) months after the Effective Date outlining the terms and conditions of the development, manufacturing and supply of the Delivery Device. The Device Supply Agreement shall contain terms and conditions
consistent with this Agreement, in addition to other terms that are reasonable and customary, including provisions to ensure quality and audit by or on behalf of Roche. All costs incurred in such optimization and development shall be shared equally
by Inovio and Roche. Delivery Devices shall be provided (i) for clinical trial supply, at Inovio’s FBMC and (ii) for commercial supply, at Inovio’s FBMC plus
‘’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’. 

  
 - 30 - 

	 	5.4.2.2	Unless Roche opts to internalize development and optimization of the Delivery Device, commencing on the Effective Date, Inovio will provide Roche with regular updates on the further development and optimization of the
Delivery Device by Inovio. Updates shall be provided at least every eight (8) weeks and otherwise at Roche’s request. In addition, on reasonable notice, Inovio shall allow representatives of Roche (including Third Party consultants) to be
on-site at Inovio to the extent necessary or useful for Roche to monitor and comment on such further development and optimization. Inovio shall endeavor to include or promptly update a Roche representative in Inovio’s meetings and discussions
around the further development of the Delivery Device such that Roche has a meaningful opportunity to understand the current status and further timelines for such development 

 

	5.4.3	Roche Options for Development and Supply of Delivery Devices. Roche shall have the right, at any time, in its sole discretion, to choose from the following two (2) options with regard to the development and supply
of the Delivery Device. Until Roche exercises such right, Inovio shall be responsible for the manufacture and supply of Delivery Devices. Under either option, the Parties or their Affiliates will promptly enter into a separate Delivery Device supply
agreement (which agreement shall supersede and replace the then current Device Supply Agreement) outlining the terms and conditions of the development, manufacturing and supply of the Delivery Device The Device Supply Agreement shall contain terms
and conditions consistent with this Agreement, in addition to other terms that are reasonable and customary, including provisions to ensure quality and audit by or on behalf of Roche. 

 

	 	5.4.3.1	Option 1: At any time, in its sole discretion and at no additional upfront cost, Roche may opt to co-develop the Delivery Device for supply to Roche hereunder. Each Party shall bear its own expenses related to such
co-development. The Parties will share equally any Third Party costs incurred after Roche exercises such option. Each Party shall have the right to oversee and to comment on such development and manufacturing activities, which comments shall be
considered in good faith. While the Parties will endeavor to make decisions by consensus, Roche shall retain final decision making authority. Co-developed Delivery Devices supplied to Roche by Inovio shall be provided at Inovio’s FBMC.

  

	 	5.4.3.2	Option 2: At any time, in its sole discretion and at no additional upfront cost to Roche, Roche may opt to solely develop and supply the Delivery Device. All cost incurred in development shall be borne by Roche. Inovio
shall support Roche in such development, including by providing promptly after such election the transfer of technology set forth in Section 5.3.4, and by providing ongoing FTE support to Roche at the FTE Rate. Roche shall keep Inovio
reasonably informed about the ongoing development of Delivery Devices. 

  

	5.4.4	For clarity, any Roche Inventions resulting from the development by Roche of Delivery Devices under this Section 5.4.3, or under a related Device Supply Agreement, shall be subject to the license granted by Roche
to Inovio under Section 3.3. 

  
 - 31 - 

	5.5	GMP 

 The Parties and/or their Affiliates and/or Third Party manufacturers shall execute, as requested by
Roche, agreements, such as a quality agreement, necessary or useful to ensure that all Products and their intermediates and manufacturing facilities comply with GMP and all applicable laws and regulations. Before any supplier or manufacturer
implements any changes having regulatory relevance, they shall require Roche’s approval before making such changes. Roche shall have the opportunity to conduct full CMC due diligence and environmental, health and safety (“EH&S”)
audits of all suppliers and manufacturers prior to entering into any agreement under this Section 5.5 and any party to an agreement under this Section 5.5 shall implement the changes and improvements stemming from such GMP and EH&S
audits. 
  

	5.6	Commercialization 

 Roche, at its own expense, shall have sole responsibility and decision making
authority for the marketing, promotion, sale and distribution of Products in the Territory. 
  

	5.7	Diligence 

 Roche shall use Commercially Reasonable Efforts to pursue further development and
commercialization of Products in the Territory. For each Research Program, Roche shall be deemed to use Commercially Reasonable Efforts if it respectively pursues development of at least one Oncology Product in at least one indication and at least
one HBV Product in one indication. Inovio shall use Commercially Reasonable Efforts to conduct its activities under the Research Plans, Development Plans, manufacturing and supply obligations, and technology transfer obligations. 

 

	5.8	Updates to Inovio 

 For each Research Program, after the Research Term until Initiation of the first
Phase II Study for a Product from such Research Program, and upon request of Inovio, Roche shall update Inovio regarding the development and commercialization of Products in the Territory by Roche, its Affiliates and Sublicensees. If Inovio requests
an update, Roche shall provide a high level summary, in writing and/or through a meeting (face to face/ tele-presence/videoconference or telephone). Inovio shall not request an update more frequently than twice per Calendar Year. 

 

	6.	Payment 

  

	6.1	Option Signing and Exclusivity Fee 

 Within thirty (30) days after the Effective Date and receipt of
an invoice from Inovio, in consideration for rights granted herein, Roche shall pay to Inovio a one-time, non-refundable, non-creditable signing and exclusivity fee of Ten Million US Dollars (US$10,000,000), attributable as follows: 

 

	a)	‘’’’’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’ ‘’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ in consideration for the rights and
licenses in the 5150 Product; 

  

	b)	‘’’’’’’’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ in consideration for the rights and
licenses under the Oncology Research Program; and 

  

	c)	‘’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’ ‘’’’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ in
consideration for the rights and licenses in and to INO-1800 and the HBV Research Program 

  
 - 32 - 

	6.2	Research and Development Support Payments 

  

	6.2.1	Oncology 

  

	 	6.2.1.1	5150 Development Support Payments 

 Roche shall reimburse Inovio for the 5150 Development Support Payments in
accordance with Section 5.1.1 and Article 7. 
  

	 	6.2.1.2	Oncology 

 Roche shall reimburse Inovio for those costs and expenses related to research and development of DNA
vaccines directed to the RC Targets under the Oncology Research Plan and the Oncology Development Plan as agreed under the associated budget’’ ‘’’’
‘’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’
‘’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’ ‘’’’ ‘’’’’’’ ‘’’’’’’’’’’’
‘’’’’’’’’’’ ‘’’’’’ ‘’’’’’’’ ‘’’’’’’’’’’
‘’’’’ ‘’’’’’ ‘’’’ ‘’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’ ‘’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’
‘’’’’’’’’’’’’’ ‘’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’ 
  

	6.2.2	HBV 

 Roche shall reimburse Inovio for those costs and expenses related to the conduct of HBV Research Plan and
any associated Development Plan as agreed under the associated budget in the Research Plan or Development Plan, as applicable. 
  

	6.3	Development Event Payments 

  

	6.3.1	Oncology Product Development Event Payments 

‘’’’’’’’’’’’’’’’
 ‘’’’’’’’’’’ ‘’’’’’’’’’ ‘’’’’’ ‘’’’ ‘’’’
‘’’’’’’’’’’ ‘’’’ ‘’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’ ‘’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’
‘’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
 ‘’’’ ‘’’’’’’’’’’’’’’’’ to the achievements of development events with respect to all Oncology
Products. The development event payments under this Section 6.3.1 shall be paid by Roche according to the following schedule of development events. 
  

													
	 Development Event
	  	Payment for 5150
Product in Prostate
Cancer (in US$M)	 	  	Payment for RC
Product in Prostate
Cancer (in US$M)	 	  	Payment for
5150 Product
or RC Product
in up to two 
(2)
Non-Prostate
Cancer
Indications (in US$M)	 
	 	  	(Column 1)	 	  	(Column 2)	 	  	(Column 3)	 
	 Initiation Phase I Study
	  	 	‘’’’’’’	  	  	 	‘’’’’’’	  	  	 	‘’’’’’’	  
	 Initiation Phase II Study
	  	 	‘’’’’’	  	  	 	‘’’’’’’’	  	  	 	‘’’’’’’’	  
	 Initiation Phase III Study
	  	 	‘’’’’’	  	  	 	‘’’’’’	  	  	 	‘’’’’’	  
	 BLA filing in US
	  	 	‘’’’’’’	  	  	 	‘’’’’’	  	  	 	‘’’’’	  
	 BLA filing in EU
	  	 	‘’’’’’	  	  	 	‘’’’’’’’	  	  	 	‘’’’’’’	  
	 BLA filing in ROW
	  	 	‘’’’’’’’	  	  	 	‘’’’’’’	  	  	 	‘’’’’’’’	  
	 BLA filing in Japan
	  	 	‘’’’’’’	  	  	 	‘’’’’’’	  	  	 	‘’’’’’’	  
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total
	  	 	‘’’’’’’’ ‘’’’’ 
‘’’’’’	  	  	 	‘’’’’’’’ ‘’’’ ‘’’’’’’’’’’	 	  	 
 	‘’’’’’’’ ‘’’’’ ‘’’’’’ ‘’’’’ 
‘’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’
	  
  
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  
 - 33 - 

 Each development event payment in Column 1 and Column 2 shall be paid only once regardless of the number of
Oncology Products achieving these development events. Each development event payment in Column 3 shall be paid up to twice for the first two indications other than prostate cancer whether achieved by a 5150 Product or an RC Product. As used herein,
the indication “prostate cancer” shall mean all indications within a given sub-block of the International Statistical Classification of Diseases and Related Health Problems 10th Revision
(ICD-10) Version for 2010, e.g. sub-block C61 “Malignant neoplasm of prostate.” With regard to other indications, each indication shall require treatment of a separate organ. For example, breast cancer and colon cancer are separate
indications but metastatic versus adjuvant breast cancer would be considered a single indication and not trigger a second set of Column 3 development event payments. Upon reaching development events, Roche shall timely notify Inovio and development
event payments shall be paid by Roche to Inovio within ninety (90) days from occurrence of the applicable event and receipt of an invoice from Inovio. If development of a given Oncology Product is discontinued for any reason, then the
development event payments paid for such discontinued Oncology Product shall be creditable against development event payments due for the next Oncology Product in development. 
  

	6.3.2	HBV Product Development Event Payments 

 Roche shall pay up to a ‘’’’’’’’’’ ‘’’’’ ‘’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’
‘’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’’ ‘’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
 in relation to the achievements of development events with respect to all HBV Products in the first two (2) indications developed for HBV Products (the “Initial Indications”). The
development event payments under this Section 6.3.2 shall be paid by Roche according to the following schedule of development events in up to two (2) indications. 

 

					
	 Development Event
	  	Payment (in US$M)	 
	 Initiation Phase I Study
	  	 	‘’’’’’’	  
	 Initiation Phase II Study
	  	 	‘’’’’’’	  
	 Initiation Phase III Study
	  	 	‘’’’’’’	  
	 BLA filing in US
	  	 	‘’’’’’	  
	 BLA filing in EU
	  	 	‘’’’’’’	  
	 BLA filing in ROW
	  	 	‘’’’’’’	  
	 BLA filing in Japan
	  	 	‘’’’’’’	  
		  	  
	  
	 
	 Total per Initial Indication
	  	 
 
 
 	‘’’’’’’ ‘’’’’
‘’’’’’
‘’’’’’’’’’’ ‘’’ ‘’’’’’’’’
‘’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’
	  
  
  
  
		  	  
	  
	 

 For the two (2) Initial Indications developed for HBV Products, each development event payment for a given Initial
Indication shall be paid only once for the first HBV Product that reaches such development event for such Initial Indication. Upon reaching development events, Roche shall timely notify Inovio and development event payments shall be paid by Roche to
Inovio within ninety (90) days from occurrence of the applicable event and receipt of an invoice from Inovio. If development of a given HBV Product is discontinued for any reason in a given 

  
 - 34 - 

 
Initial Indication, then the development event payments paid for such discontinued HBV Product in such Initial Indication shall be creditable against development event payments due for the next
HBV Product in development for such Initial Indication. 
  

	6.4	First Commercial Sale Event Payments 

  

	6.4.1	Oncology Product Commercial Sale Event Payments 

 Roche shall pay up to a total ‘’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’ ‘’’’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ in relation to the achievements of the first commercial sale events with respect to all Oncology Products. The First Commercial Sale event payments under this Section 6.4.1 shall be paid by Roche according
to the following schedule. 
  

									
	 First Commercial Sale Event
	  	5150 Product (in US$M)	 	  	RC Product (in US$M)	 
	 First Commercial Sale US
	  	 	‘’’’’’	  	  	 	‘’’’’’	  
	 First Commercial Sale EU
	  	 	‘’’’’’	  	  	 	‘’’’’’	  
	 First Commercial Sale ROW
	  	 	‘’’’’’’	  	  	 	‘’’’’’’	  
	 First Commercial Sale Japan
	  	 	‘’’’’’’’	  	  	 	‘’’’’’’’	  
		  	  
	  
	 	  	  
	  
	 
	 Total All First Commercial Sale Events
	  	 	‘’’’’’ ‘’’’’ ‘’’’’’	  	  	 	‘’’’’’ ‘’’’ ‘’’’’	  
		  	  
	  
	 	  	  
	  
	 

  

	6.4.2	HBV Product Commercial Sale Event Payments 

 Roche shall pay up to a total ‘’’’’ ‘’’’’’’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
 in relation to the achievements of the first commercial sale events with respect to each HBV Product. The First Commercial Sale event payments under this Section 6.4.2 shall be paid by Roche according
to the following schedule. 
  

					
	 First Commercial Sale Event
	  	Payment
(US$ Millions)	 
	 First Commercial Sale US
	  	 	‘’’’’	  
	 First Commercial Sale EU
	  	 	‘’’’’’’	  
	 First Commercial Sale ROW
	  	 	‘’’’’’	  
	 First Commercial Sale Japan
	  	 	‘’’’’’’	  
		  	  
	  
	 
	 Total All First Commercial Sale Events per Product
	  	 	‘’’’’’ ‘’’’ ‘’’’’	  
		  	  
	  
	 

  

	6.5	Sales Based Payments 

  

	 	i)	Oncology Sales Based Payments 

 Roche shall pay up to a ‘‘‘‘‘‘‘‘‘ ‘‘‘‘‘ ‘‘‘‘‘‘‘‘‘‘
‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘ ‘‘‘‘‘‘‘ ‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘
‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘‘ in relation to the achievements of the following Net Sales levels with respect to the first Oncology Product achieving such Net Sales levels in a single Calendar Year. 

 

					
	 First achievement of Calendar Year Net Sales of an Oncology Product (US$ Billions)
	  	Payment
(US$ Millions)	 
	 > 1.0
	  	 	‘’’’’	  
	 > 1.5
	  	 	‘’’’’’’	  
		  	  
	  
	 
	 Total All Oncology Sales Based Payments
	  	 	‘’’’’’ ‘’’’ ‘’’’’	  
		  	  
	  
	 

  
 - 35 - 

	6.5.1	HBV Product Commercial Sale Event Payments 

 Roche shall pay up to a total of ‘’’’’’’’’’’ ‘’’’’’’’’’’’’’
‘’’’’’’ ‘’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ in relation to the achievements of the following Net Sales levels with respect to the first HBV Product achieving such Net Sales levels in a single Calendar Year. 

 

					
	 First achievement of Calendar Year Net Sales of an HBV Product (US$ Billions)
	  	Payment
(US$ Millions)	 
	 > 1.0
	  	 	‘’’’’’	  
	 > 1.5
	  	 	‘’’’’’	  
		  	  
	  
	 
	 Total All HBV Sales Based Payments
	  	 	‘’’’’’ ‘’’’ ‘’’’’	  
		  	  
	  
	 

  

	6.6	Roche Royalty Payments 

  

	6.6.1	Royalty Term 

 Royalties shall be payable by Roche on Net Sales of Products on a Product-by-Product and
country-by-country basis until the expiry of the Royalty Term. Thereafter, the licenses shall be fully paid up and royalty-free. 
  

	6.6.2	Royalty Rates 

  

	 	6.6.2.1	Royalty Rates for Oncology Products 

 The following royalty rates shall apply to the respective portions of
aggregate Calendar Year Net Sales of an Oncology Product in the Territory, on an incremental basis, as follows: 
  

	a)	For a 5150 Product: 

  

					
	 Portion of Calendar Year Net Sales in million US$
	  	Percent (%) of Net Sales	 
	 ‘’’ ‘’’’
‘’’’’’’’’
	  	 	‘’’’’’’’	  
	 ‘’’ ‘’’’’’’’’’
‘’’’ ‘’’’’’’’’’’’’’’
	  	 	‘’’’’’’	  
	 ‘’’ ‘’’’’’’’’’’’
‘’’ ‘’’’’’’’’’’’’
	  	 	‘’’’’’	  
	 ‘’’
‘’’’’’’’’’’’’’
	  	 	‘’’’’’’	  

  

	b)	For an RC Product: 

  

					
	 Portion of Calendar Year Net Sales in million US$
	  	Percent (%) of Net Sales	 
	 ‘’’’ ‘’’
‘’’’’’’’’’’’’’’
	  	 	‘’’’’’’’	  
	 ‘’’’
‘’’’’’’’’’’’ ‘’’ ‘’’’’’’’’’’’’’
	  	 	‘’’’’’’	  
	 ‘’’
‘’’’’’’’’’’’
	  	 	‘’’’’’’’	  

  
 - 36 - 

 For example’’ ‘’’
‘’’’’’’’’ ‘’’’’’’’’’’’’ ‘’’’ ‘’’
‘’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’ ‘’’’’ ‘’’’’’’’
‘’’’’’’’’’’’’’’’’’’ ‘’’’’’ ‘’’
‘’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’ ‘’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’ ‘’’’’’’
‘’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’
‘’’’’’ ‘’’’’’’’’’’ ‘’’’’’’’’ ‘’’’’’’’’’’’’’’
‘’’’’ ‘’’’’’’’’’’ ‘’’’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’ ‘’’’’’’’’’ ‘’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’’’’’ 

‘’’’’’’’’’’’’
‘’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
 ‘’’ ‘’’’’’’’’’’’’ ‘’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’ ‘’’’’’’’’’’ ‘’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
 ‘’’’ ‘’’’’’’’’’’’’ ‘’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’’ 
  

	 	6.6.2.2	Royalty Rates for HBV Products 

 The following royalty rates shall apply to the respective portions of aggregate
Calendar Year Net Sales of an HCV Product in the Territory, on an incremental basis, as follows: 
  

					
	 Portion of Calendar Year Net Sales in million US$
	  	Percent (%) of Net Sales	 
	 ‘’’ ‘’’’
‘’’’’’’’’’
	  	 	‘’’’’’’’	  
	 ‘’’ ‘’’’’’’’’ ‘’’
‘’’’’’’’’’’’
	  	 	‘’’’’’’	  
	 ‘’’
‘’’’’’’’’’’’’ ‘’’’ ‘’’’’’’’’’’’’
	  	 	‘’’’’’’	  
	 ‘’’
‘’’’’’’’’’’’’
	  	 	‘’’’’’’	  

 For example’’ ‘’’
‘’’’’’’’’ ‘’’’’’’’’’’’’ ‘’’’’ ‘’’’
‘’’’’’’’’’’’’’’’’’’’ ‘’’’ ‘’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’ ‘’’
‘’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’ ‘’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’’’’’’ ‘’’’’’’ ‘’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’ ‘’’’’’’’’’’
‘’’’’’’’’ ‘’’’’’’’’’’’’’’ ‘’’’’ ‘’’’’’’’’’’’
‘’’’’’’’’’’’’’’’’ ‘’’’’’’ ‘’’’’’’’’’
‘’’’’’’’’’’’ ‘’’’’’’’’’ ‘’’’’’
‘’’’’’’’’’’’’’’’’’’’’ ‘’’’’
‘’’’’’’’’’’’’’’’ 
 ‘’’’’’’’’’’’’ ‘’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
 ‘’’’ ‘’’’’’’’’’’’ ‘’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ ‘’’’
‘’’’’’’’’’’ ‘’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
 ‘’’ ‘’’’’’’’’’’’ ‘’’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’
‘’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’’’’’’ 
 For the purpose of calculating royalties of a Product, Calendar Year Net Sales and the royalty rates, as
applicable, shall be subject to the following adjustments: 
  

	 	6.6.2.3	Combination Product 

 If Roche, its Affiliates or Sublicensees intend to sell a Combination Product, then the
Parties shall meet approximately one (1) year prior to the anticipated First Commercial Sale of such Combination Product to negotiate in good faith and agree to an appropriate adjustment to Net Sales to reflect the relative pharmaceutical
activity of the Product and the other pharmaceutically active agent(s) contained in the Combination Product. If, after such good faith negotiations not to exceed ninety (90) days, the Parties cannot agree to an appropriate adjustment to Net
Sales, the dispute shall be initially referred to the executive officers of the Parties in accordance with Section 16.2. Should the Parties fail to agree within sixty (60) days of such referral, then the Net Sales shall equal such portion
of the Net Sales of the Combination Product that is equivalent to the relative commercial value contributed by the components of the Combination Product, as determined by an Expert jointly appointed by the Parties within a further thirty
(30) days. In the absence of an agreement on the appointment of the Expert, each Party will select an Expert and the two Experts shall select a third Expert, and the three Experts will determine the relative commercial value contributed by the
components of the Combination Product. The decision of the Expert(s) shall be final and binding on the Parties and the fees of the Expert(s) shall be shared equally between the Parties. 

 

	 	6.6.2.4	Third Party Product 

 Upon the first entry in a given country of a Third Party product, the royalties in such
country for such Product shall be reduced as follows: 
  

	a)	 If in any two (2) consecutive Calendar Quarters at any time after entry of a Third Party Product there has been a decline of the sales of the
applicable Product in such country 

  
 - 37 - 

	 	
greater than
‘’’’’’’’’’’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’ of the level of the average Calendar Quarter sales of such
Product achieved in the Calendar Year immediately prior to such entry (divided by four per Calendar Quarter), then (i) if there is a Valid Claim that Covers such Product, the royalty payments due to Inovio for such Product in such country shall
(unless the Royalty Term had expired prior to such time for such Product in such country) be reduced by ‘’’’’’’’
‘’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’ and (ii) if there is no Valid Claim that
Covers such Product (or at such time as there is no Valid Claim that Covers such Product), then the Royalty Term for such Product in such country shall end (unless the Royalty Term had expired prior to such time for a given Product in a given
country), royalties shall no more be due by Roche in such country for such Product, and the license in that country for such Product shall be fully paid-up and irrevocable. 

 

	b)	If in any two (2) consecutive Calendar Quarters at any time after entry of a Third Party Product there has been a decline of the sales of the applicable Product in such country greater than ‘’’’’’’’’’ ‘’’’’’’’’’’’’’’’’’
‘’’’’’’’’’’’’ of the level of the average Calendar Quarter sales of such Product achieved in the Calendar Year immediately prior to such entry for each such Calendar Quarter,
then the royalty payments due to Inovio for such Product in such country shall be ‘’’’’’’’’’’’ (unless the Royalty Term had expired prior to
such time for such Product in such country) and ‘’’’’’
‘’’’’’’’’’’’’’’’’’’’’ shall be due by Roche in such country for such Product. 

 

	 	6.6.2.5	No Valid Claim 

 Notwithstanding Section 6.6.2.4, if no Valid Claim in the Inovio Background Patent Rights
or Joint Patent Rights Covers using, selling, offering for sale or importing a Product in a country, then the royalties on such Product in such country shall be reduced by fifty percent (50%). 

 

	 	6.6.2.6	Third Party Payments 

 Inovio shall be responsible for any consideration owed or payable to any Third Party in
relation to Third Party intellectual property rights related to the licenses and rights granted pursuant to this Agreement that, to the best of Inovio’s knowledge, exists as of the Effective Date, including any amounts due under the Existing
Agreements (as currently written or as amended either prior to or after the Effective Date) payable based on the development, manufacture or sale of Products or Delivery Devices by either Party under this Agreement. The foregoing obligation includes
the obligation to pay any amounts imposed on either Roche or Inovio resulting from any delay or failure by Inovio to pay any amounts due in accordance with the foregoing sentence. Inovio shall be responsible and liable to maintain the Existing
Agreements. Otherwise, Roche shall be responsible for and pay or have paid any consideration owed to any Third Party in relation to Third Party intellectual property rights for Products. Roche shall have the right to deduct fifty percent
(50%) of such consideration actually paid to a Third Party from payments otherwise due and payable by Roche to Inovio under this Agreement (“Third Party Offset”). Any such deduction shall be permitted on a Product-by-Product
and country-by-country basis; however, in no event shall the Third Party Offset reduce the amounts payable to Inovio under Sections 6.6.2.1 or 6.6.2.2 by more than fifty percent (50%). For clarity, the foregoing does not limit further reductions
that may be applicable under Section 6.6.2.4. 
  

	 	6.6.2.7	Apportionment of Compulsory Sublicensee Consideration 

 At such time as Roche or any of its Affiliates or
Sublicensees enters into a sublicense with a Compulsory Sublicensee, the Parties will discuss and mutually agree upon an adjustment of the royalty due to Inovio under Section 6.6 of this Agreement with respect to sales of Products by such
Compulsory Sublicensee. 

  
 - 38 - 

	6.7	Disclosure of Payments 

 Inovio acknowledges that Roche may be obligated to disclose this financial
arrangement, including all fees, payments and transfers of value, as may be advisable or required under applicable law, including the US Sunshine Act, provided that, to the extent possible, Roche gives Inovio reasonable timely notice in order for
Inovio to meet its disclosure requirements, if any. 
  

	7.	Accounting and reporting 

  

	7.1	Invoices 

 Inovio shall send invoices to Roche at the end of each Calendar Quarter for any payments due
by Roche to Inovio hereunder. Each invoice be accompanied by a DRSP Report and shall identify the trigger for the payment obligation. Unless otherwise requested by Roche in writing, Inovio shall send invoices to Roche as provide for under
Section 16.14, with a copy to the appropriate Roche Alliance Director. 
  

	7.2	DSRP Reports for Development Support Payments 

 Within thirty (30) calendar days after the end of
each Calendar Quarter, Inovio shall provide to Roche a report for such Calendar Quarter detailing the expenses incurred by Inovio pursuant to its performance of its obligations under Sections 2.1 and 5.1, including (a) expenses incurred
pursuant to the Development Plan for the Inovio 5150 Trial, provided that the cumulative total of such expenses that Roche is obligated to pay shall not exceed one hundred ten percent (110%) of the amount budgeted for the conduct of the Inovio
5150 Trial that is current and agreed as of the Effective Date, (b) such FTEs committed under the Oncology Research Plan and the HBV Research Plan during that Calendar Quarter (provided that the cumulative total of such expenses that Roche is
obligated to pay shall not exceed one hundred ten percent (110%) of the amount budgeted by the JSC, the identity of the individuals included within those FTEs, the percentage of an FTE that each individual represents, and a brief summary of the
work performed, and (c) detail around any other reimbursable costs or expenses incurred in the conduct of a Research Plan (such report a “DSRP Report”). Upon Roche’s request, Inovio will provide an annual budget of its
anticipated development and/or research support costs and such costs shall be subject to JSC approval. 
  

	7.3	Timing of Payments 

  

	7.3.1	Payment under a DSRP Report 

 Payments detailed in a DSRP Report shall be paid by Roche within thirty
(30) days after receipt by Roche of (i) an Invoice and (ii) the DSRP Report from Inovio. 
  

	7.3.2	Royalties 

 Roche shall calculate royalties on Net Sales quarterly as of
March 31, June 30, September 30 and December 31 (each being the last day of an “Accounting Period”) and shall pay royalties on Net Sales within the ninety (90) days after the end of each Accounting
Period in which such Net Sales occur. 
  

	7.4	Late Payment 

 Any payment under this Agreement that is not paid on or before the date such payment is
due shall bear interest, to the extent permitted by applicable law, at two (2) percentage points above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of days such
payment is overdue. 

  
 - 39 - 

	7.5	Method of Payment 

 Royalties on Net Sales and all other amounts payable by Roche hereunder shall be paid
by Roche in US$ (the “Payment Currency”) to account(s) designated by Inovio. 
  

	7.6	Currency Conversion 

 When calculating the Sales and Net Sales of any royalty-bearing Product that occur
in currencies other than the Payment Currency, Roche shall convert the amount of such sales into Swiss Francs and then into the Payment Currency using Roche’s then-current internal foreign currency translation actually used on a consistent
basis in preparing its audited financial statements (currently YTD average rate as reported by Thomson Reuters). 
  

	7.7	Royalty Reports 

 With each royalty payment Roche shall provide Inovio in writing for the relevant
Calendar Quarter on a Product-by-Product basis the following information: 
  

	a)	Sales in Swiss Francs on a country-by-country basis; 

  

	b)	Net Sales in Swiss Francs on a country-by-country basis; 

  

	c)	Adjustments made pursuant to Sections 6.6.2.3 - 6.6.2.6 in Swiss Francs on a country by country basis; 

  

	d)	Net Sales in Swiss Francs after adjustments made pursuant to Sections 6.6.2.3 - .6.2.6, on a country by country basis; 

  

	e)	Total Net Sales in the Territory after adjustments made pursuant to Sections 6.6.2.3 - 6.6.2.6, in Swiss Francs; 

  

	f)	Exchange rates used for the conversion of Net Sales from Swiss Francs to the Payment Currency made under Section 7.6; 

  

	g)	Total Net Sales in the Territory after adjustments made pursuant to Sections 6.6.2.3 - 6.6.2.6 in the Payment Currency; 

  

	h)	Royalty rate pursuant to Section 6.4; and 

  

	i)	Total royalty payable to Inovio in the Payment Currency. 

 For illustrative purposes only, a royalty report
template is attached as Appendix 7.7. 
  

	8.	Taxes 

 Inovio shall pay all sales, turnover, income, revenue, value added, and other taxes levied on
account of any payments accruing or made to Inovio under this Agreement. 
 If provision is made in law or regulation of any country for withholding of taxes
of any type, levies or other charges with respect to any royalty or other amounts payable under this Agreement to Inovio, then Roche shall promptly pay such tax, levy or charge for and on behalf of Inovio to the proper governmental authority, and
shall promptly furnish Inovio with receipt of payment. Roche shall be entitled to deduct any such tax, levy or charge actually paid from royalty or other payment due Inovio or be promptly reimbursed by Inovio if no further payments are due Inovio.
Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld
or deducted. 
  

	9.	Auditing 

  

	9.1	Right to Audit 

 Inovio shall keep complete and accurate records for a period of at least three
(3) years for each reporting period during which payments are due for research or development activities 

  
 - 40 - 

 
hereunder, showing the particulars necessary in sufficient detail to enable DRSP Reports to be verified. Roche shall keep, and shall require its Affiliates and Sublicensees to keep, full, true
and accurate books of account containing all particulars that may be necessary for the purpose of calculating all royalties payable under this Agreement. Such books of accounts shall be kept at their principal place of business. At the expense of
the auditing Party, the auditing Party has the right to engage an independent public accountant reasonably acceptable to the selling Party to perform, on behalf of the auditing Party an audit of such books and records of the audited Party and its
Affiliates, its licensees and Sublicensees, that are deemed necessary by the auditing Party’s independent public accountant to report on Net Sales of Product for the period or periods requested by the auditing Party and the correctness of any
financial report or payments made or invoiced under this Agreement. 
 Upon timely request and at least sixty (60) working days’ prior written
notice from the auditing Party, such audit shall be conducted in the countries specifically requested by the auditing Party, during regular business hours in such a manner as to not unnecessarily interfere with the selling Party’s normal
business activities, and shall be limited to results in the three (3) calendar years prior to audit notification. 
 Such audit shall not be performed
more frequently than once per Calendar Year nor more frequently than once with respect to records covering any specific period of time. 
 All information,
data documents and abstracts herein referred to shall be used only for the purpose of verifying the applicable invoice or statement or payment, shall be treated as the selling Party’s Confidential Information subject to the obligations of this
Agreement and need neither be retained more than one (1) year after completion of an audit hereof, if an audit has been requested; nor more than three (3) years from the end of the calendar year to which each shall pertain; nor more than
one (1) year after the date of termination of this Agreement. 
  

	9.2	Audit reports 

 The auditors shall only state factual findings in the audit reports and shall not
interpret the agreement. The auditors shall share all draft audit reports with the selling Party before the draft report is shared with the auditing Party and before the final document is issued. The final audit report shall be shared with the
selling Party at the same time it is shared with the auditing Party. 
  

	9.3	Over-or Underpayment 

 If the audit reveals an overpayment, the auditing Party shall reimburse the
audited Party for the amount of the overpayment within thirty (30) days. If the audit reveals an underpayment, the audited Party shall make up such underpayment with the next royalty payment or, if no further royalty payments are owed to the
auditing Party, the audited Party shall reimburse the auditing Party for the amount of the underpayment within thirty (30) days. The audited Party shall pay for the audit costs if the underpayment of the audited Party exceeds five percent
(5%) of the aggregate amount of payments owed with regard to the invoices or statements subject of the audit. Section 7.4 shall apply to this Section 9.3. 
  

	9.4	Duration of Audit Rights 

 The failure of an auditing Party to request an audit within the period during
which corresponding records must be maintained under this Article 9 will be deemed to be acceptance of the payments, invoices and reports. 

  
 - 41 - 

	10.	Intellectual Property 

  

	10.1	Disclosure of Inventions 

 Inovio shall promptly disclose to Roche in writing any Collaboration IP
created, discovered, conceived or reduced to practice pursuant to the activities conducted under a Research Program or Development Plan. During the Term, Inovio shall disclose to Roche all Patents within Inovio Patent Rights and Joint IP Rights,
including any such Patents which Inovio Controls after the Effective Date. 
  

	10.2	Ownership of Inventions 

 Roche shall own all Roche Inventions. Inovio shall own all Inovio Inventions.

 All Collaboration IP, and the Inventions contained therein, shall be jointly owned by the Parties. Subject to the licenses granted by one Party to the
other under this Agreement, each Party retains a full, undivided, one-half interest ownership right (including as provided under 35 U.S.C. §262) in and to such Collaboration Inventions, for any field, and including the right to license and
sublicense, and to freely exploit, transfer or encumber its ownership interest, without the consent of, or payment or accounting to, the other Party. Each Party hereby waives any right it may have under the laws of any jurisdiction to require such
payment, accounting, or consent with respect to Collaboration Inventions. Each Party hereby agrees to take such action as necessary to evidence, and shall require all of its employees, contractors, sublicensees and agents, and any Affiliates and
permitted Third Parties working on its behalf under this Agreement (and their respective employees, contractors and agents) to take such action as necessary to evidence the foregoing joint ownership rights in and to any and all Collaboration IP.

 The determination of inventorship for Inventions shall be in accordance with US inventorship laws as if such Inventions were made in the US. 

 

	10.3	German Statute on Employee’s Inventions 

 In accordance with the German Statute on Employees’
Inventions, each Party agrees to claim the unlimited use of any Invention conceived, reduced to practice, developed, made or created in the performance of, or as a result of, any Research Program by its German employees or any other German person
acting on its behalf. The Party which is the ultimate assignee of the German employee’s or other person’s Invention under this Agreement shall pay any royalty or other compensation payable to the employee or other person, and the Parties
agree that the Party which is the ultimate assignee must agree to the royalty or other compensation negotiated with the employee or other person. 
  

	10.4	Prosecution of Patent Rights Covering Inventions 

 Roche shall, at its own expense and discretion, Handle
all Roche Patent Rights and Joint Patent Rights. 
 To the extent that Roche has an exclusive license under a Development & Commercialization
License to any Inovio Patent Rights, Roche shall have the right to Handle all such Inovio Patent Rights unless Inovio is prohibited from granting Roche the right to Handle those Inovio Patent Rights Controlled pursuant to the Existing Agreements, in
which case Inovio shall use diligent efforts to amend the Existing Agreements to secure Roche’s right to Handle the Inovio Patent Rights Controlled pursuant to the Existing Agreements, which shall be subject to Third Party agreement. Inovio
shall, at its own expense and discretion, Handle Inovio Patent Rights that are not subject to the exclusively-licensed portion of the Development & Commercialization License. For clarity, if Roche is Handling Patent Rights, then Roche will
pay for such Handling; otherwise, Inovio shall pay for the Handling of Patent Rights. 

  
 - 42 - 

 Roche shall furnish Inovio with copies of all documents relevant to any such Handling of Inovio Patent Rights and
Joint Patent Rights. At Roche’s reasonable request, Inovio shall cooperate, in all reasonable ways with Roche’s Handling of Inovio Patent Rights and Joint Patent Rights. 

 

	10.5	CREATE Act 

 It is the intention of the Parties that this Agreement is a “joint research
agreement” as that phrase is defined in 35 USC §103(c)(3). 
  

	10.6	Infringement 

 Each Party shall promptly provide written notice to the other Party during the term of
this Agreement of any (i) known infringement or suspected infringement by a Third Party of any Inovio Patent Rights, Roche Patent Rights or Joint Patent Rights, or (ii) known or suspected unauthorized use or misappropriation by a Third
Party of any Inovio Know-How, Roche Know-How or Joint Know-How, and shall provide the other Party with all evidence in its possession supporting such infringement or unauthorized use or misappropriation. 

Within sixty (60) days after Roche provides or receives such written notice (“Decision Period”), Roche, in its sole discretion, shall
decide whether or not to initiate such suit or action in the Territory and shall notify Inovio in writing of its decision in writing (“Suit Notice”). 

If Roche decides to bring a suit or take action, once Roche provides Suit Notice, Roche may immediately commence such suit or take such action. In the event
that Roche (i) does not in writing advise Inovio within the Decision Period that Roche will commence suit or take action, or (ii) fails to commence suit or take action within a reasonable time after providing Suit Notice, then, solely to
the extent such suit or action relates to an Inovio Patent Right or a Joint Patent Right, Inovio shall thereafter have the right to commence suit or take action in the Territory and shall provide written notice to Roche of any such suit commenced or
action taken by Inovio. 
 Upon written request, the Party bringing suit or taking action (“Initiating Party”) shall keep the other Party
informed of the status of any such suit or action and shall provide the other Party with copies, to the extent the Initiating Party is lawfully permitted to do so, of all substantive documents or communications filed in such suit or action. The
Initiating Party shall have the sole and exclusive right to select counsel for any such suit or action. 
 The Initiating Party shall, except as provided
below, pay all expenses of the suit or action, including the Initiating Party’s attorneys’ fees and court costs. Any damages, settlement fees or other consideration received as a result of such suit or action shall be allocated as follows:

  

	a)	First, to reimburse the Initiating Party for its costs and, if any remains, to the other Party for any advisory counsel fees and costs; and 

 

	b)	Second, the balance, if any, shall be allocated seventy five percent (75%) to the Initiating Party, and twenty five percent (25%) to the other Party. 

If the Initiating Party believes it is reasonably necessary or desirable to obtain an effective remedy, upon written request the other Party agrees to be
joined as a party to the suit or action but shall be under no obligation to participate except to the extent that such participation is required as the result of its being a named party to the suit or action. At the Initiating Party’s written
request, the other Party shall offer reasonable assistance to the Initiating Party in connection therewith at no charge to the Initiating Party. The other Party shall have the right to participate and be represented in any such suit or action by its
own counsel at its own expense. 

  
 - 43 - 

 The Initiating Party may settle, consent judgment or otherwise voluntarily dispose of the suit or action
(“Settlement”) without the written consent of the other Party but only if such Settlement can be achieved without adversely affecting the other Party (including any of its Patent Rights). If a Settlement could adversely affect the
other Party, then the written consent of the other Party would be required, which consent shall not be unreasonably withheld. 
 For any patent that is not
an Inovio Patent Right, Roche, in its sole discretion, shall decide whether or not to initiate such suit or action in the Territory. Roche shall have full discretion as to how it wishes to handle such suit and may reach Settlement and retain all
damages, settlement fees or other consideration under any terms and conditions it desires and retain whatever. Only if a Settlement could adversely affect Inovio shall the written consent of Inovio be required, which consent shall not be
unreasonably withheld. 
  

	10.7	Defense 

 If an action for infringement is commenced against either Party, its licensees or its
sublicensees related to Inovio’s conduct of the Research Program or its activities within the scope of a Research Plan or Development Plan or the discovery, development, manufacture, use or sale of a Product, then Roche shall defend such action
at its own expense, and Inovio shall assist and cooperate with Roche to the extent necessary in the defense of such suit. Roche shall have the right to settle the suit or consent to an adverse judgment thereto, in its sole discretion, so long as
such settlement or adverse judgment does not adversely affect the rights of Inovio and its Affiliates (including any patent rights Controlled by any of them). Roche shall assume full responsibility for the payment of any award for damages, or any
amount due pursuant to any settlement entered into by it with such Third Party. 
 If the manufacture, use, importation, offer for sale or sale of any
Product pursuant to this Agreement results in any claim, suit or proceeding alleging patent infringement or trade secret misappropriation against Inovio or a member of the Roche Group, then such Party shall promptly notify the other Party hereto.
The Parties shall cooperate with each other in connection with any such claim, suit or proceeding and shall keep each other reasonably informed of all material developments in connection with any such claim, suit or proceeding. 

If a Third Party asserts that Patent Rights owned by or licensed to it are infringed by the development, manufacture, use, importation, offer for sale or sale
of Products by a member of the Roche Group, or that its trade secrets were misappropriated in connection with such activity, then Roche shall have the exclusive right and responsibility to resolve any such claim, whether by obtaining a license from
such Third Party, by defending against such Third Party’s claims or otherwise, and shall be solely responsible for the defense of any such action, any and all costs incurred in connection with such action (including, without limitation,
attorneys’ and expert fees) and all liabilities incurred in connection therewith. Notwithstanding the above, Roche shall not enter into any settlement of any such claim without the prior written consent of Inovio if such settlement would
require Inovio to be subject to an injunction or to make any monetary payment to Roche or any Third Party, or admit any wrongful conduct by Inovio or its Affiliates, or would limit or restrict the claims of or admit any invalidity and/or
unenforceability of any of the Patent Rights Controlled by Inovio. 
  

	10.8	Common Interest Disclosures 

 With regard to any information or opinions disclosed pursuant to this
Agreement by one Party to each other regarding intellectual property and/or technology owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property
rights may affect the conduct of the activities under this Agreement and/or DNA Plasmids and/or Adjuvants and/or Products and/or Delivery Devices, and have a 

  
 - 44 - 

 
further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights relating to the
conduct of the activities under this Agreement and/or DNA Plasmids and/or Adjuvants and/or Products and/or Delivery Devices. Accordingly, the Parties agree that all such information and materials obtained by Inovio and Roche from each other will be
used solely for purposes of the Parties’ common legal interests with respect to the conduct of the Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other
privilege or immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and materials. Neither Party shall have
the authority to waive any privilege or immunity on behalf of the other Party without such other Party’s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against any
other Party. 
  

	10.9	Hatch-Waxman 

 Notwithstanding anything herein to the contrary, should a Party receive a certification
for a Product pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417, known as the Hatch-Waxman Act), as amended, or its equivalent in a country other than the US, then such Party shall immediately provide
the other Party with a copy of such certification. Roche shall have thirty (30) days from date on which it receives or provides a copy of such certification to provide written notice to Inovio (“H-W Suit Notice”) whether Roche
will bring suit, at its expense, within a forty-five (45) day period from the date of such certification. Should such thirty (30) day period expire without Roche bringing suit or providing such H-W Suit Notice, then Inovio shall be free to
immediately bring suit in its name. 
  

	10.10	Biosimilar or interchangeable biological products 

 Notwithstanding anything herein to the contrary,
within four (4) years after the approval of a Product that has been licensed in the US as a biological product under 42 USC 262(a), and as may be needed from time to time thereafter, the Parties shall consult as to potential strategies with
respect to unexpired US Patent Rights that Cover the Product. Specifically, in anticipation of a receipt by the Product’s reference product sponsor (“Reference Product Sponsor”) of a biosimilar or interchangeable product application
pursuant to the Biologics Price Competition and Innovation Act of 2009 (Public Law 111-148), the Parties will discuss the Reference Product Sponsor’s likely course of action with regard to each such US Patent Right in the procedural steps set
forth under 42 USC §262(l), including a general plan for timely communication between the Parties in light of the statutory response deadlines. 
  

	10.11	Patent Term Extensions 

 The Parties shall use Commercially Reasonable Efforts to obtain all available
patent term extensions, adjustments or restorations, or supplementary protection certificates (“SPCs”, and together with patent term extensions, adjustments and restorations, “Patent Term Extensions”). Inovio shall
execute, or shall cause its licensor to execute, such authorizations and other documents and take such other actions as may be reasonably requested by Roche to obtain such Patent Term Extensions, including designating Roche as its agent for such
purpose as provided in 35 U.S.C. Section 156. All filings for such Patent Term Extensions shall be made by Roche; provided, that in the event that Roche elects not to file for a Patent Term Extension, Roche shall (a) promptly inform Inovio
of its intention not to file and (b) grant Inovio the right to file for such Patent Term Extension. Each Party shall execute such authorizations and other documents and take such other actions as may be reasonably requested by the other Party
to obtain such extensions. The Parties shall cooperate with each other in gaining patent term restorations, extensions and/or SPCs wherever applicable to such Inovio Patent Rights. 

  
 - 45 - 

	11.	Representations, Warranties and Covenants 

  

	11.1	Inovio Representations, Warranties and Covenants 

  

	11.1.1	Existing Agreements 

 Inovio is not currently in material breach of any of its obligations under the Existing
Agreements and the Existing Agreements are in full force and effect, and Inovio covenants that it shall use diligent efforts not to materially breach any of its obligations under the Existing Agreements after the Effective Date. 

 

	11.1.2	Safety Data 

 Inovio has disclosed to Roche and will immediately continue to disclose to Roche (i) the
results of all preclinical testing of DNA Plasmids, Adjuvants, Products and Delivery Devices in its possession or control and (ii) all information in its possession or control concerning side effects, injury, toxicity or sensitivity reaction
and incidents or severity thereof with respect to DNA Plasmids, Adjuvants, Products and Delivery Devices. 
  

	11.1.3	Third Party Rights 

 Inovio has no knowledge of the existence of any patent or patent application owned by or
licensed to any Third Party or contractual obligations to Third Parties that could prevent Roche from making, having made, using, offering for sale, selling or importing DNA Plasmids, Adjuvants, Products and Delivery Devices generally in the
Territory. Inovio is not aware of any infringement or misappropriation of the Inovio IP Rights existing as of the Effective Date by any Third Party. 
  

	11.1.4	Control of Patent Rights 

 Inovio is the exclusive owner of all right, title and interest in, or is the
exclusive licensee of the Inovio IP Rights, free and clear of any liens or encumbrances. Appendix 1.54 is a complete and accurate list of all Patent Rights owned by or Controlled by Inovio as of the Effective Date that are useful or necessary to
research, develop manufacture and commercialize Products, including the DNA Plasmids, Adjuvants and Delivery Devices associated therewith. 
  

	11.1.5	Inventors 

 All of Inovio’s employees, officers and consultants have executed agreements requiring
assignment to Inovio of all Inventions made by such individuals during the course of and as a result of their association with Inovio. 
  

	11.1.6	Grants 

 Inovio warrants that it has the full right, power and authority, and has obtained all approvals,
permits or consents necessary, to enter into this Agreement and to perform all of its obligations and to grant the licenses provided hereunder. 
  

	11.1.7	Authorization 

 The execution, delivery and performance of this Agreement by Inovio and all instruments and
documents to be delivered by Inovio hereunder: (i) are within the corporate power of Inovio; (ii) have been duly authorized by all necessary or proper corporate action; (iii) are not in contravention of any provision of the
certificate of formation or limited liability company agreement of Inovio; (iv) to the knowledge of Inovio, will not violate any law or regulation or any order or decree of any court of governmental instrumentality; (v) will not violate
the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which Inovio is a 

  
 - 46 - 

 
party or by which Inovio or any of its property is bound, which violation would have an adverse effect on the financial condition of Inovio or on the ability of Inovio to perform its obligations
hereunder; and (vi) do not require any filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other than Regulatory Approvals
required for the sale of Products and filings with Regulatory Authorities required in connection with Products). 
  

	11.1.8	Ownership and Validity of Know-How 

 Inovio’s Know-How is legitimately in the possession of Inovio and has
not been misappropriated from any Third Party. Inovio Controls the Patents and Know-How necessary to (i) use the Adjuvants’’
‘’’’’’’’’’’’’’’’’’’’’’ ‘’’’’’’’’’’’’’ in the manner contemplated by this Agreement, and (ii) grant to Roche the right to use such Adjuvants. Inovio has taken reasonable measures to protect the confidentiality of its Know-How. To the knowledge of
Inovio, none of the Patents within the Inovio Patent Rights existing as of the Effective Date are invalid or unenforceable. 
  

	11.1.9	No Claims 

 There are no claims or investigations pending or threatened against Inovio or any of its Affiliates,
at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially adversely affect Inovio’s ability to perform its obligations hereunder. No claims of
infringement, misappropriation or other conflict with any intellectual property rights or other rights owned or controlled by any Third Party have been made or threatened with respect to the Inovio IP Rights existing as of the Effective Date. 

 

	11.1.10	No Conflict 

 Neither Inovio nor any of its Affiliates is or will be under any obligation to any person,
contractual or otherwise, that is conflicting with the terms of this Agreement or that would impede the fulfillment of Inovio’s obligations hereunder. 
  

	11.1.11	No Other Representations 

 EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, THE FOREGOING REPRESENTATIONS AND
WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF PRODUCTS. 

 

	11.2	Roche Representations, Warranties and Covenants 

  

	11.2.1	Inventors 

 All of Roche’s employees, officers and consultants shall be required to assign to Roche of all
Inventions made by such individuals during the course of and as a result of their activities pursuant to this Agreement. 
  

	11.2.2	Grants 

 Roche warrants that it has the full right, power and authority, and has obtained all approvals, permits
or consents necessary, to enter into this Agreement and to perform all of its obligations hereunder. 
  

	11.2.3	Authorization 

 The execution, delivery and performance of this Agreement by Roche and all instruments and
documents to be delivered by Roche hereunder: (i) are within the corporate power of Roche; (ii) have been duly authorized by all necessary or proper corporate action; (iii) are not in 

  
 - 47 - 

 
contravention of any provision of the certificate of formation or limited liability company agreement of Roche; (iv) to the knowledge of Roche, will not violate any law or regulation or any
order or decree of any court of governmental instrumentality; (v) will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which Roche is a party or by which Roche or any of its property is
bound, which violation would have an adverse effect on the financial condition of Roche or on the ability of Roche to perform its obligations hereunder; and (vi) do not require any filing or registration with, or the consent or approval of, any
governmental body, agency, authority or any other person, which has not been made or obtained previously (other than Regulatory Approvals required for the sale of Products and filings with Regulatory Authorities required in connection with
Products). 
  

	11.2.4	No Claims 

 There are no claims or investigations pending or threatened against Roche or any of its Affiliates,
at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially adversely affect Roche’s ability to perform its obligations hereunder. 

 

	11.2.5	No Conflict 

 Neither Roche nor any of its Affiliates is or will be under any obligation to any person,
contractual or otherwise, that is conflicting with the terms of this Agreement or that would impede the fulfillment of Roche’s obligations hereunder. 
  

	11.2.6	No Other Representations 

 EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, THE FOREGOING REPRESENTATIONS AND
WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF PRODUCTS. 

 

	12.	Indemnification 

  

	12.1	Indemnification by Roche 

 Roche shall indemnify, hold harmless and defend Inovio and its directors,
officers, employees and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts Inovio becomes
legally obligated to pay because of any claim or claims against it to the extent that such claim or claims arise out of activities related to the Products (e.g. product liability claims) conducted by or on behalf of Roche, except to the extent such
losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of Inovio, its Affiliates or Third Party manufacturers. 
  

	12.2	Indemnification by Inovio 

 Inovio shall indemnify, hold harmless and defend Roche and its directors,
officers, employees and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts Roche becomes
legally obligated to pay because of any claim or claims against it to the extent that such claim or claims arise out of activities related to (i) the Products (e.g. product liability claims) conducted by or on behalf of Inovio, and/or
(ii) DNA Plasmids and/or Adjuvants conducted by or on behalf of Inovio or Roche, except to the extent such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of Roche, its Affiliates or
Third Party manufacturers. 

  
 - 48 - 

	12.3	Procedure 

 In the event of a claim by a Third Party against a Party entitled to indemnification under
this Agreement (“Indemnified Party”), the Indemnified Party shall promptly notify the other Party (“Indemnifying Party”) in writing of the claim and the Indemnifying Party shall undertake and solely manage and
control, at its sole expense, the defense of the claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its
choice. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnifying Party shall not settle any such claim unless such
settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 
  

	13.	Liability 

 Neither Party shall be liable to the other Party as a result of failure or delay to develop
and/or commercialize the Product, including but not limited to, a) a delay in timelines, or b) delay or failure to recruit patients, or c) a change in its respective study protocols, or d) failure of the other Party to obtain regulatory
approval for Products. 
 Except for breach of Section 14.1, NO PARTY SHALL BE ENTITLED TO RECOVER FROM ANOTHER PARTY ANY SPECIAL, INCIDENTAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER. 
  

	14.	Obligation Not to Disclose Confidential Information 

  

	14.1	Non-Use and Non-Disclosure 

 During the Term of this Agreement and for five (5) years thereafter, a
Receiving Party shall (i) treat Confidential Information provided by Disclosing Party as it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information to Third
Parties, without the Disclosing Party’s prior written consent, and (iii) not use such Confidential Information other than for fulfilling its obligations under this Agreement. 

 

	14.2	Permitted Disclosure 

 Notwithstanding the obligation of non-use and non-disclosure set forth in
Section 14.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial considerations. 

 

	14.3	Press Releases 

 The Parties may issue a press release announcing the existence and selected key terms of
this Agreement, in a form substantially similar to the template attached as Appendix 14.3. 
 Roche shall issue press releases in accordance with its
internal policy that typically does not issue a second press release until proof of concept has been achieved for a Product. Roche shall provide Inovio with a copy of any draft press release related to the activities contemplated by this Agreement
at least two (2) weeks prior to its intended publication for Inovio’s review. Inovio may provide Roche with suggested modification to the draft press release. Roche shall consider Inovio’s suggestions in issuing its press release.

  
 - 49 - 

 Inovio shall only issue press releases related to the activities contemplated by this Agreement that have either
(i) been approved by Roche or (ii) are required to be issued by Inovio as a matter of law. In all circumstances, Inovio shall provide Roche with a draft press release at least two (2) weeks prior to its intended publication for
Roche’s review. During such period, Roche shall (i) approve the draft press release and permit Inovio to issue the press release, (ii) contact Inovio to discuss modification to the draft press release, or (iii) contact Inovio and
disapprove the press release. If Roche asks for modification, then Inovio shall either make such modification or work with Roche to arrive at a press release that Roche approves. If Inovio issues a press release without Roche’s approval, then
Inovio’s decision must be based on a legal opinion (either written or oral) that the release was required to be issued by Inovio as a matter of law. 
  

	14.4	Publications 

 During the Term of this Agreement, the following restrictions shall apply with respect to
disclosure by any Party of Confidential Information relating to DNA Plasmids, Adjuvants (to the extent specific to a Product), Products and Delivery Devices Adjuvants (to the extent specific to a Product) in any publication or presentation: 

a) Both Parties acknowledge that it is their policy for the studies and results thereof to be registered and published in accordance with their
internal guidelines. Roche, in accordance with its internal policies and procedures, shall have the right to publish all studies, clinical trials and results thereof on the clinical trial registries that are maintained by or on behalf of Roche.
Unless authorized by Roche in writing, Inovio shall not publish any studies, clinical trials or results thereof on its clinical trial registry, provided however, that Roche’s clinical trial registry can be accessed via a link from Inovio’s
clinical trial registry. 
 b) A Party (“Publishing Party”) shall provide the other Party with a copy of any proposed
publication or presentation at least thirty (30) days (or at least twenty (20) days in the case of oral presentations) prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it
reasonably believes are necessary to continue to maintain the Confidential Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall
not be unreasonably refused; and If such other Party notifies (“Publishing Notice”) the Publishing Party in writing, within thirty (30) days after receipt of the copy of the proposed publication or presentation (or at least
twenty (20) days in the case of oral presentations), that such publication or presentation in its reasonable judgment (i) contains an invention, solely or jointly conceived and/or reduced to practice by the other Party, for which the other
Party reasonably desires to obtain patent protection or (ii) could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party
shall prevent such publication or delay such publication for a mutually agreeable period of time. In the case of inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s)
on such invention, and in no event less than ninety (90) days from the date of the Publishing Notice. 
  

	14.5	Commercial Considerations 

 Nothing in this Agreement shall prevent Roche or its Affiliates from
disclosing Confidential Information of Inovio to (i) governmental agencies to the extent required or desirable to secure government approval for the development, manufacture or sale of Product in the Territory, (ii) Third Parties acting on
behalf of Roche, to the extent reasonably necessary for the development, manufacture or sale of Product in the Territory, or (iii) Third Parties to the extent reasonably 

  
 - 50 - 

 
necessary to market the Product in the Territory. The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information is required to
be disclosed by the Receiving Party to comply with applicable law, to defend or prosecute litigation or to comply with governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing
Party and, to the extent practicable, takes reasonable and lawful actions to minimize the degree of such disclosure. 
  

	15.	Term and Termination 

  

	15.1	Commencement and Term 

 This Agreement shall commence upon the Effective Date and continue for the
Agreement Term. 
  

	15.2	Termination 

  

	15.2.1	Termination for Breach 

 A Party (“Non-Breaching Party”) shall have the right to terminate this
Agreement in its entirety or on a country-by-country, Research Program-by-Research Program, or Product-by-Product basis in the event the other Party (“Breaching Party”) is in breach of any of its material obligations under this
Agreement related thereto. The non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach and the countries, Research Program and/or Product in which the Non-Breaching Party intends to have this
Agreement terminate. The Breaching Party shall have a period of ninety (90) days after such written notice is provided (“Peremptory Notice Period”) to cure such breach. If the Breaching Party has a dispute as to whether such
breach occurred or has been cured, it will so notify the Non-Breaching Party, and the expiration of the Preemptory Notice Period shall be tolled until such dispute is resolved pursuant to Section 16.2. Upon a determination of breach or failure
to cure, the Breaching Party may have the remainder of the Preemptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching Party’s request for
termination, this Agreement shall terminate in such countries effective as of the expiration of the Preemptory Notice Period. Inovio’s failure to comply with the CAPA Plan, Product Supply Agreements and/or Device Supply Agreements in all
material regards would be a material breach of this Agreement by Inovio. Inovio shall have the Peremptory Notice Period to cure the first material breach of compliance with the CAPA Plan. However, any subsequent failure to comply with the CAPA Plans
shall give Roche the right to immediately terminate this Agreement upon written notice to Inovio. 
  

	15.2.2	Insolvency 

 A Party shall have the right to terminate this Agreement, if the other Party incurs an Insolvency
Event; provided, however, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not
dismissed within ninety (90) days after the filing thereof. 
  

	15.2.3	Termination by Roche without Cause 

 Roche shall have the right to terminate this Agreement at any time on a
Research Program-by-Research Program, Product-by-Product and/or country-by-country basis (i) upon ninety (90) days prior written notice before First Commercial Sale of the Product to which the termination applies, and (ii) upon one
hundred eighty (180) days prior written notice after the First Commercial Sale of the Product to which the termination applies. The effective date of termination under this Section 15.2.3 shall be (i) ninety (90) days after, or
(ii) one hundred eighty (180) days after, as the case may be, Roche providing written notice to Inovio. 

  
 - 51 - 

	15.3	Consequences of Termination 

  

	15.3.1	Termination by Inovio for Breach by Roche 

 Upon any termination by Inovio for breach by Roche, any ongoing
Research Program or development activities related to the subject matter of such breach shall cease, and all rights and licenses granted by Inovio to Roche under this Agreement shall also terminate in their entirety or on a country-by-country basis,
Research Program-by-Research Program, and/or Product-by-Product basis, as applicable, on the effective date of termination. Roche will pay Inovio for any unpaid Research and Development Support Payments actually incurred or committed to be incurred
under Section 6.2. 
 Any existing, permitted sublicense granted by Roche under this Agreement shall continue in full force and effect, provided that
the permitted Sublicensee did not cause the breach that gave rise to a termination under Section 15.2.1, no default exists under the sublicense with such permitted Sublicensee and such permitted Sublicensee agrees to be bound by all the terms
and conditions of this Agreement that are applicable to such permitted Sublicensee including rendering directly to Inovio all payments and other obligations due to Inovio related to such sublicense (including all event payments and royalty
payments). 
 If Inovio desires to continue development and/or commercialization of Product (s), Inovio shall give a Continuation Election Notice to Roche
within ninety (90) days of Inovio’s notice of termination for breach by Roche. If Roche receives such a timely Continuation Election Notice: 

a) After the effective date of termination Roche shall, to the extent Roche has the right to do so, assign and transfer to Inovio, at no
expense to Inovio, the Data Package to support the continued development and commercialization of Products that were being developed and/or commercialized by Roche as of the effective date of termination (each a “Termination
Product”) . All documents shall be transferred in the form and format in which such materials are maintained by Roche. Original paper copies shall only be transferred, if legally required. Roche shall not be required to prepare or finalize
any new data, reports or information solely for purposes of transfer to Inovio. In connection with research studies or clinical trials, Roche may have collected human samples and related clinical information for additional limited research and
development programs (“Samples”). Legal and contractual restrictions may apply to such Samples, in particular as Samples may qualify as personal identifiable information. Inovio acknowledges and accepts that notwithstanding anything
herein, Roche shall not be obliged to transfer any such Samples to Inovio. 
 b) At Inovio’s request, Roche shall assign all clinical
trial agreements between Roche and a Third Parties, to the extent such agreements (i) have not been cancelled and are assignable without Roche paying any consideration or commencing litigation in order to effect an assignment of any such
agreement and (ii) relate solely to the development of such Termination Products and/or the management and continued performance of any clinical trials for such Termination Product ongoing as of the effective date of such termination; provided
that, Inovio assumes all of Roche’s obligations (including payment obligations) following the effective date of such assignment under such assigned agreement and pays any fees payable to such Third Party in connection with such assignment. 

c) Inovio shall, upon transfer, have the right to disclose such filings, approvals and data to (i) governmental agencies of the country to
the extent required or desirable to secure government approval for the development, manufacturing or sale of Product(s) in the country, (ii) Third Parties acting on behalf of Inovio, its Affiliates or licensees, to the extent reasonably
necessary for the development, manufacture, or sale of Product(s) in the country, and (iii) Third Parties to the extent reasonably necessary to market Product(s) in the country. 

  
 - 52 - 

 d) Inovio shall have a
‘’’’’’’’’’’’’’’’’’’’’’’’’, non-exclusive license under the Roche IP Rights, including Roche’s interest in the Joint Patent Rights and Joint Know-How, solely to the extent necessary to allow Inovio, its Affiliates or licensees to
develop, manufacture, have manufactured, use, export and import the applicable Termination Product(s) in the applicable country(ies), provided that with respect to any Roche IP Rights obtained pursuant to an agreement with a Third Party, Inovio
assumes all of Roche’s obligations (including payment obligations) under such agreement to the extent applicable to the Termination Product(s). Inovio shall have a
‘’’’’’’’’’’’’’’’’’’’’’’’’’’, exclusive license under the Roche IP Rights, including Roche’s interest in the Joint Patent Rights and Joint Know-How, solely to the extent necessary to allow Inovio, its Affiliates or licensees to offer
for sale and sell the applicable Termination Product(s) in the applicable country(ies), provided that with respect to any Roche IP Rights obtained pursuant to an agreement with a Third Party, Inovio assumes all of Roche’s obligations (including
payment obligations) under such agreement to the extent applicable to the Termination Product(s). For clarity, the licenses under this Section 15.3.1(d) shall not include any licenses that Roche has with a Third Party for which such grant would
be prohibited or under which a member of the Roche Group would incur financial obligations to such Third Party. 
  

	15.3.2	Termination by Roche for Breach by Inovio or Inovio Insolvency 

 Upon any termination of this Agreement for
breach by Inovio or Inovio’s Insolvency pursuant to Section 15.2.1 or Section 15.2.2, as applicable, all rights and licenses granted by Roche to Inovio under this Agreement shall terminate in their entirety or on a Research Program-by
Research Program, country-by-country, and/or Product-by-Product basis, as applicable, on the effective date of termination (except to the extent necessary to conduct any additional activities as contemplated under this Article 15). All rights and
licenses granted to Roche under Article 3 shall become perpetual and irrevocable, provided that Roche must exercise its Option Right for any RC Targets within thirty (30) days after notice of an applicable termination. Inovio’s obligations
of exclusivity set forth in Section 2.1.5 shall continue for Products and RC Targets (for those RC Targets subject to the Option Right, such exclusivity shall only apply to those RC Targets for which Roche exercises its Option Right). Inovio
will promptly disclose to or provide Roche with any Collaboration Invention not previously provided or disclosed to Roche. Section 6.6 shall survive provided that all payments required to be paid shall be reduced by fifty percent (50%) of
what would otherwise have been owned. In addition, if Inovio is responsible for conducting a Clinical Study for a Terminated Product hereunder, then Section 15.3.4 shall apply. 

 

	15.3.3	Termination by Roche without Cause 

 Upon any termination by Roche without cause, any ongoing Research Program
or development activities related to the subject matter of such termination shall cease, and all rights and licenses granted by Inovio to Roche under this Agreement shall terminate in its entirety or on a country-by-country, Research
Program-by-Research Program, and/or Product-by Product basis, as applicable, on the effective date of termination, provided that Roche shall have a fully paid-up, non-exclusive license for Roche and its Affiliates to use the Inovio Know-How for
research purposes only. Roche will pay Inovio for any unpaid Research and Development Support Payments actually incurred or committed to be incurred under Section 6.2. 

  
 - 53 - 

 If Inovio desires to continue development and/or commercialization of Product(s), Inovio shall give a
Continuation Election Notice to Roche within ninety (90) days of receipt of Roche’s notice of termination without cause. If Roche receives such a timely Continuation Election Notice: 

a) After the effective date of termination Roche shall, to the extent Roche has the right to do so, transfer to Inovio, at no expense to
Inovio, the Data Package to support the continued development and commercialization of Termination Product(s). All documents shall be transferred in the form and format in which such materials are maintained by Roche. Original paper copies shall
only be transferred, if legally required. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to Inovio. In connection with research studies or clinical trials, Roche may have
collected Samples for additional limited research and development programs. Legal and contractual restrictions may apply to such Samples, in particular as Samples may qualify as personal identifiable information. Inovio acknowledges and accepts that
notwithstanding herein, Roche shall not be obliged to transfer any such Samples to Inovio. 
  

	b)	At Inovio’s request, Roche shall assign all clinical trial agreements between Roche and a Third Parties, to the extent such agreements (i) have not been cancelled and are assignable without Roche paying any
consideration or commencing litigation in order to effect an assignment of any such agreement and (ii) relate solely to the development of such Termination Products and/or the management and continued performance of any clinical trials for such
Termination Product ongoing as of the effective date of such termination; provided that, Inovio assumes all of Roche’s obligations (including payment obligations) following the effective date of such assignment under such assigned agreement and
pays any fees payable to such Third Party in connection with such assignment. 

  

	c)	Inovio shall, upon transfer, have the right to disclose such filings, approvals and data to (i) governmental agencies of the country to the extent required or desirable to secure government approval for the
development, manufacture or sale of Product(s) in the country; (ii) Third Parties acting on behalf of Inovio, its Affiliates or licensees, to the extent reasonably necessary solely for the development, manufacture, or sale of Product(s) in the
country, or (iii) Third Parties to the extent reasonably necessary to market Product(s) in the country. 

  

	d)	Inovio shall have a ‘’’’’’’’’’’’’’’’’’’’’’’’,
non-exclusive license under the Roche IP Rights, including Roche’s interest in the Joint Patent Rights and Joint Know-How, solely to the extent necessary to allow Inovio, its Affiliates or licensees to develop, manufacture, have manufactured,
use, export and import the applicable Termination Product(s) in the applicable country(ies), provided that with respect to any Roche IP Rights obtained pursuant to an agreement with a Third Party, Inovio assumes all of Roche’s obligations
(including payment obligations) under such agreement to the extent applicable to the Termination Product(s). Inovio shall have a
‘’’’’’’’’’’’’’’’’’’’’’’’’’’, exclusive license under the Roche IP
Rights, including Roche’s interest in the Joint Patent Rights and Joint Know-How, solely to the extent necessary to allow Inovio, its Affiliates or licensees to offer for sale and sell the applicable Termination Product(s) in the applicable
country(ies), provided that with respect to any Roche IP Rights obtained pursuant to an agreement with a Third Party, Inovio assumes all of Roche’s obligations (including payment obligations) under such agreement to the extent applicable to the
Termination Product(s). For clarity, the licenses under this Section 15.3.3(d) shall not include any licenses that Roche has with a Third Party for which such grant would be prohibited or under which a member of the Roche Group would incur
financial obligations to such Third Party. 

  
 - 54 - 

	15.3.4	Other Obligations 

  

	 	15.3.4.1	Obligations Related to Ongoing Activities 

 If Inovio does not provide timely Continuation Election Notice, then
Roche shall have the right to cancel all ongoing obligations. 
 If Inovio provides such timely Continuation Election Notice, then from the date of notice
of termination until the effective date of termination, Roche shall continue activities, including preparatory activities, ongoing as of the date of notice of termination. However, Roche shall not be obliged to initiate any new activities not
ongoing at the date of notice of termination. 
 After the effective date of termination, Roche shall not have any obligation to perform and/or complete any
activities or to make any payments for performing or completing any activities under this Agreement, except as expressly stated herein. 
 Notwithstanding
the foregoing, in case of any termination, upon the request of the Party taking responsibility for a Termination Product, if the other Party is conducting a Clinical Study for such Termination Product, then such Party shall complete any Clinical
Study related to the Termination Product that is being conducted under its IND for the Termination Product and is ongoing as of the effective date of termination; provided, however, that 

 

	a)	both Inovio and Roche in their reasonable judgment have concluded that completing any such Clinical Studies does not present an unreasonable risk to patient safety; 

 

	b)	neither Party shall have any obligation to recruit or enroll any additional patients after the date of termination; and 

  

	c)	the Party taking responsibility for the Termination Product agrees to reimburse the other Party for all of its development costs that arise after the effective date of termination in completing such Clinical Studies.

  

	 	15.3.4.2	Obligations Related to Manufacturing 

  

	 	a)	Clinical Supplies 

 In the case of termination by Inovio according to Section 15.2.1 or
15.2.2 or by Roche under Section 15.2.3, if Inovio elects to develop the Product(s), to the extent that Roche is the party responsible for the manufacture of the Termination Product, Roche shall transfer all existing and available clinical
material to Inovio at Roche’s fully burdened manufacturing cost. Roche shall have no obligation to perform any additional activities concerning the clinical supplies (e.g. retesting, analyses). Inovio shall assume all liability for the use of
such material. In the case of termination by Roche according to Section 15.2.1 or 15.2.2, to the extent that Inovio is responsible for manufacture of a Termination Product, Inovio will continue to manufacture such Terminated Product for Roche,
on the terms agreed to herein, unless Roche elects to exercise its right of portability set forth in Section 5.3.4, which right shall survive. 
  

	 	b)	Commercial Supplies 

 In the case of termination by Inovio according to Section 15.2.1 or
15.2.2 or by Roche under Section 15.2.3, if a Product is marketed in any country of Territory on the date of the notice of termination of this Agreement, upon the request of Inovio, to the extent that Roche is the party responsible for the
manufacture of the Termination Product, Roche shall manufacture and supply such Product to Inovio for a period that shall not exceed eighteen (18) months from the effective date of the termination of this Agreement at a price to be agreed by
the Parties in good faith. Inovio shall use Commercially Reasonable Efforts to take over the manufacturing as soon as possible after the effective date of termination. In the case of termination by Roche according to Section 15.2.1 or 15.2.2,
to the extent that Inovio is 

  
 - 55 - 

 
responsible for manufacture of a Termination Product, Inovio will continue to manufacture such Terminated Product for Roche, on the terms agreed to herein, unless Roche elects to exercise its
right of portability set forth in Section 5.3.4, which right shall survive. 
 Unless otherwise agreed by the Parties, the termination of this
Agreement shall cause the automatic termination of all ancillary agreements related hereto, if any. 
  

	 	15.3.4.3	Royalty and Payment Obligations 

 Termination of this Agreement by a Party, for any reason, shall not release
Roche from any obligation to pay royalties or make any payments to Inovio that were due and payable prior to the effective date of termination. Unless otherwise expressly provided for herein, termination of this Agreement by a Party, for any reason,
will release Roche from any obligation to pay royalties or make any payments to Inovio that would otherwise become due or payable after the effective date of termination. 
  

	15.4	Survival 

 Section 3.5 (Retained Rights), Section 10.1 (Ownership of Inventions); Article 12
(Indemnification), Article 14 (Obligation Not to Disclose Confidential Information), Article 15 (Term and Termination), Section 16.2 (Governing Law) and Section 16.5 (Arbitration) shall survive any expiration or termination of this
Agreement for any reason. 
  

	16.	Miscellaneous 

  

	16.1	Bankruptcy 

 All licenses (and to the extent applicable rights) granted under or pursuant to this
Agreement by Inovio to Roche are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined under
Section 101(60) of the Bankruptcy Code. Unless Roche elects to terminate this Agreement, the Parties agree that Roche, as a licensee or sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and
elections under the Bankruptcy Code, subject to the continued performance of its obligations under this Agreement. 
  

	16.2	Change of Control 

 If there is a Change of Control of Inovio, then Inovio shall provide written notice
to Roche at least thirty (30) days prior to completion of such Change of Control, subject to any confidentiality obligations of Inovio then in effect (but in any event shall notify Roche within fifteen (15) days after completion of such
Change of Control). 
 The Change of Control Group in connection with such Change of Control shall agree in writing with Roche that it will not utilize any
of Roche’s Know-How, Patent Rights, Inventions, Materials or Confidential Information or Joint Know-How, Joint Patent Rights or Collaboration IP (collectively, “Sensitive Information”) for the research, development or
commercialization of any product for the treatment of any indication or patient population for which a Product may be developed or commercialized. 

Following consummation of the Change of Control, Roche and the Change of Control Group shall adopt in writing reasonable procedures to prevent the disclosure
of Sensitive Information beyond Inovio’s personnel who need to know the Sensitive Information solely for the purpose of fulfilling the Acquired Party’s obligations under this Agreement. 

If there is a Change of Control of Inovio then Roche may, in its sole discretion, cause Inovio to immediately cease any work under the Research Plans. Upon
any such ceasation, Inovio will 

  
 - 56 - 

 
immediately cease all activity, transfer to Roche all data developed by Inovio, and reconcile actual FTE costs in the quarter against the quarterly prepayment made by Roche. Within thirty
(30) days of such reconciliation, Inovio will refund to Roche the difference between the quarterly prepayment by Roche and Inovio actual FTE expenditures in the quarter. All licenses granted by Roche to Inovio shall terminate, except the
license granted by Roche to Inovio under Section 3.3, above, shall survive . In addition, Roche shall have the right to suspend Inovio or its successor’s participation and rights under Article 4, and Roche shall have the right to make all
decisions under the Agreement unilaterally and without consultation with Inovio or its successor. 
  

	16.3	Governing Law 

 This Agreement shall be governed by and construed in accordance with the laws of New
Jersey, without reference to its conflict of laws principles. 
  

	16.4	Disputes 

 Unless otherwise set forth in this Agreement, in the event of any dispute in connection with
this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows:

  

			
	For Inovio:	  	CEO
	For Roche:	  	Head of Roche Partnering

  

	16.5	Arbitration 

 Should the Parties fail to agree within two (2) months after such dispute has first
arisen, it shall be finally settled by arbitration in accordance with the Rules of American Arbitration Association (AAA) as in force at the time when initiating the arbitration. The tribunal shall consist of three arbitrators. Each Party shall
select one (1) arbitrator and the arbitrators shall select the third arbitrator. The place of arbitration shall be Newark, New Jersey, US. The language to be used shall be English. 

 

	16.6	Assignment 

 Neither Party may assign its rights or obligations under this Agreement absent the prior
written consent of the other Party, except to any of its Affiliates or in the context of a merger, acquisition, sale or other transaction involving all or substantially all of the assets of the Party seeking to assign, provided that, in the case of
an assignment to an Affiliate, the assigning Party shall be responsible for the actions of its Affiliates, in which case such Party in its sole discretion may assign its rights and obligations under this Agreement. Any permitted assignment shall be
binding on the successors of the assigning Party. 
  

	16.7	Debarment 

 Inovio represents and warrants that it has never been debarred under 21 U.S.C. §335a,
disqualified under 21 C.F.R. §312.70 or §812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred,
suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event Inovio receives notice of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the
above-referenced statutes, Inovio shall immediately notify Roche in writing and Roche shall have the right, but not the obligation, to terminate this Agreement, effective, at Roche’s option, immediately or at a specified future date. 

 

	16.8	Independent Contractor 

 No employee or representative of either Party shall have any authority to bind
or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose 

  
 - 57 - 

 
any contractual or other liability on the other Party without said Party’s prior written approval. For all purposes, and notwithstanding any other provision of this Agreement to the
contrary, Inovio legal relationship to Roche under this Agreement shall be that of independent contractor. 
  

	16.9	Unenforceable Provisions and Severability 

 If any of the provisions of this Agreement are held to be
void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement
will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions. 

 

	16.10	Waiver 

 The failure by either Party to require strict performance and/or observance of any obligation,
term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any
obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
  

	16.11	Appendices 

 All Appendices to this Agreement shall form an integral part to this Agreement. 

 

	16.12	Entire Understanding 

 This Agreement contains the entire understanding between the Parties hereto with
respect to the within subject matter and supersedes any and all prior agreements, understandings and arrangements, whether written or oral. 
  

	16.13	Amendments 

 No amendments of the terms and conditions of this Agreement shall be binding upon either
Party hereto unless in writing and signed by both Parties. 
  

	16.14	Invoices 

 All invoices that are required or permitted hereunder shall be in writing and sent by Inovio
to Roche at the following address or other address as Roche may later provide: 
 F. Hoffmann-La Roche Ltd 

Kreditorenbuchhaltung 
 4070 Basel

 Switzerland 
 With a copy to the Roche
Alliance Director as directed by Roche. 

  
 - 58 - 

	16.15	Notice 

 All notices that are required or permitted hereunder shall be in writing and sufficient if
delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid,
return receipt requested, addressed as follows: 
  

			
	if to Inovio, to:	  	
		  	 Inovio Pharmaceuticals, Inc.
 1787 Sentry
Parkway West, Building 18, Suite 400
 Blue Bell, Pennsylvania 19422 U.S.A.

Attn: Niranjan Sardesai, COO
 Facsimile No.:
267-440-4242

		
	And:	  	 Attn: Legal Department
 Facsimile No.:
267-440-4242

		
	if to Roche, to:	  	 F. Hoffmann-La Roche Ltd
 Grenzacherstrasse
124
 4070 Basel
 Switzerland

Attn: Legal Department
 Facsimile No.: +41 61 688 13
96

		
	And:	  	 Hoffmann-La Roche Inc.
 340 Kingsland Street

Nutley, New Jersey 07110
 U.S.A.

Attn. Corporate Secretary
 Facsimile No.: +1 973
235-3500

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. 
 [Signature Page Follows] 

  
 - 59 - 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 

 

									
	Inovio Pharmaceuticals, Inc.	 		 		 	
				
	 /s/ J. Joseph Kim
	 		 		 	
	Name:	 	J. Joseph Kim, Ph.D.	 		 		 	
	Title:	 	President and CEO	 		 		 	
				
	F. Hoffmann-La Roche Ltd	 		 		 	
			
	 /s/ Christophe Carissimo
	 		 	 /s/ Melanie Frey Wick

	Name:	 	Christophe Carissimo	 		 	Name:	 	Dr. Melanie Frey Wick
	Title:	 	Global Licensing Director	 		 	Title:	 	Vice Director
				
	Hoffmann-La Roche Inc.	 		 		 	
				
	 /s/ John P. Parise
	 		 		 	
	Name:	 	John J. Parise	 		 		 	
	Title:	 	Authorized Signatory	 		 		 	

  
 - 60 - 

 Appendix 1.54 

Inovio Background Patent Rights 
 INOVIO
PATENT/IP SCHEDULE 
  

	1	PATENT RIGHTS TO DELIVERY DEVICES 

  

	A.	Electroporation 

  

	1)	CELLECTRA® 

  

	2)	SKIN/MUSCLE 

  

	3)	SKIN 

  

	4)	MUSCLE 

  

	5)	ONCOLOGY - TUMORS 

  

	6)	OTHER 

  

	2	PATENT RIGHTS TO ENABLING TECHNOLOGIES 

  

	A.	Vaccine Additives 

  

	1.	ADJUVANTS 

 IL-15 

IL-15 R-ALPHA 
 CTACK, MEK, TECK 

RANTES 
 IL-28 

IL-12 

 

	 	1.	FORMULATIONS 

 PLG - LIPID ADDITIVES 

PLG - LYOPHILIZATION FORMULA 
  

	B.	Functional DNA 

  

	1.	PLASMIDS 

  

	2.	LEADER SEQUENCES 

  

	3.	PROMOTERS 

  

	3	Patent rights to ProducTs 

  

	1	Hepatitis B 

  

	2	Prostate cancer 

	1	PATENT RIGHTS TO DELIVERY DEVICES 

  

	A.	Electroporation 

  

	1.	CELLECTRA® 

 AVSI-0010 - ELECTRODE ASSEMBLY FOR
CONSTANT-CURRENT ELECTROPORATION AND USE 
 AVSI-0048 - ELECTROPORATION DEVICES AND METHODS OF USING SAME FOR ELECTROPORATION OF CELLS IN MAMMALS 

 

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	AVSI0010	 	AU	 	Granted	 	2009251157	 	23-Dec-2009	 	2009251157	 	09-Aug-2012
	AVSI0010	 	CA	 	Published	 	2477870	 	06-Mar-2003	 		 	
	AVSI0010	 	EP	 	Published	 	03717937.1	 	06-Mar-2003	 		 	
	AVSI0010	 	MX	 	Granted	 	PA/A/2004/008670	 	06-Mar-2003	 	263479	 	06-Jan-2009
	AVSI0010	 	SG	 	Granted	 	200405195-9	 	06-Mar-2003	 	106747	 	29-Sep-2006
	AVSI0010	 	TW	 	Granted	 	92104867	 	06-Mar-2003	 	239855	 	21-Sep-2005
	AVSI0010	 	US	 	Granted	 	10/360768	 	07-Mar-2002	 	7245963	 	17-Jul-2007
	AVSI0010	 	US	 	Granted	 	11/495021	 	28-Jul-2006	 	7664545	 	16-Feb-2010
	AVSI0010	 	WO	 	Reportable	 	PCT/US03/06833	 	06-Mar-2003	 		 	
	AVSI0010 P1	 	CA	 	Allowed	 	2578847	 	03-Sep-2004	 		 	
	AVSI0010 P1	 	EP	 	Published	 	04788598.3	 	03-Sep-2004	 		 	
	AVSI0010 P1	 	TW	 	Granted	 	93127152	 	08-Sep-2004	 	246930	 	11-Jan-2006
	AVSI0010 P1	 	US	 	Granted	 	10/657725	 	08-Sep-2003	 	8209006	 	26-Jun-2012
	AVSI0010 P1	 	WO	 	Reportable	 	PCT/US04/28998	 	03-Sep-2004	 		 	
							
	AVSI0048	 	AU	 	Granted	 	2007313203	 	17-Oct-2007	 	2007313203	 	29-Nov-2012
	AVSI0048	 	CA	 	Published	 	2666501	 	17-Oct-2007	 		 	
	AVSI0048	 	CN	 	Published	 	200780046652.7	 	17-Oct-2007	 		 	

  
 - 62 - 

													
	AVSI0048	 	EP	 	Published	 	07839621.5	 	17-Oct-2007	 		 	
	AVSI0048	 	EP	 	Published	 	11184546.7	 	10-Oct-2011	 		 	
	AVSI0048	 	HK	 	Published	 	09111461.8	 	08-Dec-2009	 		 	
	AVSI0048	 	IN	 	Pending	 	2366/DELNP/2009	 	17-Oct-2007	 		 	
	AVSI0048	 	JP	 	Published	 	2009-533358	 	15-Jun-2009	 		 	
	AVSI0048	 	KR	 	Pending	 	2009-7007847	 	17-Oct-2007	 		 	
	AVSI0048	 	SG	 	Pending	 	200902629-5	 	17-Oct-2007	 		 	
	AVSI0048	 	SG	 	Granted	 	201107493-7	 	12-Oct-2011	 	175627	 	15-Apr-2013
	AVSI0048	 	US	 	Published	 	11/874072	 	17-Oct-2007	 		 	
	AVSI0048	 	WO	 	Reportable	 	PCT/US07/022139	 	17-Oct-2007	 		 	

  
 - 63 - 

	2.	SKIN/MUSCLE 

 GTI-1130 - SKIN AND MUSCLE-TARGETED GENE THERAPY BY PULSED ELECTRICAL FIELD 

GTI-2010 - VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD 

VGX0118 - Multiple Tissue Layer Electroporation Applicator and Device 

SPHERG1 - method of transferring nucleic acid into multicelled eukaryotic cells and combination therefor 

 

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	GTI-1130	 	AU	 	Granted	 	49883/99	 	13-Jul-1999	 	770092	 	27-May-2004
	GTI-1130	 	CA	 	Granted	 	2337652	 	13-Jul-1999	 	2337652	 	26-Mar-2013
	GTI-1130	 	EP	 	Published	 	99933937.7	 	13-Jul-1999	 		 	
	GTI-1130	 	EP	 	Published	 	11180420.9	 	07-Sep-2011	 		 	
	GTI-1130	 	EP	 	Published	 	11180419.1	 	07-Sep-2011	 		 	
	GTI-1130	 	US	 	Granted	 	09/352809	 	13-Jul-1999	 	6697669	 	24-Feb-2004
	GTI-1130	 	US	 	Granted	 	10/165657	 	07-Jun-2002	 	6678556	 	13-Jan-2004
	GTI-1130	 	US	 	Granted	 	10/756946	 	13-Jan-2004	 	7570992	 	04-Aug-2009
	GTI-1130	 	US	 	Granted	 	09/625825	 	26-Jul-2000	 	6654636	 	25-Nov-2003
	GTI-1130	 	US	 	Granted	 	10/233007	 	30-Aug-2002	 	6972013	 	06-Dec-2005
	GTI-1130	 	US	 	Granted	 	11/291459	 	30-Nov-2005	 	7922709	 	12-Apr-2011
							
	GTI-2010	 	AU	 	Published	 	2009205643	 	16-Jan-2009	 		 	
	GTI-2010	 	CA	 	Published	 	2710408	 	16-Jan-2009	 		 	
	GTI-2010	 	CN	 	Published	 	200980103021.3	 	16-Jan-2009	 		 	
	GTI-2010	 	EP	 	Published	 	09702445.9	 	16-Jan-2009	 		 	
	GTI-2010	 	HK	 	Published	 	11106149.4	 	15-Jun-2011	 		 	

  
 - 64 - 

													
	GTI-2010	 	IN	 	Published	 	4726/DELNP/2010	 	30-Jun-2010	 		 	
	GTI-2010	 	JP	 	Published	 	2010-543139	 	16-Jan-2009	 		 	
	GTI-2010	 	KR	 	Pending	 	10-2010-7018104	 	16-Aug-2010	 		 	
	GTI-2010	 	US	 	Published	 	12836163	 	14-Jul-2010	 		 	
	GTI-2010	 	WO	 	Published	 	PCT/US2009/000273	 	16-Jan-2009	 		 	
							
	VGX0118	 	AU	 	Published	 	2011223768	 	01-Mar-2011	 		 	
	VGX0118	 	CA	 	Published	 	2789733	 	01-Mar-2011	 		 	
	VGX0118	 	EP	 	Published	 	11751203.8	 	01-Mar-2011	 		 	
	VGX0118	 	KR	 	Pending	 	10-2012-7025737	 	01-Mar-2011	 		 	
	VGX0118	 	US	 	Expired	 	61309423	 	01-Mar-2010	 		 	
	VGX0118	 	US	 	Expired	 	61309860	 	02-Mar-2010	 		 	
	VGX0118	 	US	 	Published	 	13581700	 	29-Aug-2012	 		 	
	VGX0118	 	WO	 	Published	 	PCT/US2011/026688	 	01-Mar-2011	 		 	
							
	SPHERG1	 	US	 	Granted	 		 	2000-02-02	 	6528315	 	04-Mar-2003
	SPHERG1	 	 EP BE,
 CH,DE, FR, GB, IT
	 	Granted	 	1998935066	 	1998-06-30	 	EP0991425	 	12-Apr-2000

  

	3.	SKIN 

 GTI-1530 - Applicator for the electroporation of drugs and genes into surface cells 

GTI-3010 - Contactless Electropermeabilization Electrode and Method 

VGX0117 - A Tolerable and Minimally Invasive Skin Electroporation Device 

VGX0123 - A NONINVASIVE DERMAL ELECTROPORATION DEVICE 
 USF-A3 -
ELECTROMANIPULATION DEVICE AND METHOD 
  

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	GTI-1530	 	AT	 	Granted	 	99966432.9	 	17-Dec-1999	 	1140283	 	08-Mar-2006

  
 - 65 - 

													
	GTI-1530	 	AU	 	Granted	 	14354/95	 	13-Dec-1994	 	691237	 	27-Aug-1998
	GTI-1530	 	AU	 	Granted	 	68821/98	 	02-Apr-1998	 	741399	 	14-Mar-2002
	GTI-1530	 	AU	 	Granted	 	21969/00	 	17-Dec-1999	 	763535	 	06-Nov-2003
	GTI-1530	 	CA	 	Granted	 	2185024	 	13-Dec-1994	 	2185024	 	08-May-2001
	GTI-1530	 	CA	 	Granted	 	2311474	 	02-Apr-1998	 	2311474	 	02-Oct-2012
	GTI-1530	 	CH	 	Granted	 	99966432.9	 	17-Dec-1999	 	1140283	 	08-Mar-2006
	GTI-1530	 	DE	 	Granted	 	95905926.2	 	13-Dec-1994	 	P69426210.2	 	25-Oct-2000
	GTI-1530	 	DE	 	Granted	 	98914475.3	 	02-Apr-1998	 	69806794.0	 	24-Jul-2002
	GTI-1530	 	DE	 	Granted	 	99966432.9	 	17-Dec-1999	 	1140283	 	08-Mar-2006
	GTI-1530	 	EP	 	Granted	 	95905926.2	 	13-Dec-1994	 	0751802	 	25-Oct-2000
	GTI-1530	 	EP	 	Granted	 	98914475.3	 	02-Apr-1998	 	1028777	 	24-Jul-2002
	GTI-1530	 	EP	 	Granted	 	99966432.9	 	17-Dec-1999	 	1140283	 	08-Mar-2006
	GTI-1530	 	ES	 	Granted	 	99966432.9	 	17-Dec-1999	 	1140283	 	08-Mar-2006
	GTI-1530	 	FR	 	Granted	 	95905926.2	 	13-Dec-1994	 	0751802	 	25-Oct-2000
	GTI-1530	 	FR	 	Granted	 	98914475.3	 	02-Apr-1998	 	1028777	 	24-Jul-2002
	GTI-1530	 	FR	 	Granted	 	99966432.9	 	17-Dec-1999	 	1140283	 	08-Mar-2006
	GTI-1530	 	GB	 	Granted	 	95905926.2	 	13-Dec-1994	 	0751802	 	25-Oct-2000
	GTI-1530	 	GB	 	Granted	 	98914475.3	 	02-Apr-1998	 	1028777	 	24-Jul-2002
	GTI-1530	 	GB	 	Granted	 	99966432.9	 	17-Dec-1999	 	1140283	 	08-Mar-2006
	GTI-1530	 	IT	 	Granted	 	95905926.2	 	13-Dec-1994	 	0751802	 	25-Oct-2000
	GTI-1530	 	IT	 	Granted	 	99966432.9	 	17-Dec-1999	 	1140283	 	08-Mar-2006
	GTI-1530	 	JP	 	Granted	 	525651/95	 	13-Dec-1994	 	3554935	 	21-May-2004

  
 - 66 - 

													
	GTI-1530	 	NL	 	Granted	 	99966432.9	 	17-Dec-1999	 	1140283	 	08-Mar-2006
	GTI-1530	 	TW	 	Granted	 	87106879	 	05-May-1998	 	NI-108036	 	01-Sep-1999
	GTI-1530	 	US	 	Granted	 	08/310647	 	22-Sep-1994	 	5464386	 	07-Nov-1995
	GTI-1530	 	US	 	Granted	 	08/552200	 	02-Nov-1995	 	5688233	 	18-Nov-1997
	GTI-1530	 	US	 	Granted	 	08/964436	 	04-Nov-1997	 	6009345	 	28-Dec-1999
	GTI-1530	 	US	 	Granted	 	09/213782	 	17-Dec-1998	 	5968006	 	19-Oct-1999
							
	GTI-3010	 	CA	 	Published	 	2756276	 	16-Apr-2010	 		 	
	GTI-3010	 	EP	 	Published	 	10765277.8	 	16-Apr-2010	 		 	
	GTI-3010	 	KR	 	Pending	 	10-2011-7027142	 	16-Apr-2010	 		 	
	GTI-3010	 	US	 	Published	 	13263802	 	10-Oct-2011	 		 	
	GTI-3010	 	WO	 	Published	 	PCT/US10/31431	 	16-Apr-2010	 		 	
							
	VGX0117	 	AU	 	Published	 	2011223753	 	01-Mar-2011	 		 	
	VGX0117	 	BR	 	Pending	 	11 2012 0218050	 	01-Mar-2011	 		 	
	VGX0117	 	CA	 	Published	 	2789736	 	01-Mar-2011	 		 	
	VGX0117	 	CN	 	Published	 	201180011473.6	 	01-Mar-2011	 		 	
	VGX0117	 	EA	 	Pending	 	201201203	 	01-Mar-2011	 		 	
	VGX0117	 	EP	 	Published	 	11751208.7	 	01-Mar-2011	 		 	
	VGX0117	 	HK	 	Pending	 	201180011473.6	 	01-Mar-2011	 		 	
	VGX0117	 	IN	 	Pending	 	7555/DELNP/2012	 	01-Mar-2011	 		 	
	VGX0117	 	JP	 	Published	 	2012556176	 	01-Mar-2011	 		 	
	VGX0117	 	KR	 	Pending	 	10-2012-7025208	 	01-Mar-2011	 		 	
	VGX0117	 	MX	 	Pending	 	MX/a/2012/009986	 	01-Mar-2011	 		 	

  
 - 67 - 

													
	VGX0117	 	US	 	Expired	 	61309422	 	01-Mar-2010	 		 	
	VGX0117	 	US	 	Published	 	13581702	 	05-Oct-2012	 		 	
	VGX0117	 	ZA	 	Pending	 	201206478	 	01-Mar-2011	 		 	
	VGX0117	 	WO	 	Published	 	PCT/US11/26701	 	01-Mar-2011	 		 	
							
	VGX0123	 	US	 	Expired	 	61402712	 	28-Jun-2011	 		 	
	VGX0123	 	WO	 	Published	 	PCT/US12/44539	 	28-Jun-2012	 		 	
							
	USF-A3	 	CA	 	Published	 	2478614	 	13-Mar-2002	 		 	
	USF-A3	 	US	 	Granted	 	10605126	 	10-Sep-2003	 	7769440	 	03-Aug-2010

  

	4.	MUSCLE 

 GTI-1370 - METHOD AND APPARATUS FOR REDUCING ELECTROPORATION-MEDIATED MUSCLE REACTION AND PAIN RESPONSE

 GTI-5000 - METHOD FOR INTRODUCING PHARMACEUTICAL DRUGS AND NUCLEIC ACIDS INTO SKELETAL MUSCLE 

GTI-5001 - ELECTROPORATION DEVICE AND INJECTION APPARATUS 

GTI-7001 - DEVICE AND METHOD FOR SINGLE-NEEDLE IN VIVO ELECTROPORATION 

spherg2 - method of transferring nucleic acid into straited muscles 
  

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	GTI-1370	 	AU	 	Granted	 	41771/00	 	23-Mar-2000	 	778736	 	14-Apr-2005
	GTI-1370	 	EP	 	Published	 	00921451.1	 	23-Mar-2000	 		 	
	GTI-1370	 	TW	 	Granted	 	89105497	 	11-Apr-2000	 	NI-153798	 	06-Aug-2002
	GTI-1370	 	US	 	Granted	 	10/215963	 	08-Aug-2002	 	7054685	 	30-May-2006
	GTI-1370	 	US	 	Granted	 	09/535683	 	23-Mar-2000	 	6678558	 	13-Jan-2004

  
 - 68 - 

													
	GTI-5000	 	AT	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	AU	 	Granted	 	69906/98	 	03-Apr-1998	 	733628	 	30-Aug-2001
	GTI-5000	 	BE	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	CA	 	Granted	 	2285056	 	03-Apr-1998	 	2285056	 	14-Dec-2004
	GTI-5000	 	CH	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	CN	 	Granted	 	98803980.X	 	03-Apr-1998	 	ZL98803980	 	24-Apr-2006
	GTI-5000	 	DE	 	Granted	 	98909691.2	 	03-Apr-1998	 	69835761.2	 	30-Aug-2006
	GTI-5000	 	DK	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	EA	 	Granted	 	199900882	 	03-Apr-1998	 	002087	 	24-Dec-2001
	GTI-5000	 	EP	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	ES	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	FR	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	GB	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	IE	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	IT	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	KR	 	Granted	 	1999-7009009	 	03-Apr-1998	 	427786	 	07-Apr-2004
	GTI-5000	 	KZ	 	Granted	 	199900882	 	03-Apr-1998	 	2087	 	24-Dec-2001
	GTI-5000	 	LU	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	MX	 	Granted	 	999026	 	03-Apr-1998	 	253159	 	09-Jan-2008
	GTI-5000	 	NL	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	NO	 	Granted	 	19994820	 	03-Apr-1998	 	327806	 	28-Sep-2009
	GTI-5000	 	NZ	 	Granted	 	337853	 	03-Apr-1998	 	337853	 	08-Jul-2002
	GTI-5000	 	RU	 	Granted	 	199900882	 	03-Apr-1998	 	2087	 	24-Dec-2001

  
 - 69 - 

													
	GTI-5000	 	SE	 	Granted	 	98909691.2	 	03-Apr-1998	 	1023107	 	30-Aug-2006
	GTI-5000	 	US	 	Granted	 	09/565140	 	05-May-2000	 	6261281	 	17-Jul-2001
	GTI-5000	 	US	 	Granted	 	09/055084	 	03-Apr-1998	 	6110161	 	29-Aug-2000
	GTI-5000	 	US	 	Granted	 	10/141561	 	07-May-2002	 	6610044	 	26-Aug-2003
	GTI-5000	 	US	 	Granted	 	10/620271	 	14-Jul-2003	 	6958060	 	25-Oct-2005
	GTI-5000	 	US	 	Granted	 	12/070233	 	15-Feb-2008	 	7931640	 	26-Apr-2011
	GTI-5000	 	WO	 	Reportable	 	IB9800487	 	03-Apr-1998	 		 	
	GTI-5000	 	WO	 	Reportable	 	2001GB01970	 	04-May-2001	 		 	
							
	GTI-5001	 	AU	 	Granted	 	2009202678	 	01-Jul-2009	 	2009202678	 	29-Nov-2012
	GTI-5001	 	CA	 	Published	 	2491000	 	04-Jul-2003	 		 	
	GTI-5001	 	CN	 	Granted	 	03820724.9	 	04-Jul-2003	 	03820724.9	 	28-Apr-2010
	GTI-5001	 	EA	 	Granted	 	200401558	 	04-Jul-2003	 	009203	 	28-Dec-2007
	GTI-5001	 	EP	 	Allowed	 	03762794.0	 	04-Jul-2003	 		 	
	GTI-5001	 	HK	 	Published	 	05108751.7	 	04-Jul-2003	 		 	
	GTI-5001	 	IN	 	Pending	 	4137/DELNP/2004	 	04-Jul-2003	 		 	
	GTI-5001	 	JP	 	Granted	 	2004-518966	 	04-Jul-2003	 	4461012	 	19-Feb-2010
	GTI-5001	 	JP	 	Published	 	2009-279074	 	09-Dec-2009	 		 	
	GTI-5001	 	MX	 	Granted	 	PA/A/2005/000155	 	04-Jul-2003	 	277428	 	21-Jul-2010
	GTI-5001	 	NZ	 	Granted	 	562306	 	04-Jul-2003	 	562306	 	08-Oct-2009
	GTI-5001	 	NZ	 	Granted	 	566578	 	04-Jul-2003	 	566578	 	12-Nov-2009
	GTI-5001	 	RU	 	Granted	 	200401558	 	04-Jul-2003	 	9203	 	28-Dec-2007
	GTI-5001	 	US	 	Granted	 	10/612304	 	03-Jul-2003	 	7328064	 	05-Feb-2008

  
 - 70 - 

													
	GTI-5001	 	US	 	Published	 	11/985825	 	16-Nov-2007	 		 	
	GTI-5001	 	WO	 	Reportable	 	PCT/GB2003/002887	 	04-Jul-2003	 		 	
	GTI-5001	 	ZA	 	Granted	 	2005/0058	 	04-Jul-2003	 	2005/0058	 	29-Mar-2006
							
	GTI-7001	 	AU	 	Granted	 	2007215263	 	09-Feb-2007	 	2007215263	 	20-Oct-2011
	GTI-7001	 	CA	 	Published	 	2635437	 	09-Feb-2007	 		 	
	GTI-7001	 	CA	 	Pending	 	2686855	 	16-May-2008	 		 	
	GTI-7001	 	CN	 	Granted	 	200780002313.9	 	09-Feb-2007	 	200780002313.9	 	25-Dec-2012
	GTI-7001	 	EP	 	Published	 	07750450.4	 	09-Feb-2007	 		 	
	GTI-7001	 	EP	 	Published	 	08767759.7	 	20-Nov-2009	 		 	
	GTI-7001	 	IN	 	Pending	 	6100/DELNP/2008	 	11-Jul-2008	 		 	
	GTI-7001	 	JP	 	Granted	 	2008-554405	 	09-Feb-2007	 	5059786	 	10-Aug-2012
	GTI-7001	 	KR	 	Published	 	7019463/2008	 	09-Feb-2007	 		 	
	GTI-7001	 	MX	 	Granted	 	MX/a/2008/008981	 	09-Feb-2007	 	311676	 	24-Jul-2013
	GTI-7001	 	NO	 	Pending	 	20083811	 	09-Feb-2007	 		 	
	GTI-7001	 	US	 	Published	 	11/704591	 	09-Feb-2007	 		 	
	GTI-7001	 	WO	 	Reportable	 	PCT/US2007/003615	 	09-Feb-2007	 		 	
	GTI-7001	 	WO	 	Reportable	 	PCT/US2008/006311	 	16-May-2008	 		 	
							
	SPHERG2	 	US	 	Granted	 		 	2001-11-07	 	6939862	 	06-Sep-2005
	SPHERG2	 	 EP BE,
 CH,DE, FR, GB, IT
	 	Granted	 	1998935067	 	1998-06-30	 	EP0991426	 	12-Apr-2000

  
 - 71 - 

	5.	ONCOLOGY-TUMORS 

 GTI-1110 - Synergism of photodynamic and electropermeation effect on cell vitality as a novel
cytotoxic agent 
 GTI-1160 - ELECTROPORATION SYSTEM WITH VOLTAGE CONTROL FEEDBACK FOR CLINICAL APPLICATIONS 

GTI-1200 - Apparatus for addressing needle array electrodes for electroporation therapy 

GTI-1230 - Electrically induced vessel vasodilation 
 GTI-1250 -
ELECTROPORATION APPARATUS WITH CONNECTIVE ELECTRODE TEMPLATE 
 GTI-1360 - Method of electroporation-enhanced delivery of active agents 

 

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	 GTI-1110
	 	US	 	Granted	 	10677214	 	01-Oct-2003	 	7181271	 	20-Feb-2007
							
	 GTI-1160
	 	CA	 	Granted	 	2216131	 	10-Apr-1995	 	2216131	 	05-Feb-2002
	 GTI-1160
	 	CA	 	Granted	 	2218255	 	22-May-1996	 	2218255	 	20-Nov-2001
	 GTI-1160
	 	CN	 	Granted	 	96194608.3	 	22-May-1996	 	ZL96194608.3	 	26-May-2004
	 GTI-1160
	 	DE	 	Granted	 	02008920.7	 	10-Apr-1995	 	1240917	 	23-Jun-2004
	 GTI-1160
	 	DE	 	Granted	 	96916550.5	 	22-May-1996	 	69604509.5	 	29-Sep-1999
	 GTI-1160
	 	EP	 	Granted	 	02008920.7	 	10-Apr-1995	 	1240917	 	23-Jun-2004
	 GTI-1160
	 	EP	 	Granted	 	96916550.5	 	22-May-1996	 	0874663	 	29-Sep-1999
	 GTI-1160
	 	FR	 	Granted	 	02008920.7	 	10-Apr-1995	 	1240917	 	23-Jun-2004
	 GTI-1160
	 	FR	 	Granted	 	96916550.5	 	22-May-1996	 	0874663	 	29-Sep-1999
	 GTI-1160
	 	GB	 	Granted	 	02008920.7	 	10-Apr-1995	 	1240917	 	23-Jun-2004
	 GTI-1160
	 	GB	 	Granted	 	96916550.5	 	22-May-1996	 	0874663	 	29-Sep-1999
	 GTI-1160
	 	JP	 	Granted	 	530968/96	 	10-Apr-1995	 	3338880	 	16-Aug-2002
	 GTI-1160
	 	KR	 	Granted	 	706014/97	 	10-Apr-1995	 	247255	 	10-Dec-1999
	 GTI-1160
	 	KR	 	Granted	 	708424/97	 	22-May-1996	 	260238	 	04-Apr-2000
	 GTI-1160
	 	MX	 	Granted	 	PA/A/1997/006929	 	10-Apr-1995	 	218786	 	21-Jan-2004

  
 - 72 - 

													
	 GTI-1160
	 	MX	 	Granted	 	PA/A/1997/008316	 	22-May-1996	 	248023	 	13-Aug-2007
	 GTI-1160
	 	US	 	Granted	 	08/467566	 	06-Jun-1995	 	5702359	 	30-Dec-1997
	 GTI-1160
	 	US	 	Granted	 	09/427151	 	25-Oct-1999	 	6451002	 	17-Sep-2002
	 GTI-1160
	 	US	 	Granted	 	10/053861	 	17-Jan-2002	 	6567694	 	20-May-2003
	 GTI-1160
	 	US	 	Granted	 	09/551327	 	18-Apr-2000	 	6418341	 	09-Jul-2002
	 GTI-1160
	 	US	 	Granted	 	90/005590	 	15-Dec-1999	 	5702359C1	 	28-Mar-2006
	 GTI-1160
	 	US	 	Granted	 	08/930168	 	10-Apr-1995	 	5810762	 	22-Sep-1998
	 GTI-1160
	 	US	 	Granted	 	08/042039	 	01-Apr-1993	 	5439440	 	08-Aug-1995
	 GTI-1160
	 	US	 	Granted	 	08/537265	 	29-Sep-1995	 	5993434	 	30-Nov-1999
	 GTI-1160
	 	US	 	Granted	 	10/177560	 	21-Jun-2002	 	6569149	 	27-May-2003
	 GTI-1160
	 	US	 	Granted	 	10/213514	 	06-Aug-2002	 	6763264	 	13-Jul-2004
							
	 GTI-1200
	 	AR	 	Granted	 	P990105331	 	21-Oct-1999	 	AR020932B1	 	30-May-2006
	 GTI-1200
	 	AU	 	Granted	 	86823/98	 	31-Jul-1998	 	734343	 	27-Sep-2001
	 GTI-1200
	 	AU	 	Granted	 	17074/00	 	21-Oct-1999	 	767814	 	11-Mar-2004
	 GTI-1200
	 	CA	 	Granted	 	2268026	 	31-Jul-1998	 	2268026	 	29-Jul-2003
	 GTI-1200
	 	CN	 	Granted	 	98801461.0	 	31-Jul-1998	 	98801461.0	 	07-Sep-2005
	 GTI-1200
	 	CN	 	Granted	 	200510084733.9	 	31-Jul-1998	 	1768873	 	28-Jan-2011
	 GTI-1200
	 	DE	 	Granted	 	98938256.9	 	31-Jul-1998	 	999867	 	08-Sep-2010
	 GTI-1200
	 	EP	 	Granted	 	98938256.9	 	31-Jul-1998	 	999867	 	08-Sep-2010
	 GTI-1200
	 	FR	 	Granted	 	98938256.9	 	31-Jul-1998	 	999867	 	08-Sep-2010
	 GTI-1200
	 	GB	 	Granted	 	98938256.9	 	31-Jul-1998	 	999867	 	08-Sep-2010
	 GTI-1200
	 	HK	 	Granted	 	00106147.9	 	31-Jul-1998	 	1027049	 	28-Apr-2006

  
 - 73 - 

													
	 GTI-1200
	 	JP	 	Granted	 	2002-57679	 	31-Jul-1998	 	4180285	 	05-Sep-2008
	 GTI-1200
	 	KR	 	Granted	 	10-1999-7002781	 	31-Jul-1998	 	756252	 	31-Aug-2007
	 GTI-1200
	 	US	 	Granted	 	09/177678	 	22-Oct-1998	 	6241701	 	05-Jun-2001
	 GTI-1200
	 	US	 	Granted	 	09/861016	 	18-May-2001	 	6516223	 	04-Feb-2003
	 GTI-1200
	 	US	 	Granted	 	09/189062	 	09-Nov-1998	 	6233482	 	15-May-2001
	 GTI-1200
	 	US	 	Granted	 	09/189360	 	09-Nov-1998	 	6181964	 	30-Jan-2001
	 GTI-1200
	 	US	 	Granted	 	09/189070	 	09-Nov-1998	 	6068650	 	30-May-2000
	 GTI-1200
	 	US	 	Granted	 	08/905240	 	01-Aug-1997	 	6055453	 	25-Apr-2000
	 GTI-1200
	 	US	 	Granted	 	09/900601	 	05-Jul-2001	 	7412284	 	12-Aug-2008
	 GTI-1200
	 	US	 	Granted	 	09/227417	 	08-Jan-1999	 	6216034	 	10-Apr-2001
	 GTI-1200
	 	US	 	Granted	 	09/227416	 	08-Jan-1999	 	6014584	 	11-Jan-2000
	 GTI-1200
	 	ZA	 	Granted	 	98/7596	 	21-Aug-1998	 	98/7596	 	31-Aug-1999
							
	 GTI-1230
	 	US	 	Granted	 	09969367	 	01-Oct-2001	 	6865416	 	08-Mar-2005
	 GTI-1230
	 	US	 	Granted	 	09307216	 	07-May-1999	 	6347247	 	12-Feb-2002
							
	 GTI-1250
	 	US	 	Granted	 	09/206635	 	07-Dec-1998	 	6120493	 	19-Sep-2000
	 GTI-1250
	 	US	 	Granted	 	09/014291	 	27-Jan-1998	 	6009347	 	28-Dec-1999
	 GTI-1250
	 	US	 	Granted	 	09/234770	 	21-Jan-1999	 	6208893	 	27-Mar-2001
							
	 GTI-1360
	 	US	 	Granted	 	10/339708	 	08-Jan-2003	 	7171264	 	30-Jan-2007
	 GTI-1360
	 	US	 	Granted	 	09/567404	 	08-May-2000	 	6520950	 	18-Feb-2003

  
 - 74 - 

	6.	OTHER 

 GTI-4010 - Oral Mucosal Electroporation Device and Use Thereof 

GTI-9000 - METHODS OF ENHANCING IMMUNE RESPONSE USING ELECTROPORATION-ASSISTED VACCINATION AND BOOSTING 

 

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	 GTI-4010
	 	CA	 	Pending	 	2795547	 	28-Apr-2011	 		 	
	 GTI-4010
	 	CN	 	Published	 	201180021234.9	 	28-Apr-2011	 		 	
	 GTI-4010
	 	EP	 	Published	 	11775553.8	 	28-Apr-2011	 		 	
	 GTI-4010
	 	HK	 	Pending	 	13108500.1	 	28-Apr-2011	 		 	
	 GTI-4010
	 	KR	 	Pending	 	10-2012-7027162	 	28-Apr-2011	 		 	
	 GTI-4010
	 	US	 	Published	 	13641977	 	18-Oct-2012	 		 	
	 GTI-4010
	 	WO	 	Published	 	PCT/US11/34277	 	28-Apr-2011	 		 	
							
	 GTI-9000
	 	AU	 	Allowed	 	2007322075	 	16-Nov-2007	 		 	
	 GTI-9000
	 	AU	 	Pending	 	2013206520	 	16-Nov-2007	 		 	
	 GTI-9000
	 	CA	 	Published	 	2668649	 	16-Nov-2007	 		 	
	 GTI-9000
	 	CN	 	Published	 	200780037742.X	 	16-Nov-2007	 		 	
	 GTI-9000
	 	EP	 	Published	 	07840065.2	 	16-Nov-2007	 		 	
	 GTI-9000
	 	HK	 	Published	 	10101823.9	 	22-Feb-2010	 		 	
	 GTI-9000
	 	JP	 	Published	 	2009-537218	 	16-Nov-2007	 		 	
	 GTI-9000
	 	KR	 	Published	 	7007135/2009	 	07-Apr-2009	 		 	
	 GTI-9000
	 	US	 	Published	 	11/985871	 	16-Nov-2007	 		 	
	 GTI-9000
	 	WO	 	Reportable	 	PCT/US2007/24051	 	16-Nov-2007	 		 	

  
 - 75 - 

	2.	Patent rights to enabling technologies 

  

	A.	Vaccine Additives 

  

	1.	ADJUVANTS 

 UPVG0017 - VACCINES AND IMMUNOTHERAPEUTICS USING CODON OPTIMIZED IL-15 AND METHODS FOR USING THE
SAME 
 upVG0028 - VACCINES AND IMMUNOTHERAPEUTICS COMPRISING IL-15 RECEPTOR ALPHA AND/OR NUCLEIC ACID MOLECULES ENCODING THE SAME, AND METHODS FOR USING
THE SAME 
 UPVG0018 - IMPROVED VACCINES AND METHOD FOR USING THE SAME (CTACK, MEK, TECK) 

UPVG0029 - Nucleic Acid Molecules Encoding Rantes, and Compositions and Methods of Using The Same 

UPVG0031 - Vaccines and Immunotherapeutics Comprising IL-28 and/or Nucleic Acid Molecules Encoding the Same, and Methods for Using the Same 

UPVG0041 - COMPOSITIONS, COMPRISING IMPROVED IL-12 GENETIC CONSTRUCTS AND VACCINES, IMMUNOTHERAPEUTICS AND METHODS OF USING THE SAME 
  

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	 UPVG0017
	 	AU	 	Granted	 	2007208452	 	12-Jan-2007	 	2007208452	 	18-Oct-2012
	 UPVG0017
	 	CA	 	Published	 	2636867	 	12-Jan-2007	 		 	
	 UPVG0017
	 	CH	 	Granted	 	7762574.7	 	12-Jan-2007	 	1976871	 	16-Nov-2011
	 UPVG0017
	 	DE	 	Granted	 	7762574.7	 	12-Jan-2007	 	1976871	 	16-Nov-2011
	 UPVG0017
	 	DK	 	Granted	 	7762574.7	 	12-Jan-2007	 	1976871	 	16-Nov-2011
	 UPVG0017
	 	EP	 	Granted	 	7762574.7	 	12-Jan-2007	 	1976871	 	16-Nov-2011
	 UPVG0017
	 	ES	 	Granted	 	7762574.7	 	12-Jan-2007	 	1976871	 	16-Nov-2011
	 UPVG0017
	 	FR	 	Granted	 	7762574.7	 	12-Jan-2007	 	1976871	 	16-Nov-2011
	 UPVG0017
	 	GB	 	Granted	 	7762574.7	 	12-Jan-2007	 	1976871	 	16-Nov-2011
	 UPVG0017
	 	IN	 	Pending	 	2971/KOLNP/2008	 	12-Jan-2007	 		 	
	 UPVG0017
	 	JP	 	Allowed	 	2008-550435	 	12-Jan-2007	 		 	
	 UPVG0017
	 	KR	 	Pending	 	10-2008-7019727	 	12-Jan-2007	 		 	

  
 - 76 - 

													
	 UPVG0017
	 	LU	 	Granted	 	7762574.7	 	12-Jan-2007	 	1976871	 	16-Nov-2011
	 UPVG0017
	 	MC	 	Granted	 	7762574.7	 	12-Jan-2007	 	1976871	 	16-Nov-2011
	 UPVG0017
	 	MX	 	Granted	 	MX/A/2008/008928	 	12-Jan-2007	 	296941	 	09-Mar-2012
	 UPVG0017
	 	NL	 	Granted	 	7762574.7	 	12-Jan-2007	 	1976871	 	16-Nov-2011
	 UPVG0017
	 	US	 	Granted	 	12160766	 	30-Mar-2009	 	8178660	 	15-May-2012
	 UPVG0017
	 	WO	 	Reportable	 	PCT/US07/000886	 	12-Jan-2007	 		 	
							
	 UPVG0028
	 	AU	 	Pending	 	PCT/US10/48827	 	14-Sep-2010	 		 	
	 UPVG0028
	 	CA	 	Pending	 	PCT/US10/48827	 	14-Sep-2010	 		 	
	 UPVG0028
	 	CN	 	Published	 	PCT/US10/48827	 	14-Sep-2010	 		 	
	 UPVG0028
	 	EP	 	Published	 	10816292.6	 	14-Sep-2010	 		 	
	 UPVG0028
	 	IN	 	Pending	 	406/MUMNP/2012	 	14-Sep-2010	 		 	
	 UPVG0028
	 	JP	 	Published	 	PCT/US10/48827	 	14-Sep-2010	 		 	
	 UPVG0028
	 	KR	 	Pending	 	10-2012-7006494	 	14-Sep-2010	 		 	
	 UPVG0028
	 	US	 	Published	 	13391615	 	21-Feb-2012	 		 	
	 UPVG0028
	 	WO	 	Published	 	PCT/US10/48827	 	14-Sep-2010	 		 	
							
	 UPVG0018
	 	US	 	Pending	 	13284824	 	28-Oct-2011	 		 	
	 UPVG0018
	 	WO	 	Reportable	 	PCT/US05/42231	 	18-Nov-2005	 		 	
							
	 UPVG0029
	 	AU	 	Pending	 	2011213559	 	08-Feb-2011	 		 	
	 UPVG0029
	 	CA	 	Pending	 	2788902	 	08-Feb-2011	 		 	
	 UPVG0029
	 	CN	 	Published	 	201180008582.2	 	08-Feb-2011	 		 	
	 UPVG0029
	 	EP	 	Published	 	11740539.9	 	08-Feb-2011	 		 	
	 UPVG0029
	 	IN	 	Pending	 	7013/DELNP/2012	 	08-Feb-2011	 		 	
	 UPVG0029
	 	JP	 	Published	 	2012-552154	 	08-Feb-2011	 		 	
	 UPVG0029
	 	KR	 	Pending	 	10-2012-7020794	 	08-Feb-2011	 		 	
	 UPVG0029
	 	US	 	Published	 	13577387	 	04-Ocy-2012	 		 	

  
 - 77 - 

													
	 UPVG0029
	 	WO	 	Published	 	PCT/US11/24098	 	08-Feb-2011	 		 	
							
	 UPVG0031
	 	AU	 	Pending	 	2009231598	 	06-Apr-2009	 		 	
	 UPVG0031
	 	CA	 	Pending	 	2720168	 	06-Apr-2009	 		 	
	 UPVG0031
	 	CN	 	Published	 	200980112452.6	 	06-Apr-2009	 		 	
	 UPVG0031
	 	EP	 	Published	 	09726983.1	 	06-Apr-2009	 		 	
	 UPVG0031
	 	HK	 	Pending	 	11110692.7	 	10-Oct-2011	 		 	
	 UPVG0031
	 	IN	 	Published	 	3545/KOLNP/2010	 	06-Apr-2009	 		 	
	 UPVG0031
	 	JP	 	Published	 	2011-503239	 	06-Apr-2009	 		 	
	 UPVG0031
	 	KR	 	Pending	 	10-2010-7024735	 	06-Apr-2009	 		 	
	 UPVG0031
	 	US	 	Pending	 	12936192	 	01-Oct-2010	 		 	
	 UPVG0031
	 	WO	 	Published	 	PCT/US2009/039648	 	06-Apr-2009	 		 	
							
	 UPVG0041
	 	WO	 	Published	 	PCT/US12/69017	 	11-Dec-2012	 		 	
	 UPVG0041
	 	US	 	Expired	 	61569600	 	12-Dec-2011	 		 	

  

	1.	FORMULATIONS 

 PLG - AVSI-0021 - PLASMID MEDIATED GENE SUPPLEMENTATION AND IN VIVO EXPRESSION OF THE
POLY-L-GLUTAMATE SYSTEM 
 PLG - VAL1008 - FORMULATED NUCLEIC ACID COMPOSITIONS AND METHODS OF ADMINISTERING THE SAME FOR GENE THERAPY 

PLG - VAL1012 NUCLEIC ACID FORMULATIONS FOR GENE DELIVERY AND METHODS OF USE 

PLG - VAL1001 - CATIONIC AMPHIPHILES 
 PLG - VAL1002 - CATIONIC
LIPID: DNA COMPLEXES FOR GENE TARGETING 
 PLG - VAL1003 - AMPHIPHILIC BIGUANIDE DERIVATIVES 

PLG - VAL1004 - IMPROVED METHODS OF DELIVERY USING CATIONIC LIPIDS AND HELPER LIPIDS 

PLG - VAL1005 - COMPOSITIONS AND METHODS USING NOVEL SUBSTITUTED IMIDAZOLIUM LIPIDS 

  
 - 78 - 

 PLG - VAL1006 - TRANSFORMATION OF CELLS ASSOCIATED WITH FLUID SPACES 

PLG - VAL1010 PROTECTED ONE-VIAL FORMULATION FOR NUCLEIC ACID MOLECULES 
  

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	 AVSI0021 P1
	 	SG	 	Granted	 	200406924-1	 	23-May-2003	 	108408	 	29-Dec-2006
	 AVSI0021 P2
	 	KR	 	Pending	 	10-2010-7013178	 	15-Jun-2010	 		 	
							
	 VAL1001
	 	US	 	Granted	 	08/971951	 	17-Nov-1997	 	5902802	 	11-May-1999
	 VAL1002
	 	US	 	Granted	 	08/480923	 	07-Jun-1995	 	5932241	 	03-Aug-1999
	 VAL1003
	 	US	 	Granted	 	08/825854	 	04-Apr-1997	 	5958894	 	28-Sep-1999
	 VAL1004
	 	US	 	Granted	 	09/054769	 	03-Apr-1998	 	6235310	 	22-May-2001
	 VAL1005
	 	US	 	Granted	 	09/183634	 	30-Oct-1998	 	6121457	 	19-Sep-2000
	 VAL1005
	 	US	 	Granted	 	09/626268	 	25-Jul-2000	 	6245520	 	12-Jun-2001
	 VAL1006
	 	US	 	Granted	 	08/184547	 	21-Jan-1994	 	5792751	 	11-Aug-1998
	 VAL1008
	 	US	 	Granted	 	08/372213	 	13-Jan-1995	 	6040295	 	21-Mar-2000
	 VAL1008
	 	US	 	Granted	 	08/798974	 	11-Feb-1997	 	6514947	 	04-Feb-2003
	 VAL1010
	 	AT	 	Granted	 	99939113.9	 	10-Aug-1999	 	1104309	 	03-May-2006

  
 - 79 - 

													
	 VAL1010
	 	CA	 	Granted	 	CA19992340416	 	10-Aug-1999	 	2340416	 	25-Aug-2009
	 VAL1010
	 	DE	 	Granted	 	99939113.9	 	10-Aug-1999	 	1104309	 	03-May-2006
	 VAL1010
	 	EP	 	Granted	 	99939113.9	 	10-Aug-1999	 	1104309	 	03-May-2006
	 VAL1010
	 	FR	 	Granted	 	99939113.9	 	10-Aug-1999	 	1104309	 	03-May-2006
	 VAL1010
	 	GB	 	Granted	 	99939113.9	 	10-Aug-1999	 	1104309	 	03-May-2006
	 VAL1010
	 	IE	 	Granted	 	99939113.9	 	10-Aug-1999	 	1104309	 	03-May-2006
	 VAL1010
	 	JP	 	Granted	 	2000-564589	 	10-Aug-1999	 	4538150	 	25-Jun-2010
	 VAL1010
	 	NL	 	Granted	 	99939113.9	 	10-Aug-1999	 	1104309	 	03-May-2006
	 VAL1010
	 	US	 	Granted	 	09/371619	 	10-Aug-1999	 	6534483	 	18-Mar-2003
	 VAL1012
	 	CA	 	Published	 	2401327	 	02-Mar-2001	 		 	
	 VAL1012
	 	CH	 	Granted	 	01918339	 	02-Mar-2001	 	1259265	 	01-Jun-2011
	 VAL1012
	 	DE	 	Granted	 	01918339	 	02-Mar-2001	 	1259265	 	01-Jun-2011
	 VAL1012
	 	DK	 	Granted	 	01918339	 	02-Mar-2001	 	1259265	 	01-Jun-2011
	 VAL1012
	 	EP	 	Granted	 	01918339	 	02-Mar-2001	 	1259265	 	01-Jun-2011
	 VAL1012
	 	ES	 	Granted	 	01918339	 	02-Mar-2001	 	1259265	 	01-Jun-2011

  
 - 80 - 

													
	 VAL1012
	 	FR	 	Granted	 	01918339	 	02-Mar-2001	 	1259265	 	01-Jun-2011
	 VAL1012
	 	GB	 	Granted	 	01918339	 	02-Mar-2001	 	1259265	 	01-Jun-2011
	 VAL1012
	 	JP	 	Granted	 	2001-564801	 	02-Mar-2001	 	5253499	 	17-Apr-2012
	 VAL1012
	 	LU	 	Granted	 	01918339	 	02-Mar-2001	 	1259265	 	01-Jun-2011
	 VAL1012
	 	MC	 	Granted	 	01918339	 	02-Mar-2001	 	1259265	 	01-Jun-2011
	 VAL1012
	 	NL	 	Granted	 	01918339	 	02-Mar-2001	 	1259265	 	01-Jun-2011
	 VAL1012
	 	US	 	Granted	 	10/234406	 	03-Sep-2002	 	7173116	 	06-Feb-2007
	 VAL1012
	 	US	 	Granted	 	11/561847	 	20-Nov-2006	 	7491537	 	17-Feb-2009

  
 - 81 - 

 INOVIO PATENT/IP SCHEDULE 
  

	B)	Functional DNA 

  

	1.	PLASMIDS 

 AVSI-0013 - EXPRESSION VECTOR SYSTEMS AND METHOD OF USE 

AVSI-0015 - FORMULATED NUCLEIC ACID COMPOSITIONS AND METHODS OF ADMINISTERING THE SAME FOR GENE THERAPY 

AVSI-0023 - CODON OPTIMIZED SYNTHETIC PLASMIDS 

AVSI-0043 - OPTIMIZED HIGH YIELD SYNTHETIC PLASMIDS 
  

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	 AVSI0013
	 	US	 	Granted	 	08/472809	 	07-Jun-1995	 	5925564	 	20-Jul-1999
							
	 AVSI0015
	 	US	 	Granted	 	08/372213	 	13-Jan-1995	 	6,040,295	 	21-Mar-2000
							
	 AVSI0023
	 	AU	 	Granted	 	2003249208	 	15-Jul-2003	 	2003249208	 	18-Jun-2010
	 AVSI0023
	 	DE	 	Granted	 	03764596.7	 	15-Jul-2003	 	1543020	 	13-Apr-2011
	 AVSI0023
	 	EP	 	Granted	 	03764596.7	 	15-Jul-2003	 	1543020	 	13-Apr-2011
	 AVSI0023
	 	FR	 	Granted	 	03764596.7	 	15-Jul-2003	 	1543020	 	13-Apr-2011
	 AVSI0023
	 	GB	 	Granted	 	03764596.7	 	15-Jul-2003	 	1543020	 	13-Apr-2011
	 AVSI0023
	 	US	 	Granted	 	10/619939	 	15-Jul-2003	 	7316925	 	08-Jan-2008
							
	 AVSI0043
	 	US	 	Granted	 	11339894	 	26-Jan-2006	 	7846720	 	07-Dec-2010
	 AVSI0043
	 	US	 	Published	 	12948061	 	17-Nov-2010	 		 	

  

	2.	LEADER SEQUENCES 

 UPVG0044 - HIGHLY EXPRESSIBLE GENES (IgE) 

 

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	 UPVG0044
	 	DE	 	Granted	 	01979579.8	 	04-Oct-2001	 	1328653	 	01-Aug-2012
	 UPVG0044
	 	EP	 	Granted	 	01979579.8	 	04-Oct-2001	 	1328653	 	01-Aug-2012

  
 - 82 - 

													
	 UPVG0044
	 	FR	 	Granted	 	01979579.8	 	04-Oct-2001	 	1328653	 	01-Aug-2012
	 UPVG0044
	 	GB	 	Granted	 	01979579.8	 	04-Oct-2001	 	1328653	 	01-Aug-2012
	 UPVG0044
	 	IE	 	Granted	 	01979579.8	 	04-Oct-2001	 	1328653	 	01-Aug-2012
	 UPVG0044
	 	JP	 	Granted	 	2002-532657	 	04-Oct-2001	 	4472250	 	12-Mar-2010
	 UPVG0044
	 	US	 	Granted	 	09971806	 	04-Oct-2001	 	6733994	 	11-May-2004
	 UPVG0044
	 	WO	 	Published	 	PCT/US01/31451	 	04-Oct-2001	 		 	

  

	3.	PROMOTERS 

 AVSI-0012 - METHOD FOR THE IDENTIFICATION OF SYNTHETIC CELL-OR TISSUE- SPECIFIC
TRANSCRIPTIONAL REGULATORY REGIONS 
 AVSI-0027 - SYNTHETIC MUSCLE PROMOTERS WITH ACTIVITIES EXCEEDING NATURALLY OCCURRING REGULATORY
SEQUENCES IN CARDIAC CELLS 
 VAL1009 - METHOD FOR THE IDENTIFICATION OF SYNTHETIC CELL-OR TISSUE-SPECIFIC TRANSCRIPTIONAL REGULATORY
REGIONS C5/C12 
  

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	 AVSI0012
	 	US	 	Granted	 	09/115407	 	14-Jul-1998	 	6,410,228	 	25-Jun-2002
							
	 AVSI0027
	 	AU	 	Granted	 	2003295366	 	30-Oct-2003	 	2003295366	 	08-Mar-2012
	 AVSI0027
	 	CA	 	Published	 	2504593	 	30-Oct-2003	 		 	
	 AVSI0027
	 	TW	 	Granted	 	92130336	 	30-Oct-2003	 	290174	 	21-Nov-2007
							
	 VAL1009
	 	US	 	Granted	 	11/080827	 	14-Mar-2005	 	7960536	 	14-Jun-2011

  
 - 83 - 

	3.	Patent rights to ProducTs 

  

	1.	Hepatitis B 

 hepb - upvg0037 - NUCLEIC ACID MOLECULE ENCODING HEPATITIS B VIRUS CORE PROTEIN AND VACCINE
COMPRISING THE SAME 
  

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	 UPVG0037
	 	WO	 	Published	 	PCT/US12/24905	 	13-Feb-2012	 		 	
	 UPVG0037
	 	US	 	Expired	 	61442162	 	11-Feb-2011	 		 	
	 UPVG0037
	 	US	 	Published	 	13622965	 	09-Sep-2012	 		 	
	 UPVG0037
	 	US	 	Pending	 	13984771	 	09-Aug-2013	 		 	
	 UPVG0037
	 	AU	 	Filed	 	*	 	13-Feb-2012	 		 	
	 UPVG0037
	 	BR	 	Filed	 	*	 	13-Feb-2012	 		 	
	 UPVG0037
	 	CA	 	Filed	 	*	 	13-Feb-2012	 		 	
	 UPVG0037
	 	EA	 	Filed	 	*	 	13-Feb-2012	 		 	
	 UPVG0037
	 	EP	 	Filed	 	*	 	13-Feb-2012	 		 	
	 UPVG0037
	 	IN	 	Filed	 	*	 	13-Feb-2012	 		 	
	 UPVG0037
	 	JP	 	Filed	 	*	 	13-Feb-2012	 		 	
	 UPVG0037
	 	KR	 	Filed	 	*	 	13-Feb-2012	 		 	
	 UPVG0037
	 	MX	 	Filed	 	*	 	13-Feb-2012	 		 	
	 UPVG0037
	 	ZA	 	Filed	 	*	 	13-Feb-2012	 		 	

 * -Cases filed during Aug.–Sept. 2013 

  
 - 84 - 

	2.	PROSTATE CANCER 

 prostate - upvg0036 - CONSENSUS PROSTATE ANTIGENS, NUCLEIC ACID MOLECULE ENCODING THE SAME AND
VACCINE AND USES COMPRISING THE SAME 
  

													
	 Inovio Ref
	 	 Country
	 	 Status
	 	 Serial Number
	 	 Filing Date
	 	 Patent No.
	 	 Issue Date

	 UPVG0036
	 	AU	 	Filed	 		 	14-Nov-2011	 		 	
	 UPVG0036
	 	BR	 	Pending	 	BR11 2013 011705.2	 	14-Nov-2011	 		 	
	 UPVG0036
	 	CA	 	Pending	 	2720277	 	14-Nov-2011	 		 	
	 UPVG0036
	 	CN	 	Filed	 		 	14-Nov-2011	 		 	
	 UPVG0036
	 	EA	 	Pending	 	201390689	 	14-Nov-2011	 		 	
	 UPVG0036
	 	EP	 	Pending	 	11839215.8	 	14-Nov-2011	 		 	
	 UPVG0036
	 	IN	 	Pending	 	4088/KOLNP/2013	 	14-Nov-2011	 		 	
	 UPVG0036
	 	JP	 	Pending	 	100078282	 	14-Nov-2011	 		 	
	 UPVG0036
	 	KR	 	Pending	 	10-2013-7014954	 	14-Nov-2011	 		 	
	 UPVG0036
	 	MX	 	Pending	 	MX/a/2013/005195	 	14-Nov-2011	 		 	
	 UPVG0036
	 	US	 	Expired	 	61413176	 	12-Nov-2010	 		 	
	 UPVG0036
	 	US	 	Expired	 	61417817	 	29-Nov-2010	 		 	
	 UPVG0036
	 	US	 	Pending	 	13883978	 	29-Jul-2013	 		 	
	 UPVG0036
	 	WO	 	Reportable	 	PCT/US11/60592	 	14-Nov-2011	 		 	
	 UPVG0036
	 	ZA	 	Pending	 	201303390	 	14-Nov-2011	 		 	

  
 - 85 - 

 August 9. 2013 

Appendix 1.84 
 Excluded
Patent Rights 
 Cabilly Patent Rights, which means (a) U.S. Patent No. 4,816,567, issued March 28, 1989, and any and all patents issuing
from divisionals, continuations, or continuations-in part of any application from which U.S. Patent No. 4,816,567 claims priority, as well as reissues, reexaminations, extensions, and foreign patent counterparts, including inventors
certificates, of any of the foregoing, and including any related supplemental protection certificates; and (b) U.S. Patent No. 6,331,415, issued December 18, 2001, and any and all patents issuing from divisionals, continuations, or
continuations-in-part of any application from which U.S. Patent No. 6,331,415 claims priority, as well as reissues, reexaminations, extensions, and foreign patent counterparts, including inventors certificates, of any of the foregoing, and
including any related supplemental protection certificates. 
 Itakura/Riggs Patent Rights, which means any of the U.S. patents listed below and any and all
patents issuing from divisionals, continuations or continuations-in-part, and any reissues, reexaminations or extensions, of these patents or of any application from which these U.S. patents claim priority, as well as foreign counterparts, including
inventors certificates, of the foregoing, and including any related supplemental protection certificates: 
 U.S. Patent No. 4,356,270

 U.S. Patent No. 4,366,246 

U.S. Patent No. 4,425,437 

U.S. Patent No. 4,431,739 

 U.S. Patent No. 4,563,424 

U.S. Patent No. 4,571,421 

U.S. Patent No. 4,704,362 

U.S. Patent No. 4,812,554 

U.S. Patent No. 5,221,619 

U.S. Patent No. 5,420,020 

U.S. Patent No. 5,583,013 
 Capon/Lasky
Patent Rights, which means any of the U.S. patents/patent application listed below and any and all patents issuing from divisionals, continuations or continuations-in-part, and any reissues, reexaminations or extensions, of these patents or of any
application from which these U.S. patents claim priority, as well as foreign counterparts, including inventors certificates, of the foregoing, and including any related supplemental protection certificates: 

U.S. Patent No. 5,428,130 

U.S. Patent No. 5,514,582 

U.S. Patent No. 6,406,697 
 Presta Patents,
which means the following U.S. patent and any and all divisionals, continuations, continuations-in-part of any application from which these U.S patents claim priority, including reissues, reexaminations or extensions of these patents and foreign
counterparts and supplementary protection certificates of the foregoing: 
 U.S. Patent No. 6,737,056 

  
 - 87 - 

 Appendix 7.7 

Royalty Report Template 

(for illustrative purposes only - subject to change) 
  

 

 Appendix 14.3 

Form of Press Release 
  

			
	Media Release	  	

 Basel, Switzerland and Blue Bell, PA, USA - 10 September 2013 

Roche and Inovio Pharmaceuticals partner on Inovio’s prostate cancer and hepatitis B immunotherapy products 

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that they have entered into an exclusive worldwide license
agreement to research, develop and commercialize Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust
T-cell responses in animal models. 
 Roche acquired an exclusive license for Inovio’s DNA-based vaccines INO-5150 (targeting prostate cancer) and
INO-1800 (targeting hepatitis B) as well as the use of Inovio’s CELLECTRA® electroporation technology for delivery of the vaccines. Roche also obtained an option to license additional
vaccine opportunities in connection with a collaborative research program in oncology. Roche and Inovio will collaborate to further develop INO-5150 and INO-1800. 

Under the terms of the agreement, Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&D support and
payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche
pursues other indications with INO-5150 or INO-1800. In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales. 

 Commenting on the deal, Hy Levitsky, Head of Cancer Immunology Experimental Medicine at Roche, said: “At
Roche we are always interested in finding first-in-class and best-in-class therapies that may become the next generation treatments for patients with different types of cancer. INO-5150 will allow promising combination opportunities with the Roche
portfolio, particularly with our emerging cancer immunotherapy molecules.” Janet Hammond, Head of Infectious Diseases Discovery & Translational Area at Roche, added: “We are very excited to have this potentially very important and
novel mechanism of action as part of our portfolio as we seek to address the significant unmet medical need in chronic hepatitis B infection.” 

“This partnership represents an important milestone in Inovio’s growth and maturing product portfolio. Roche brings to our immunotherapy candidates
its leadership position and track record for developing and marketing innovative first-in-class therapies,” said Dr. J. Joseph Kim, Inovio’s President and CEO. “Collaborating with the world’s preeminent oncology development
partner allows us to rapidly advance two of our promising near-clinical stage immunotherapy products from our product pipeline as we continue development of our phase II lead product, VGX-3100, for treatment of HPV-related cancers and
dysplasia.” 
 - ### - 
 About
INO-5150 for Prostate Cancer 
 Inovio’s dual-antigen synthetic DNA vaccine (INO-5150) targets prostate-specific membrane antigen (PSMA) and
prostate-specific antigen (PSA). A study in monkeys showed that vaccination with INO-5150 generated strong and robust T-cell immune responses that were the highest generated by a PSA-based immunotherapy in animal studies and were similar to the
immune responses generated by VGX-3100, Inovio’s phase II-stage therapeutic HPV vaccine that generated best-in-class T-cell responses in a phase I study. 

Inovio’s SynCon® DNA vaccine for prostate cancer was designed with PSA and PSMA synthetic
consensus immunogens based on human and macaque sequences, resulting in amino acid sequences that differ slightly from the native human protein. In humans, this novel approach is utilized to help the body’s immune system recognize cancerous
cells created in the body as ‘foreign’, overcoming the body’s self-tolerance of these cells and mounting an immune response to clear them. 

  
 - 90 - 

 About INO-1800 for Hepatitis B 

Inovio has reported preclinical data showing its hepatitis B vaccine (INO-1800) generated strong T-cell and antibody responses that led to the elimination of
targeted liver cells in mice. These results indicate this DNA vaccine’s potential to treat hepatitis B infection and prevent further development of the infection into liver cancer in humans. 

In a preclinical study, researchers found the vaccine-specific T-cells exhibited a killing function, and could migrate to and stay in the liver and cause
clearance of target cells without evidence of liver injury. This was the first study to provide evidence that intramuscular immunization can induce killer T-cells that can migrate to the liver and eliminate target cells. 

To provide worldwide rights to Roche, Inovio has re-acquired its hepatitis B, Asian-country rights from Inovio’s international affiliate. 

Disease Background 
 Prostate Cancer 

Prostate cancer is the second most frequently diagnosed cancer of men. Nearly three-quarters of the registered cases occur in developed countries. Accounting
for nearly 300,000 deaths each year, prostate cancer is the sixth leading cause of death from cancer in men. The development of a new treatment for prostate cancer would be a significant medical advancement given that present treatment options
(surgery, radiation and hormone deprivation), while somewhat effective, all carry deleterious side effects and are often not a long-term cure. 

Hepatitis B and Liver Cancer 
 Hepatitis B is a disease
characterized by inflammation of the liver. The virus is extremely infectious - 100 times more so than HIV - and 400 million people are chronically infected worldwide. Hepatitis B contributes to an estimated 1 million deaths worldwide each
year. 
 Liver cancer is the third most common cancer and the most deadly, killing most patients within five years of diagnosis. About 600,000 new cases
arise each year. One of the major causes and risk factors for liver cancer is infection by hepatitis B. 

  
 - 91 - 

 About Inovio Pharmaceuticals, Inc. 

Inovio is revolutionizing vaccines to prevent and treat today’s cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of
magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio’s lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target
prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV
Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com. 

About Roche 
 Headquartered in Basel, Switzerland, Roche
is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism
and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools
that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. 

This press release contains certain forward-looking statements relating to Inovio’s partnership with Roche related to Inovio’s Hepatitis B and
prostate cancer immunotherapeutic products, in addition to Inovio’s business, including our plans to develop other electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results
may differ from the expectations set forth herein, including realization of any and all projected development or sales milestone payments, as a result of a number of factors, including Roche’s change in business resulting in the amendment or
termination of the Agreement, uncertainties inherent in pre-clinical 

  
 - 92 - 

 
studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of
results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods
anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of
funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its
collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered
technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government
healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended June 30, 2013, and other regulatory filings from time to time. There can be no
assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the
forward-looking information provided herein will be proven accurate. 
 For further information: 

Roche Partnering 
 Emilie Vincent, Head of Roche Partnering
Communications, emilie.vincent@roche.com 
 Inovio 

Investors: Bernie Hertel, Inovio Pharmaceuticals, +1858-410-3101, bhertel@inovio.com 

Media: Jeff Richardson, Inovio Pharmaceuticals, +1 267-440-4211, jrichardson@inovio.com 

  
 - 93 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]